tenofovir has been researched along with Hepatitis B, Chronic in 1000 studies
*Hepatitis B, Chronic: INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 88 (8.80) | 29.6817 |
| 2010's | 555 (55.50) | 24.3611 |
| 2020's | 357 (35.70) | 2.80 |
| Authors | Studies |
|---|---|
| Brunelle, MN; Holy, A; Lucifora, J; Neyts, J; Trepo, C; Villet, S; Zoulim, F | 1 |
| Boyd, A; Chas, J; Delaugerre, C; Dezanet, LNC; Gabassi, A; Lacombe, K; Lascoux-Combe, C; Maylin, S; Miailhes, P; Rougier, H | 1 |
| Ahn, SH; Chon, YE; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Lee, HA; Lee, HW; Park, JY; Park, SY; Roh, YH; Seo, YS; Tak, WY | 1 |
| Chen, L; Chen, W; Cui, H; Ding, Y; Gao, Y; Gong, H; Han, T; Jia, J; Jin, W; Jin, X; Jin, Z; Kong, F; Li, G; Liu, C; Liu, W; Mao, Q; Mu, M; Niu, J; Peng, Y; Shang, J; Song, X; Wang, D; Wang, P; Wen, X; Wu, X; Xia, J; Yan, X; Yang, Y; Yao, L; Zhang, D; Zhang, Z; Zhao, C; Zhu, Q | 1 |
| Burns, GS; Hall, SAL; Sundararajan, V; Thompson, A; Visvanathan, K; Vogrin, S; Wawryk, O | 1 |
| Krzowska-Firych, J; Pokora-Rodak, A; Tomasiewicz, K | 1 |
| Anderson, M; Bazinet, M; Cebotarescu, V; Cloherty, G; Cojuhari, L; Dittmer, U; Gersch, J; Holzmayer, V; Iarovoi, L; Jimbei, P; Jucov, A; Kuhns, M; Moscalu, I; Musteata, T; Pântea, V; Placinta, G; Smesnoi, V; Vaillant, A | 1 |
| Chen, E; Gao, Z; Gong, G; Gong, H; Hou, J; Hu, P; Huang, Y; Jin, Q; Li, C; Lin, S; Liu, Z; Mao, Q; Niu, J; Shang, J; Sun, C; Wang, F; Wen, X; Wu, G; Wu, Q; Xiao, L; Yang, D; Yao, L; Yin, H; Zhang, Y; Zhong, L | 1 |
| Choi, WM; Kim, WR; Lim, YS; Wong, GL; Yip, TC | 1 |
| Jin, YJ; Lee, JW; Lim, JH; Suh, YJ; Yu, JH | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yamashige, D | 1 |
| Ahn, SB; Berg, T; Buti, M; Calleja, JL; Cho, YK; Dalekos, GN; Goulis, J; Idilman, R; Jang, ES; Jang, MJ; Janssen, HLA; Jeong, SW; Jun, DW; Jung, YJ; Kim, HS; Kim, HY; Kim, SE; Kim, SU; Kim, YJ; Lampertico, P; Lee, HA; Lee, HC; Lee, JH; Lee, YB; Lim, YS; Manolakopoulos, S; Nam, JY; Papatheodoridis, GV; Park, SY; Seo, YS; Shim, JJ; Sinn, DH; Sohn, JH; Sypsa, V; Yoon, EL; Yoon, JH | 1 |
| Baik, SK; Cho, DH; Choi, J; Gwon, JG; Kang, SH; Kim, MY | 1 |
| Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Nguyen, MH; Trinh, S; Yeh, ML; Yu, ML | 1 |
| An, H; Byun, KS; Jung, YK; Kim, JH; Kim, TH; Lee, YS; Seo, YS; Um, SH; Yeon, JE; Yim, HJ; Yim, SY | 1 |
| Li, J; Li, X; Lin, L; Liu, Z; Mei, Y; Peng, L; Wu, L; Yuan, J; Zhu, S | 1 |
| Jeong, S; Kim, HI; Shin, HP | 1 |
| Feld, JJ; Gehring, AJ; Janssen, HLA; Kuipery, A; Mehrotra, A; Sanchez Vasquez, JD | 1 |
| Cai, DC; Hu, P; Ren, H; Zhang, Q | 1 |
| Brakenhoff, SM; Chan, HLY; Chen, CH; Chien, RN; Choi, HSJ; Cornberg, M; Feld, J; Forns, X; Hansen, BE; Hirode, G; Hsu, YC; Janssen, HLA; Jeng, WJ; Kao, JH; Lens, S; Papatheodoridi, M; Papatheodoridis, GV; Seto, WK; Sonneveld, MJ; Su, TH; Van Hees, S; Vanwolleghem, T; Wong, G; Yuen, MF | 1 |
| Ahn, SH; Chon, HY; Kim, SU; Kim, YJ; Lee, JH; Sinn, DH; Yoon, JH | 1 |
| Chen, WC; Cheng, JS; Kao, SS; Li, YD; Li, YR; Lin, HS; Lu, CM; Sun, WC; Tsai, TJ; Tsai, WL; Tsay, FW; Wang, HM; Yin, CH | 1 |
| Ahn, SB; Chen, CH; Cheung, R; Cho, YK; Chuang, WL; Dai, CY; Dao, A; Enomoto, M; Hoang, J; Huang, CF; Huang, DQ; Huang, JF; Huang, R; Hui, RW; Jeong, JY; Jeong, SW; Jun, DW; Khine, HHTW; Kim, HS; Kim, SE; Kozuka, R; Lee, DH; Lim, SG; Liu, L; Mak, LY; Nguyen, MH; Ogawa, E; Oh, H; Peng, CY; Quek, S; Shim, JJ; Trinh, H; Trinh, L; Tsai, PC; Tsui, V; Wong, GLH; Wu, C; Xie, Q; Yeh, ML; Yoon, E; Yu, ML; Yuen, MF | 1 |
| Furquim d'Almeida, A; Ho, E; Van Hees, S; Vanwolleghem, T | 1 |
| Fernández Cano, MC; Librero Jiménez, M; López Garrido, MÁ | 1 |
| Gao, P; Hou, J; Jia, J; Liang, X; Meng, Q; Ping, J; Shang, J; Sheng, J; Tang, H; Wang, G; Wang, H; Wu, S; Xie, Q; Xu, M; Zhang, J | 1 |
| Chen, CH; Hu, TH; Hung, CH; Kuo, YH; Lu, SN; Peng, CY; Wang, JH | 1 |
| Chen, ZM; Cui, GL; Feng, YH; Huang, S; Li, GM; Li, GT; Li, J; Li, W; Li, WZ; Li, ZQ; Liang, HX; Lin, WB; Liu, N; Liu, YM; Lv, J; Pan, YJ; Song, N; Sun, CY; Wang, FS; Wang, M; Xu, GH; Xu, JH; Yu, ZJ; Zeng, QL; Zeng, YL; Zhang, DW; Zhang, GF; Zhang, GQ; Zhang, HX; Zhang, JY; Zhou, YH | 1 |
| Chien, RN; Jeng, WJ; Liaw, YF; Liu, YC; Peng, CW | 1 |
| Dai, J; Jiang, K; Leng, S; Li, C; Qi, W; Ran, S; Shen, J; Wen, T; Zhang, Y | 1 |
| Jeong, J; Jung, SW; Park, EJ; Park, NH; Shin, JW | 1 |
| Chang, IW; Chen, CY; Gaggar, A; Hsu, YC; Huang, YT; Lin, JT; Nguyen, MH; Pan, DZ; Podlaha, O; Suri, V; Tseng, CH; Wu, CY | 1 |
| Çalhan, T; Doğanay, L; Kahraman, R; Kanat, E; Özdil, K; Öztürk, O; Şahin, A; Sayar, S | 1 |
| Han, N; Tang, H; Yan, LL | 1 |
| Ito, T; Kumada, T; Tanaka, J; Toyoda, H; Yasuda, S | 1 |
| Abiko, S; Kawagishi, N; Kimura, M; Kinoshita, K; Kitagataya, T; Maehara, O; Miyamoto, S; Morikawa, K; Nakai, M; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shigesawa, T; Sho, T; Suda, G; Sugiura, R; Suzuki, K; Yamada, R; Yamamoto, Y | 1 |
| Amagase, H; Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Ichiki, Y; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Kuniyoshi, M; Morita, C; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Sugimoto, R; Takahashi, K; Yamashita, N | 2 |
| Huo, RR; Li, MJ; Li, RH; Papatheodoridis, G; Yuan, BH; Zhong, JH | 1 |
| Huang, DQ; Ishigami, M; Landis, CS; Liu, JK; Nguyen, MH; Vutien, P | 1 |
| Chokkalingam, AP; Flaherty, J; Gaggar, A; Gordon, SC; Jump, B; Kim, WR; Lu, M; Ramroth, H; Telep, LE | 1 |
| Chayanupatkul, M; Dilokthornsakul, P; Permsuwan, U; Sawangjit, R; Sriuttha, P; Sukeepaisarnjaroen, W; Tangkijvanich, P; Tanwandee, T | 1 |
| Chen, MS; Fu, YZ; Hou, JY; Hu, ZL; Li, WX; Wang, XH; Xu, L; Zhang, YJ; Zhou, QF; Zhou, ZG | 1 |
| Agarwal, K; Flaherty, JF; Fung, S; Gordon, SC; Hou, J; Kao, JH; Kurosaki, M; Lampertico, P; Lim, YS; Seto, WK; Yee, LJ; Zhao, Y | 1 |
| Imai, Y; Kouyama, JI; Mochida, S; Naiki, K; Nakao, M; Nakayama, N; Sugawara, K; Tomiya, T; Tsuji, S; Uchida, Y; Uemura, H; Yamada, S | 1 |
| Lin, HY; Tseng, TC | 1 |
| Aghemo, A; Masetti, C; Pugliese, N; Viganò, M | 1 |
| Chien, RN; Liaw, YF | 2 |
| El-Serag, HB; Hsu, YC; Kanwal, F; Kim, H; Kramer, JR; Richardson, PA | 1 |
| Huang, SJ; Huang, Y; Huang, ZH; Liu, XH; Lu, GY; Qiu, LX; Su, YY; Wang, YB; Wu, T; Xia, NS; Yao, XM; Yuan, Q; Zhang, J; Zhong, GH | 1 |
| Adali, G; Bahadir, O; Degirmenci Salturk, AG; Doganay, HL; Gokcen, P; Guzelbulut, F; Kanatsiz, E; Kiyak, M; Ozdil, K; Ozturk, O | 1 |
| Choi, J; Choi, WM; Kim, KM; Lee, D; Lee, HC; Lim, J; Lim, YS; Shim, JH | 1 |
| Agarwal, K; Berg, T; Biermer, M; Carey, I; Lok, J; Lonjon-Domanec, I; Shivkar, Y | 1 |
| Afdhal, NH; Ankoma-Sey, V; Bae, H; Curry, MP; Dieterich, D; Frazier, L; Frick, A; Hann, HW; Kim, WR; Kwo, P; Milligan, S; Pan, CQ; Reddy, KR; Tong, MJ | 1 |
| Chen, M; Hou, J; Hu, Z; Wang, J; Xu, L; Zeng, H; Zhang, Y; Zhou, Z | 1 |
| Cho, JY; Choi, D; Choi, DL; Hong, G; Hwang, S; Kang, KJ; Kim, BW; Kim, DS; Kim, JM; Kim, MS; Lee, J; Lee, JG; Lee, KW; Moon, JI; Nah, YW; Ryu, JH; You, YK; Yu, HC | 1 |
| Chen, LW; Chien, CH; Chien, RN; Hu, CC; Huang, TS; Liang, KH; Lin, CL; Lin, YL; Shyu, YC; Yeh, CT | 1 |
| Bajpai, PS; Bukh, J; Dalegaard, MI; Fahnøe, U; Lundh, A; Ryom, L; Weis, N; Winckelmann, A | 1 |
| Jin, Y; Lu, L; Mao, Y; Wang, S; Yang, S; Yu, Y; Zhang, L; Zhao, A | 1 |
| Boglione, L; Chiecchio, M; D'Avolio, A; De Benedetto, I; De Nicolò, A; Di Perri, G; Dodaro, V | 1 |
| Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A | 1 |
| Cen, S; Gu, J; Liu, T; Sun, Q; Zhang, Q | 1 |
| Gedik, H | 1 |
| Rabenjanahary, TH; Rakotondrasoa, SR; Rakotozafindrabe, ALR; Ramanampamonjy, RM; Randriamifidy, NH; Rasolonjatovo, AS; Razafimahefa, SH; Razafindrazoto, CI | 1 |
| Chang, ML; Cheng, JS; Chien, RN; Lee, KC; Liaw, YF | 1 |
| Balkan, II; Bayramlar, OF; Karaali, R; Mete, B; Ozdemir, YE; Sahin Ozdemir, M; Saltoglu, N; Surme, S; Tabak, F; Yildiz Kaya, S | 1 |
| Agorastou, P; Dalekos, GN; Deutsch, M; Elefsiniotis, I; Gatselis, N; Goulis, J; Kapatais, A; Karaoulani, T; Karatapanis, S; Kranidioti, H; Kyriazidou, A; Manesis, E; Manolakopoulos, S; Mimidis, K; Mylopoulou, T; Papatheodoridi, M; Papatheodoridis, GV; Samonakis, D; Sevastianos, V; Triantos, C; Vasiliadis, T; Zisimopoulos, K | 1 |
| Chen, CH; Hu, TH; Hung, CH; Kuo, YH; Lu, SN; Tseng, TN; Wang, JH | 1 |
| Chen, YC; Chien, RN; Hsu, CW; Tai, DI | 1 |
| Fung, J; Huang, DQ; Kim, BK; Lim, GEH; Lim, KE; Lim, WH; Loomba, R; Muthiah, MD; Ng, CH; Nguyen, MH; Syn, N; Tamaki, N; Tan, DJH; Tang, ASP; Tay, PWL; Teng, MLP | 1 |
| Foucault, T; Gaudy-Graffin, C; Handala, L; Marlet, J; Paintaud, G | 1 |
| Fan, R; Jiang, Y; Liang, J; Liao, X; Wu, L; Yin, J; Yu, N; Zhang, Q; Zhao, S | 1 |
| Kumar, M | 1 |
| Gane, E; Kashuba, A; Levy, MT | 1 |
| Lee, MH | 1 |
| Ran, R; Wang, M; Zhang, H; Zhu, Y | 1 |
| Boyd, A; Coffie, PA; Freedberg, KA; Hyle, EP; Kim, AY; Kouamé, MG; Larmarange, J; Mohareb, AM | 1 |
| Ahn, SH; Kim, BK; Oh, J; Yoon, JH; Yun, B | 1 |
| Bai, L; Gu, J; Jia, H; Kuang, W; Lian, J; Lu, X; Lu, Y; Lv, Y; Wang, K; Yang, D; Yang, Y; Ye, C; Yu, J; Yu, Y; Zhang, J; Zhang, X; Zhang, Y; Zhao, P; Zhao, Y | 1 |
| Chen, J; Hu, X; Li, Q; Li, R; Yuan, G; Zang, M | 1 |
| Cai, H; Gao, X; Li, Z; Xie, B; Yi, N; Yi, W | 1 |
| Brakenhoff, SM; Chan, HLY; Chen, CH; Chien, RN; Choi, HSJ; Cornberg, M; Feld, JJ; Forns, X; Hansen, BE; Hirode, G; Hsu, YC; Janssen, HLA; Jeng, WJ; Kao, JH; Lens, S; Papatheodoridi, M; Papatheodoridis, GV; Seto, WK; Sonneveld, MJ; Su, TH; Van Hees, S; Vanwolleghem, T; Wong, GLH; Yuen, MF | 1 |
| Choe, WH; Kang, SH; Kim, JH; Kwon, SY; Yoo, BC; Yoon, EL | 1 |
| Chien, RN; Jeng, WJ; Liaw, YF; Liu, YC; Peng, CW; Yang, HI | 1 |
| Atalay, R; Ayrancı, FG; Çakmak, Ş; Doğanay, L; Özdil, K; Sayar, S; Tanboğa, İH | 1 |
| Lim, TO; Lim, ZZ; Tan, AC; Teo, JS | 1 |
| Papatheodoridis, GV | 2 |
| Chen, CH; Tseng, TN | 1 |
| Ahn, SH; Jung, CY; Kim, BS; Kim, HW; Kim, SU; Lee, HW; Lee, JI | 1 |
| Chang, KC; Chen, CH; Chiu, SM; Hu, TH; Hung, CH; Lu, SN; Wang, JH | 1 |
| Chen, EQ; Wang, ML | 1 |
| Ogawa, E | 2 |
| Accarino, EV; Ahn, SB; Buti, M; Chen, CH; Cheung, R; Cho, YK; Chuang, WL; Dai, CY; Enomoto, M; Gadano, A; Hoang, J; Hsu, YC; Huang, CF; Huang, D; Huang, JF; Huang, YT; Istratescu, D; Jeong, JY; Jeong, SW; Jun, DW; Kim, HS; Kim, SE; Kozuka, R; Lee, DH; Lim, SG; Lin, CH; Liu, L; Marciano, S; Nguyen, MH; Oh, H; Peng, CY; Preda, C; Riveiro-Barciela, M; Su, JY; Toyoda, H; Trinh, H; Trinh, L; Tsai, PC; Wong, GL; Wong, VW; Xie, Q; Yasuda, S; Yeh, ML; Yoon, E; Yu, ML; Yuen, MF | 1 |
| Bi, X; Deng, W; Jiang, T; Li, M; Lin, Y; Lu, Y; Sun, F; Xie, Y; Yang, L; Yi, W; Zhang, L | 1 |
| Guo, P; Qin, X; Yan, H; Yang, X; Zhang, X | 1 |
| Baek, YH; Chae, HB; Cheon, GJ; Cho, HC; Cho, YK; Chon, YE; Hwang, JS; Kang, MK; Kim, JH; Kim, SU; Koh, MS; Kweon, YO; Lee, C; Lee, JH; Lee, JS; Lim, YS; Park, NH; Park, YM; Sohn, JH; Yim, HJ | 1 |
| Akahane, T; Inoue, J; Iwata, T; Kisara, N; Kobayashi, T; Masamune, A; Ninomiya, M; Onuki, M; Sano, A; Sato, K; Sato, S; Tsuruoka, M | 1 |
| Béguelin, C; Bernasconi, E; Boillat-Blanco, N; Calmy, A; Günthard, HF; Hofmann, E; Rauch, A; Schmid, P; Stöckle, M; Surial, B; Suter-Riniker, F; Wandeler, G | 1 |
| Akahane, T; Inoue, J; Iwata, T; Kimura, O; Kobayashi, T; Masamune, A; Nakamura, T; Niitsuma, H; Ninomiya, M; Onuki, M; Sano, A; Sato, K; Sato, T; Sawahashi, S; Takai, S; Tsuruoka, M | 1 |
| Xu, D; Yu, J | 1 |
| Adjei, G; Adu, F; Anyanful, A; Ephraim, RKD; Gavor-KWashi, C; Nsiah, P; Nyarko, SB; Thomford, NE | 1 |
| Brakenhoff, SM; de Knegt, RJ; de Man, RA; Katwaroe, WK; Sonneveld, MJ; van der Meer, AJP; van der Spek, DPC; van Kleef, LA | 1 |
| Afdhal, NH; Chan, HLY; Chen, CY; Coffin, CS; Elkhashab, M; Fung, SK; Greenbloom, S; Iyer, RP; Jackson, K; Jang, JW; Jeng, WJ; Kim, DJ; Kim, W; Kim, YJ; Lee, KS; Lim, YS; Liu, CJ; Locarnini, SA; Macfarlane, C; Ramji, A; Yuen, MF | 1 |
| Arribas, JR; Cahn, P; Daar, ES; Gibas, KM; Kelly, SG; Orkin, C; Sax, PE; Taiwo, BO | 1 |
| Afzalpurkar, S; Agrawal, D; Angadi, S; Giri, S; Gopan, A; Sundaram, S | 1 |
| Adekanle, O; Adeyemi, A; Anyabolu, C; Awowole, I; Ijadunola, M; Ijarotimi, O; Kuti, O; Makinde, O; Ndububa, D | 1 |
| Beck, A; Fichtl, A; Seufferlein, T; Zizer, E | 1 |
| Baum, MM; Kiser, JJ; Thomas, DL | 1 |
| Aeschbacher, T; Buti Ferret, M; Feierbach, B; Gaggar, A; Gane, E; Jackson, K; Janssen, HLA; Littlejohn, M; Marcellin, P; Martin, R; Meagher, N; Price, DJ; Revill, PA; Sozzi, V; Suri, V; Tan, SK; Thompson, AT; Wagner, J; Wong, D; Yuen, L | 1 |
| Chen, CH; Hu, TH; Hung, CH; Jeng, WJ; Lu, SN; Tseng, TN; Wang, JH | 1 |
| Hou, J; Li, Y; Qiang, Z; Zhang, Y | 1 |
| Cao, XY; Chen, JW; Qi, X; Zhang, JM | 1 |
| Brooks-Rooney, C; Cant, H; Chen, CH; Chen, CY; Choi, WM; Curteis, T; Huang, YH; Jin, YJ; Jun, DW; Kim, JW; Kim, WR; Lim, YS; Park, NH; Peng, CY; Shin, HP; Shin, JW; Wong, GL; Yang, YH; Yee, LJ; Yip, TC | 1 |
| Chen, T; Feng, Y; He, Y; Liu, J; Shi, L; Yao, N; Zhao, Y; Zhu, Y | 1 |
| Deng, Y; Pan, CQ; Park, J; Zhu, L | 1 |
| Belle, SH; Chung, RT; Cooper, SL; Di Bisceglie, AM; Fried, MW; Ghany, MG; Janssen, HLA; Khalili, M; Lau, DTY; Lisker-Melman, M; Lok, AS; Patel, K; Perrillo, RP; Roberts, LR; Sterling, RK; Terrault, NA; Wahed, AS; Wong, DK | 1 |
| Guo, Y; Han, J; He, J; Huang, Y; Mao, R; Sun, J; Zhang, J; Zhang, X; Zhang, Y | 1 |
| Byun, KS; Choi, J; Kim, JH; Lim, YS; Yoo, BC | 1 |
| Hu, L; Lyu, C; Shao, J; Wang, Y; Zhang, L | 1 |
| Chen, B; Jiang, L; Jin, L; Lu, H; Yang, J; Ye, P; Zhang, H | 1 |
| Chang, MH; Eom, HS; Hyun, SY; Jo, JC; Kang, HJ; Kim, DY; Kim, HJ; Kim, IH; Kim, JS; Kim, MK; Kim, WS; Kim, YR; Kwak, JY; Lee, JO; Lee, WS; Lim, SN; Mun, YC; Park, Y; Shin, HJ; Suh, C; Yang, DH; Yoo, KH; Yoon, DH | 1 |
| Gao, F; Li, C; Qi, W; Shen, J; Zhang, Y | 1 |
| Albillos, A; Amador-Navarrete, A; Arenas, JI; Badía, E; Bañares, R; Bernal-Monterde, V; Buti, M; Cabezas, J; Calleja, JL; Conde, MH; Cordero, P; Crespo, J; de Santiago, ER; Diago, M; Díaz-Fontenla, F; Fernández-Rodríguez, C; García-Buey, L; García-Retortillo, M; Garcia-Samaniego, J; Gea, F; Hoyas, E; Lens, S; Madejón, A; Mancebo, A; Marcos-Fosch, C; Mateos-Muñoz, B; Miquel, M; Moreno, JJ; Moreno, S; Morillas, RM; Pardo, A; Ramos-Merino, L; Rodríguez, M; Rodríguez-Tajes, S; Romero-Gomez, M; Santiago, JMG; Simón, MÁ; Turnes, J; Vázquez, IF | 1 |
| Cheng, H; Guo, Y; Tang, K; Wang, H | 1 |
| Chan, HL; Hui, VW; Lai, JC; Lai, MS; Liang, LY; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Nguyen, TK; Van Le, D | 1 |
| Chen, CL; Chen, PJ; Hong, CM; Kao, JH; Lin, MJ; Liou, JM; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC | 1 |
| Ahn, SB; Chen, CH; Chen, CY; Cho, YK; Choi, WM; Hur, MH; Jang, MJ; Jeong, SW; Jin, YJ; Jun, DW; Kim, HS; Kim, HY; Kim, SE; Kim, SU; Kim, YJ; Lee, HA; Lee, HC; Lee, JH; Lim, YS; Park, MK; Park, SY; Peng, CY; Seo, YS; Shim, JJ; Shin, HP; Sinn, DH; Sohn, JH; Wong, GL; Yip, TC; Yoon, EL; Yoon, JH | 1 |
| Chang, CC; Chiou, JF; Hou, MC; Huang, YH; Huo, TI; Kao, WY; Lee, HL; Su, CW; Tan, EC; Wu, JC | 1 |
| Mizokami, M; Murata, K | 1 |
| Barreiro, P; Corral, O; Mendoza, C; Moreno-Torres, V; Soriano, V | 1 |
| Chan, KM; Cheng, CH; Chou, HS; Hung, HC; Lee, CF; Lee, JC; Lee, WC; Wang, YC; Wu, TH; Wu, TJ | 1 |
| Hwang, EG; Jung, EA; Kim, SG; Kim, YS; Yoo, JJ | 1 |
| Ahn, SH; Jung, CY; Kim, BS; Kim, SU; Lee, JI; Lee, JS | 1 |
| Hu, X; Li, Y; Luo, H; Qin, B; Tan, G | 1 |
| Chen, CH; Hu, TH; Hung, CH; Lu, SN; Peng, CY; Wang, JH | 1 |
| Belle, SH; Ghany, MG; Janssen, HLA; Leonard, K; Lok, AS; Perrillo, R; Terrault, N | 1 |
| Cho, H; Chon, YE; Ha, Y; Hwang, SG; Kim, MN; Lee, JH; Lee, YB; Park, H; Rim, KS | 1 |
| Chuan, L; Linye, H; Tianfu, W; Xiaoyun, Z; Zhihui, L; Zijing, X | 1 |
| Arai, K; Hayakawa, N; Honda, M; Horii, R; Kagaya, T; Kaneko, S; Kawaguchi, K; Komura, T; Mizukoshi, E; Nio, K; Nishikawa, M; Orita, N; Sakai, Y; Shimakami, T; Shimode, T; Takatori, H; Terashima, T; Yamashita, T | 1 |
| Ahn, SH; Chon, YE; Kim, BK; Kim, DY; Kim, H; Kim, SU; Lee, HW; Lee, JS; Park, JY; Park, SY; Park, T; Seo, YS | 1 |
| Cho, EJ; Jang, H; Kim, TM; Kim, YJ; Lee, HG; Lee, JH; Lee, YB; Yoon, JH; Yu, SJ | 1 |
| Cho, JY; Choi, D; Choi, Y; Hwang, S; Joo, DJ; Kang, KJ; Kim, BW; Kim, DG; Kim, DS; Kim, MS; Lee, JG; Nah, YW; Rhu, J; Ryu, JH; Yang, JD; You, YK | 1 |
| Jiang, L; Lou, Z; Pan, L; Ruan, B; Xu, X; Zeng, Y | 1 |
| Chon, YE; Ha, Y; Han, S; Hwang, SG; Kim, KM; Kim, MN; Lee, D; Lee, HC; Lee, JH; Lim, J; Shim, JH | 1 |
| Chang, JI; Cho, YY; Jang, ES; Kim, E; Kim, HJ; Kim, SS; Lee, HW; Seo, GH; Yoon, E | 1 |
| Amin, MM; Darmadi, D; Eyanoer, PC; Lindarto, D; Lubis, M; Rey, I; Rusda, M; Siregar, J; Widyawati, T; Yusuf, F | 1 |
| Behrendt, H; Bieda, A; Leśniak, K; Niemczyk, S | 1 |
| Li, ZH; Liu, ZX; Luo, JX; Su, JY; Wang, YY; Wu, KJ; Wu, XL; Wu, YL; Zhong, JH | 1 |
| Aberra, H; Berhe, N; Desalegn, H; Grude, S; Gundersen, SG; Hommersand, K; Johannessen, A; Mamo, E; Orlien, SMS | 1 |
| Choi, J; Choi, WM; Lim, YS | 2 |
| Evon, DM; Fontana, RJ; Hoofnagle, JH; Khalili, M; Lin, HS; Wahed, AS; Yim, C | 1 |
| Abdullah, T; Aydin, O; Çolak, M; Kinaci, E; Ocak, İ; Özcan, FG; Özden, İ; Poturoğlu, Ş | 1 |
| Aladag, M; Yakut, A | 1 |
| Cai, W; Gu, F; Guo, P; He, Y; Hu, F; Lan, Y; Li, H; Li, L; Li, Y; Lin, W; Tang, X; Zhong, H | 1 |
| Chandiwana, P; Duri, K; Gumbo, FZ; Marere, T; Mataramvura, H; Mazengera, LR; Mazhandu, AJ; Munjoma, PT | 1 |
| Liu, S; Liu, Z; Ma, X; Xin, Y; Zhao, Z | 1 |
| He, S; Wang, L; Wang, N; Zheng, Y | 1 |
| Duan, YQ; Hu, P | 1 |
| Fan, R; Fan, Y; Guo, L; Liao, X; Tan, W; Yin, J; Zhao, S; Zhong, C | 1 |
| Li, C; Peng, W; Qi, W; Qi, X; Wen, T; Yi, M | 1 |
| Chen, R; Huang, B; Li, Q; Li, X; Lin, S; Liu, L; Liu, Y; Luo, D; Niu, M; Wang, J; Xu, D | 1 |
| Chen, XY; Cheng, J; Dai, J; Gao, ZL; Li, J; Liang, RY; Mao, Q; Shang, J; Si, CW; Tang, H; Wang, H; Wang, L; Wang, S; Wu, SM; Xie, Q; Xu, JH; Xu, ZN; Yu, YY; Yu, ZJ; Zhang, WH; Zhao, W | 1 |
| Chen, MB; Ding, YL; Fan, JN; Wang, H; Yue, MX; Zheng, QH; Zheng, XW | 1 |
| Koh, YH; McCartney, E; Morgan, J; Narayana, S; Ong, JHY; Tse, E | 1 |
| Chang, KC; Chang, MH; Chen, HL; Lin, LH | 1 |
| Han, Z; Hou, H | 1 |
| Jiang, D; Li, Y; Song, C; Wang, J; Wang, X; Zeng, H; Zhang, Q; Zhao, X | 1 |
| Chan, HL; Chan, SL; Choi, J; Le, A; Lim, YS; Liu, K; Nguyen, MH; Wong, GL; Wong, VW; Yip, TC | 1 |
| Kimura, A; Mizokami, M; Murata, K; Noguchi, M; Sugiyama, M; Suizu, F; Tsukuda, S; Watashi, K | 1 |
| Choe, WH; Choi, YM; Kim, BJ; Kim, JH; Kim, K; Kwon, SY; Lee, SY | 1 |
| Liaw, YF | 2 |
| Blackard, JT; Kwara, A; Sherman, KE | 1 |
| Cui, FQ; Hou, JL; Jia, JD; Liu, J; Liu, YY; Liu, ZH; Tao, LB; Xie, L; Yin, XR; Zhuang, GH | 1 |
| Chan, HL; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Chen, CH; Hu, TH; Hung, CH; Lu, SN; Ma, TL; Wang, JH | 1 |
| Kim, KH; Lee, JH | 1 |
| Benhong, Z; Jiexin, L; Peng, C | 1 |
| Chen, EQ; Liao, J; Tang, H; Tao, YC; Wang, ML; Wang, YH; Wu, DB; Zhang, DM | 2 |
| Lin, L; Liu, L; Lu, J; Shen, H; Xue, Y; Zhang, H; Zhang, X; Zheng, S | 1 |
| Chen, CH; Cheung, KS; Eguchi, Y; Enomoto, M; Furusyo, N; Hoang, J; Hsu, YC; Huang, CF; Huang, R; Huang, YT; Jang, TY; Kozuka, R; Kumada, T; Lee, DH; Li, J; Liu, C; Liu, L; Nguyen, MH; Ogawa, E; Peng, CY; Takahashi, H; Tanaka, Y; Toyoda, H; Trinh, H; Tsai, PC; Wong, C; Wong, GL; Wu, C; Xie, Q; Yang, HI; Yasuda, S; Yeh, ML; Yu, ML; Yuen, MF; Zhang, JQ; Zhao, C | 1 |
| Janjua, NZ; Krajden, M; Samji, H; Wilton, J; Yu, A | 1 |
| Ahn, SH; Ferrari, C; Gish, RG; Given, BD; Hamilton, J; Heo, J; Kim, JH; Klinker, H; Lai, CL; Lik Yuen Chan, H; Locarnini, SA; Manns, M; Petersen, J; Schiefke, I; Schluep, T; Yoon, JH; Yoon, KT; Yuen, MF | 1 |
| Bae, SH; Choi, JY; Han, NI; Jang, JW; Kwon, JH; Lee, HL; Lee, SW; Nam, HC; Nam, SW; Sung, PS; Yoo, SH; Yoon, SK | 1 |
| Alsabbagh, MW; Houle, SKD; Tian, F; Wong, WWL | 1 |
| Agarwal, K; Carey, I; Cloherty, G; Dusheiko, G; Gersch, J; Kuhns, M; Moigboi, C; Wang, B | 1 |
| Liang, B; Zheng, X | 1 |
| Lampertico, P; Papatheodoridis, GV | 2 |
| Kim, BK | 2 |
| Gao, J; Yu, Y; Zhang, B; Zhang, J | 1 |
| Chen, MB; Ding, YL; Fan, JN; Niu, JL; Wang, H; Zheng, QH; Zheng, XW | 1 |
| Lee, HW | 1 |
| Imai, Y; Kouyama, JI; Mochida, S; Motoya, D; Naiki, K; Nakao, M; Nakayama, N; Sugawara, K; Tomiya, T; Tsuji, S; Uchida, Y; Uemura, H | 1 |
| Jiang, D; Wang, X; Zeng, H | 1 |
| Zhang, D; Zhang, Q; Zhu, F | 1 |
| Chen, H; Ding, Y; Jin, W; Li, C; Li, X; Liu, C; Liu, J; Niu, J; Wu, M; Zhang, D; Zhang, H; Zhu, X | 1 |
| Li, MJ; Teng, YX; Xiang, BD; Zhong, JH | 1 |
| Arslan, F; Vahaboglu, H | 1 |
| Han, BH; Jeong, J; Lee, D; Lee, JW; Lee, SU; Park, ET; Seo, KI; Yun, BC | 1 |
| Khamrin, P; Kumthip, K; Malasao, R; Maneekarn, N; Sirilert, S; Tongsong, T | 1 |
| Chan, HL; Hui, VW; Lee, HW; Liang, LY; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Chan, AC; Cheung, TT; Chok, KS; Dai, WC; Fung, J; Lai, CL; Lo, CM; Ma, KW; Mak, LY; Seto, WK; She, WH; Sin, SL; Wong, TC; Yuen, MF | 1 |
| Bak, H; Byun, KS; Chang, SW; Hyun, MH; Jung, YK; Kim, JH; Kim, S; Lee, CU; Lee, HS; Lee, MJ; Lee, YS; Seo, YS; Um, SH; Yeon, JE; Yim, HJ | 1 |
| Li, RH; Yuan, BH; Zhu, YK | 1 |
| Wong, GL; Yip, TC | 2 |
| Choi, J; Han, S; Kim, GA; Lim, YS | 1 |
| Cai, H; Duan, X; Fu, D; Gao, X; Hu, Y; Kang, K; Liu, M; Yi, W; Zhou, M | 1 |
| Chow, SC; Jia, J; Kong, Y; Li, M; Lv, T; Ma, H; Ou, X; Wei, W; Wu, S; Wu, X; You, H | 1 |
| Hsu, YC; Nguyen, MH | 1 |
| Chung, RT; Holmes, JA | 1 |
| Amano-Teranishi, Y; Enomoto, M; Kawada, N; Kawasaki, Y; Kioka, K; Nakai, T; Suoh, M; Tamori, A | 1 |
| Boyd, A; Chas, J; Delaugerre, C; Dezanet, LNC; Gabassi, A; Girard, PM; Lacombe, K; Lascoux-Combe, C; Maylin, S; Miailhes, P; Rougier, H | 1 |
| Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Okada, M; Osawa, L; Sekiguchi, S; Shimizu, T; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Watakabe, K; Yamashita, K; Yasui, Y | 1 |
| Berg, T; Buti, M; Calleja, JL; Chi, H; Dalekos, GN; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HLA; Keskin, O; Kourikou, A; Lampertico, P; Loglio, A; Lopez-Gomez, M; Manolakopoulos, S; Papatheodoridis, GV; Savvidou, S; Sypsa, V; Van Boemmel, F; Veelken, R; Vlachogiannakos, J; Voulgaris, T; Yurdaydin, C | 1 |
| Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Kweon, YO; Lee, EJ; Lee, HA; Lee, HW; Lee, YR; Park, JY; Park, SY; Seo, YS; Shin, HJ; Tak, WY; Um, SH | 1 |
| Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Okada, M; Osawa, L; Sekiguchi, S; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Yamashita, K; Yasui, Y | 1 |
| Babudieri, S; Bagella, P; Bandiera, F; Calvisi, DF; Fiore, V; Garrucciu, G; Madeddu, G; Mannu, F; Melis, M; Muredda, AA; Ortu, S; Zaru, S | 1 |
| Yalaki, S; Yalcin, MS | 1 |
| Ahn, SH; Chan, HL; Lee, HW; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Ahmed, A; Kamal, F; Khan, MA; Nair, S | 1 |
| Arslan, K; Ataman Hatipoğlu, Ç; Çerçioğlu, D; Cesur, S; Gönültaş, M; Kınıklı, S | 1 |
| Chen, F; Fu, X; Gao, X; Lin, Z; Lou, H | 1 |
| Chaung, KT; Cheung, R; Henry, L; Hoang, JK; Le, AK; Li, J; Nguyen, MH | 1 |
| Mak, LY | 1 |
| Agarwal, K; Ahn, SH; Bae, H; Buti, M; Chan, HLY; Chen, CY; Chuang, WL; Flaherty, JF; Fung, S; Gaggar, A; Lampertico, P; Lau, A; Lim, YS; Liu, Y; Ma, X; Ramji, A; Subramanian, GM; Suri, V; Tak, WY; Tam, E; Tan, SK; Trinh, H; Wu, G; Yoon, SK | 1 |
| Ergen, P; Yilmaz Karadağ, F | 1 |
| Ahn, SB; Cho, YK; Jeong, JY; Jeong, SW; Jun, DW; Kim, HS; Kim, SE; Lee, HY; Oh, H; Shim, JJ; Sohn, JH; Yoon, EL | 1 |
| Bazinet, M; Cebotarescu, V; Cojuhari, L; Dittmer, U; Iarovoi, L; Jimbei, P; Jucov, A; Krawczyk, A; Moscalu, I; Musteata, T; Pântea, V; Placinta, G; Smesnoi, V; Vaillant, A | 1 |
| Gül, S; Köse, Ş; Pala, E; Tatar, B | 1 |
| Chung, JW; Ha, I; Jang, ES; Jeong, SH; Kim, JW | 1 |
| Chen, B; Chen, P; Gu, L; He, Y; Mao, F; Ng, DM; Shen, Z; Yang, T; Yao, Q; Yu, Q | 1 |
| Kim, SU; Lee, HA; Seo, YS | 1 |
| Kamal, F; Khan, MA | 1 |
| Ahn, SH; Baek, YH; Chang, Y; Choe, WH; Jang, JW; Jang, JY; Kim, GA; Kim, HY; Kim, JH; Kim, M; Kim, MA; Kim, SG; Kim, SU; Kim, YJ; Kim, YS; Koh, M; Kwon, JH; Lee, HA; Lee, HW; Lee, JH; Lee, SW; Lee, YS; Lim, YS; Park, Y; Seo, YS; Shim, JJ; Sinn, DH; Yang, H; Yim, HJ; Yoon, JH; Zoulim, F | 1 |
| Bai, X; Chen, X; Fan, R; Hou, J; Niu, J; Peng, J; Ren, H; Sheng, J; Sun, J; Tan, D; Tang, H; Wang, H; Wang, M; Wu, Y; Xie, Q; Xu, M; Zhou, B | 1 |
| Berry, K; Ioannou, GN; Su, F | 1 |
| Adams, LA; Barnard, A; Dave, S; Loomba, R; Murad, MH; Park, S; Prokop, L; Singh, S | 1 |
| Kumada, T; Miyake, N; Tada, T; Tanaka, J; Toyoda, H; Yasuda, S | 1 |
| Joo, DJ; Kim, DG; Kim, MS; Kim, SI; Lee, J; Lee, JG; Lee, JY; Park, JY; Yang, SJ | 1 |
| Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Takahashi, K | 1 |
| Chang, HY; Kim, S; Lee, HW; Lee, JI; Lee, KS | 1 |
| Choi, J; Jo, C; Lim, YS | 1 |
| Bao, H; Chen, Y; Geng, J; Shi, L; Wang, Q; Yu, H | 1 |
| El-Serag, HB; Hsu, YC; Tseng, CH; Tseng, CM; Wu, JL | 1 |
| Chen, CH; Chiu, SM; Hu, TH; Hung, CH; Kuo, YH; Lu, SN; Wang, JH | 1 |
| Ahn, SH; Cho, YK; Han, KH; Hong, GY; Jang, JY; Jung, YK; Kim, DJ; Kim, HS; Kim, JH; Kim, MY; Kim, W; Kim, YJ; Kweon, YO; Lee, BS; Lee, JW; Lee, KS; Lee, WS; Lim, YS; Park, SJ; Sohn, JH; Um, SH; Yang, JM; Yim, HJ; Yoon, SK | 1 |
| Chang, KK; Kuo, MJ; Lin, RC; Tseng, YT; Wang, CH; Yang, CC | 1 |
| Chen, CH; Hu, TH; Hung, CH; Jeng, WJ; Kuo, YH; Lu, SN; Tseng, TN; Wang, JH | 1 |
| Shu, YF; Xu, L; Xu, XF; Yang, W | 1 |
| Ahn, SH; Han, KH; Jeon, MY; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Lee, JS; Park, JY | 1 |
| Chang, KC; Hu, TH; Lin, MT; Tsai, MC; Wu, CK; Yen, YH | 1 |
| Cheong, JY; Chung, WJ; Jang, BK; Jang, JY; Jeong, SW; Kim, IH; Kim, SG; Kim, SS; Kim, SU; Kim, YS; Lee, BS; Lee, CH; Lee, HA; Lee, HW; Lee, JI; Lee, JW; Lim, TS; Park, SY; Rou, WS; Seo, YS; Suh, SJ; Tak, WY; Yim, HJ; Yu, JH | 1 |
| Chang, WY; Chen, DS; Chen, PJ; Cheng, PN; Chiu, FW; Chiu, YC; Hsu, YC; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC; Yang, SS | 1 |
| Ahn, SH; Bae, SH; Heo, J; Jang, JY; Kim, CW; Kim, DJ; Kim, IH; Park, JY; Tak, WY; Woo, HY | 1 |
| Berg, T; Buti, M; Calleja, JL; Dalekos, GN; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HLA; Kourikou, A; Lampertico, P; Loglio, A; Lopez-Gomez, M; Manolakopoulos, S; Papatheodoridi, M; Papatheodoridis, GV; Savvidou, S; Sypsa, V; Van Boemmel, F; Veelken, R; Vlachogiannakos, J; Yurdaydin, C | 1 |
| Ahn, SH; Chon, YE; Ha, Y; Han, KH; Hwang, SG; Jung, KS; Kim, DY; Kim, MN; Lee, JH; Park, JY | 1 |
| Berg, T; Botros, I; Buti, M; Flaherty, JF; Jump, B; Lampertico, P; Op den Brouw, ML; Pathil, A; Petersen, J; Ramroth, H; Ryder, SD; van Troostenburg, A; Zoulim, F | 1 |
| Kim, BK; Kim, SU | 1 |
| Cheng, M; Feng, X; Ma, L; Wang, B; Wang, L; Yang, Y | 1 |
| Jang, BK | 1 |
| Andersson, M; Barnes, E; Bonsall, D; de Cesare, M; Gabriel, S; Hugo, S; Maponga, TG; Matthews, PC; McNaughton, AL; Mokaya, J; Preiser, W; Singer, JB; Sreenu, VB; Taljaard, J; Van Rensburg, C; Van Schalkwyk, M | 1 |
| Alam, A; Charlton, MR; Cua, IHY; Dashtseren, B; Duger, D; Duy Cuong, D; Gani, RA; Hashmi, ZY; Hien, PTD; Jargalsaikhan, G; Kyi, KP; Lesmana, CRA; Madan, K; Mohamed, R; Naing, W; Payawal, DA; Piratvisuth, T; Rastogi, M; Salih, M; Saraf, N; Shukla, A; Singh, KR; Sollano, JD; Sukeepaisarnjaroen, W; Tanwandee, T; Thuy, PTT; Tun, KS; Win, KM | 1 |
| Chayama, K; Enomoto, H; Enomoto, M; Hiramatsu, N; Ikeda, F; Ito, K; Kagawa, T; Kanda, T; Kang, JH; Kondo, Y; Masaki, T; Matsui, T; Matsumoto, A; Miyase, S; Morihara, D; Murata, K; Nagaoka, S; Nishiguchi, S; Okuse, C; Saito, S; Shinkai, N; Takaguchi, K; Tanaka, E; Tanaka, Y; Tsuge, M; Yamada, R; Yatsuhashi, H | 1 |
| Audsley, J; Avihingsanon, A; Bowden, S; Fairley, CK; Lewin, SR; Littlejohn, M; Matthews, GV; Sasadeusz, J | 1 |
| Borghi, M; Buti, M; di Paolo, D; Esteban, R; Facchetti, F; Lampertico, P; Loglio, A; Lunghi, G; Riveiro-Barciela, M; Roade, L; Soffredini, R; Tabernero, D | 1 |
| Hwang, SG; Jang, JY; Jung, YK; Kim, HS; Kim, IH; Kim, JH; Kim, YS; Lee, SH; Lee, YS; Park, JY; Seo, YS; Song, MJ; Suh, SJ; Um, SH; Yim, HJ; Yoon, EL | 1 |
| Eminler, AT; Koksal, AS; Parlak, E; Toka, B; Tozlu, M; Uslan, MI | 1 |
| Anugwom, CM; Bane, A; Braimoh, GA; Debes, JD; Sultan, A; Wondifraw, Z | 1 |
| Agah, S; Bagheri-Hosseinabadi, Z; Bahardoust, M; Barati, M; Karimi Behnagh, A; Keyvani, H; Mokhtare, M | 1 |
| Ge, Z; Gou, W; Ma, J; Qiao, B; Wang, Y; Zhang, H | 1 |
| Chon, YE; Ha, Y; Hwang, SG; Kim, MN; Lee, JH | 1 |
| Boucheron, P; Bulterys, M; Chou, R; Funk, AL; Lu, Y; Shimakawa, Y; van Holten, J; Yoshida, K; Zhao, T | 1 |
| Bin, W; Jianfei, L; Jiming, Z; Ling, L; Yu, Z | 1 |
| Cao, L; Chen, B; Chen, R; Ding, Y; Fan, J; Gan, W; Huang, Y; Lin, C; Liu, Y; Pan, CQ; Sheng, Q; Wang, S; Wang, Y; Zhu, L | 1 |
| Kim, SU; Lee, SW | 1 |
| Chen, J; Wang, Y; Wu, J | 1 |
| Chen, EQ; Tao, YC | 1 |
| Hall, S; Howell, J; Thompson, A; Visvanathan, K | 1 |
| Con, D; Goodwin, T; Kemp, W; Majeed, A; Roberts, S | 1 |
| Feld, JJ; Fung, S; Hansen, BE; Janssen, HLA; Liem, KS; Wong, DK; Yim, C; Zahirieh, A; Zanjir, WR | 1 |
| Angkurawaranon, C; Bierhoff, M; Carrara, V; Ehrhardt, S; Guo, N; Jia, Y; Jittamala, P; Ling, C; McGready, R; Nelson, KE; Nosten, F; Rijken, M; Thio, CL; Tongprasert, F; van Vugt, M; Watthanaworawit, W | 1 |
| Flomo, KT; Ma, Y; Yang, Q; Yang, Y; Zhong, Z | 1 |
| Lampertico, P; Papatheodoridis, G; Sypsa, V | 1 |
| Danta, M; Dore, GJ; Matthews, GV | 1 |
| Borghi, JA; Chen, IS; Chen, TH; Cheung, R; Enomoto, M; Hai, H; Hosaka, T; Hsu, YC; Ji, F; Nguyen, MH; Sezaki, H; Thuy, LTT; Tsai, YN; Tseng, CH | 1 |
| Feng, Y; Wen, Z; Yan, X | 1 |
| He, S; Xie, X; Yao, J; Yu, J; Yuan, G | 1 |
| Ahn, SH; Chang, JW; Hwang, SG; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Kweon, YO; Lee, HA; Lee, HW; Lee, JS; Lee, YR; Park, JY; Park, SY; Rim, KS; Seo, YS; Tak, WY; Um, SH | 1 |
| Cheng, HM; Cheung, KS; Lai, CL; Liu, SH; Mak, LY; Seto, WK; Yuen, MF | 1 |
| Chainuvati, S; Chotiyaputta, W; Kiattisunthorn, K; Poosanasuwansri, K; Tanwandee, T | 1 |
| Aspinall, AI; Barkema, HW; Borman, MA; Burak, KW; Castillo, E; Coffin, CS; Congly, SE; Israelson, H; Lee, SS; Martin, SR; Pinto, J; Sadler, MD; Samadi Kochaksaraei, G; Seow, CH; Shaheen, AA; Stinton, LM; Swain, MG; Williams, S | 1 |
| Chang, KC; Chen, CH; Chien, RN; Hu, TH; Hung, CH; Kee, KM; Lin, MC; Lin, MT; Lu, SN; Tseng, PL; Wang, JH; Yueh-Hsia Chiu, S | 1 |
| Abdel Alem, S; Atef, M; Hamed, M; Saber, M; Salama, R; Yosry, A; Yousof, H; Zayed, N | 1 |
| Abraham, P; Isaac, B; Ramamoorthy, H | 1 |
| Cloherty, G; Fung, J; Gersch, J; Mak, LY; Seto, WK; Wong, DK; Yuen, MF | 1 |
| Ostankova, YV; Semenov, AV; Serikova, EN; Totolian, AA; Zueva, EB | 1 |
| Liu, Y; Mo, Y; Wu, A | 1 |
| Cheng, CY; Cheng, SH; Ho, MW; Huang, SH; Huang, YS; Hung, CC; Lee, CH; Lee, YT; Lin, SP; Liou, BH; Liu, CE; Lu, PL; Sun, HY; Tang, HJ; Tsai, HC; Yang, CJ | 1 |
| Daugherty, T; Goel, A; Kim, WR; Kwo, PY; Kwong, A; Mannalithara, A; Sripongpun, P | 1 |
| Chang, JW; Kim, SU | 1 |
| Chen, ZM; Cui, GL; Ji, F; Li, GM; Li, J; Li, W; Li, ZQ; Liang, HX; Liu, YM; Lv, J; Pan, YJ; Sun, CY; Wang, FS; Xu, JH; Yu, ZJ; Zeng, QL; Zhang, DW; Zhang, GF | 1 |
| Chen, G; Chen, SH; Fu, YM; Ji, D; Li, L; Li, ZB; Liu, Y; Niu, XX; Shao, Q; Wang, CY | 1 |
| Lai, J; Li, J; Li, X; Peng, L; Shu, X; Xie, C; Xie, J; Xu, W; Zhang, Y; Zhu, X | 1 |
| Choi, J; Choi, WM; Han, S; Lim, YS; Wong, GL | 1 |
| Hsu, YC; Nguyen, MH; Tseng, CH | 1 |
| Chang, TS; Chen, WM; Hsieh, YY; Hung, CH; Lee, CP; Lu, SN; Shen, CH; Tsai, ML; Tung, SY; Yang, YH; Yen, CW | 1 |
| Pol, S | 1 |
| Ahn, SH; Cho, YK; Han, KH; Hong, GY; Jang, JY; Jung, YK; Kim, DJ; Kim, HS; Kim, JH; Kim, KH; Kim, MY; Kim, W; Kim, YJ; Kweon, YO; Lee, BS; Lee, JW; Lee, KS; Lee, WS; Lim, YS; Park, SJ; Sohn, JH; Song, DS; Um, SH; Yang, JM; Yim, HJ; Yoon, SK | 1 |
| Hu, C; Li, M; Liao, M; Liu, J; Song, Y; Tang, C; Zhang, YY; Zhou, F; Zhou, Y | 1 |
| Chan, HL | 1 |
| Bair, MJ; Chang, CY; Chang, IW; Chen, CC; Chen, CY; Chen, JJ; Hsu, YC; Huang, YT; Ku, WH; Lee, TY; Lin, JT; Mo, LR; Tai, CM; Tseng, CH; Wu, CY; Wu, MS | 1 |
| Ahn, CH; Cho, JY; Choo, SY; Dezhbord, M; Kim, DS; Kim, JC; Kim, KH; Kim, NY; Lee, AR; Lee, JH; Park, ES; Park, S; Shin, JJ; Won, J | 1 |
| Carrat, F; Fontaine, H; Luzivika Nzinga, C; Pol, S | 1 |
| Chen, R; Li, J; Li, L; Li, X; Liu, LM; Liu, Y; Shao, J; Xu, D; Zhao, L; Zhou, Y | 1 |
| Boglione, L; Cariti, G; Cusato, J; De Benedetto, I; Di Perri, G; Lupia, T | 1 |
| Adalı, G; Bahadır, Ö; Can, G; Değirmenci Saltürk, AG; Doğanay, HL; Gökçen, P; Güzelbulut, F; Özdil, K | 1 |
| Hao, FB; Peng, Y; Wang, CR; Wang, YQ; Yuan, J; Zhong, GC | 1 |
| Jain, MK; Kshirsagar, O; Niu, B; Thamer, M; Therapondos, G; Wong, RJ | 1 |
| Tseng, TC | 1 |
| Arai, T; Asai, A; Atsukawa, M; Cheung, R; Chien, N; Chuma, M; Dang, H; Fukunishi, S; Henry, L; Hoang, J; Huang, DQ; Ishikawa, T; Landis, C; Le, RH; Leong, J; Lim, SG; Liu, J; Maeda, M; Nguyen, MH; Quek, SXZ; Senoo, T; Takaguchi, K; Thin, KN; Toyoda, H; Tran, S; Trinh, HN; Uojima, H; Watanabe, T; Yasuda, S; Yokohama, K | 1 |
| Bai, L; Liu, H; M Ise, R; Shang, J; Tang, H; Tu, Y; Wen, Q | 1 |
| Bhan, AK; Chung, RT; Ghany, MG; Hinerman, AS; Jain, MK; Khalili, M; King, WC; Kleiner, DE; Lisker-Melman, M; Sterling, RK; Sulkowski, M; Wahed, AS; Wong, DK | 1 |
| Brahmania, M; Coffin, CS; Conway, B; Cooper, C; Doucette, K; Farag, MS; Fung, S; Hansen, BE; Haylock-Jacobs, S; Janssen, HLA; Ramji, A; Sebastiani, G; Tam, E; Tsoi, K; Wong, A; Wong, P | 1 |
| Chan, HL; Hui, VW; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Chen, X; Chen, Y; Dai, E; Duan, Z; Han, G; Jiang, H; Pan, CQ; Wang, Y; Zhang, H; Zhang, S; Zhang, X; Zhao, W; Zhu, B; Zou, H | 1 |
| Ahn, SH; Kim, BK; Kim, DY; Kim, SU; Lee, JH; Park, JY; Park, SY; Sinn, DH; Tak, WY | 1 |
| Gedik, H; Sonmezisik, M | 1 |
| Carrat, F; Lusivika Nzinga, C; Pol, S | 1 |
| Huang, R; Liu, J; Wang, J; Wu, C | 1 |
| Chen, R; Wang, JG; Wang, LC | 1 |
| Chang, KC; Chien, RN; Chiu, SY; Hu, TH | 1 |
| Choi, H; Seo, GH | 1 |
| Cho, Y; Jeong, S; Kim, W; Park, SM | 1 |
| Cho, S; Kim, GA; Kim, HJ; Ko, MJ; Lee, J; Lim, YS | 1 |
| Dubey, G; Jindal, A; Vyas, A | 1 |
| Byun, KS; Choi, J; Gwak, GY; Kim, JH; Kim, YJ; Kwon, SY; Lee, HC; Lee, YS; Lim, YS; Yoo, BC | 1 |
| Bae, SH; Brunetto, M; Çelen, MK; Chang, TT; Coffin, CS; Flaherty, JF; Gaggar, A; Gane, EJ; Mo, S; Nguyen, MH; Pan, CQ; Seto, WK; Tan, SK; Thompson, A | 1 |
| de Carvalho Santana, R; de Lourdes Candolo Martinelli, A; Dessordi, R; Guimarães, MP; Navarro, AM; Romão, EA; Watanabe, LM | 1 |
| Accarino, EV; Buti, M; Chen, CH; Cheung, KS; Cheung, R; Chuang, WL; Dai, CY; Enomoto, M; Hoang, J; Hsu, YC; Huang, CF; Huang, JF; Istratescu, D; Kozuka, R; Lee, DH; Liu, L; Nguyen, MH; Peng, CY; Preda, C; Riveiro-Barciela, M; Trinh, H; Tsai, PC; Wong, GL; Wong, VW; Wu, JL; Xie, Q; Yeh, ML; Yeo, YH; Yu, ML; Yuen, MF | 1 |
| Bhardwaj, N; Combet, C; Gaggar, A; Hedskog, C; Mo, H; Murray, KF; Podlaha, O; Svarovskaia, E; Zoulim, F | 1 |
| Sonneveld, MJ; van Erpecum, KJ | 1 |
| Ahn, SH; Jung, CY; Kim, BS; Kim, HW; Kim, SU | 1 |
| Iatan, I; Lee, TC; McDonald, EG | 1 |
| Abid, H; Abkari, ME; Adil, N; Aqodad, N; M'bodj, K | 1 |
| Bernstein, DE; Fried, MW; Lok, AS; Mospan, AR; Schiff, ER; Smith, CI; Trinh, HN; Zink, RC | 1 |
| Arai, T; Atsukawa, M; Cheung, R; Chuma, M; Dang, H; Enomoto, M; Fukunishi, S; Hsu, YC; Ishikawa, T; Jun, DW; Kawada, N; Maeda, M; Nguyen, MH; Nozaki, A; Ogawa, E; Takaguchi, K; Takahashi, H; Toyoda, H; Trinh, HN; Tseng, CH; Watanabe, T; Yasuda, S; Yokohama, K | 1 |
| Chen, XB; Liu, FF; Liu, JY; Shu, FL; Yang, JH | 1 |
| Chen, T; Chen, Y; Fu, M; Fu, S; Gao, Z; He, Y; Hu, C; Li, J; Liu, J; Yan, T; Yang, Y; Zhang, R; Zhao, Y; Zhou, M | 1 |
| Buti, M; Esteban, R; Marcos-Fosch, C | 1 |
| Choi, J; Kim, SU; Lee, SW; Lim, YS | 1 |
| Choe, WH; Kim, JH; Kwon, SY; Na, JH; Yoo, BC | 1 |
| Chien, RN; Jeng, WJ; Liaw, YF | 1 |
| Hsu, YC; Huang, YT; Lin, JT | 1 |
| Barnes, E; Campbell, C; Collier, J; Cripps, S; Davies, J; Freeman, O; Jeffery, K; Matthews, PC; McNaughton, AL; Mokaya, J; Noble, T; Salih, H; Smith, DA; Várnai, KA; Wang, T; Woods, K | 1 |
| Dai, Z; Lau, EHY; Peng, L; Wong, IOL; Xiang, Y; Xie, C; Xu, W | 1 |
| Chen, J; Chen, L; Gao, Y; Gong, Q; Han, Y; Jiang, J; Li, J; Liu, Y; Qu, L; She, W; Sun, X; Wei, D; Yu, D; Zhang, D; Zhang, J; Zhang, Q; Zhang, X | 1 |
| Adalı, G; Aslan, E; Can, G; Değirmenci Saltürk, AG; Doğanay, HL; Gökçen, P; Güzelbulut, F; Özdil, K | 1 |
| Chen, CH; Fang, HW; Hu, TH; Hung, CH; Lu, SN; Wang, JH; Yen, YH | 1 |
| Baek, SY; Choi, MS; Gwak, GY; Jang, HJ; Kang, WS; Kim, KA; Kim, YJ; Koh, KC; Lee, JH; Na, JE; Paik, SW; Paik, YH; Sinn, DH; Yoon, JH | 1 |
| Busca Arenzana, C; Daroca, G; Martin-Carbonero, L; Mican, R; Perez-Valero, I; Vasquez, J | 1 |
| Balkan, II; Erturk, US; Guney, B; Kacmaz, B; Mert, A; Mete, B; Ozaras, R; Saglam, O; Saltoglu, N; Sayman, OA; Tabak, F | 1 |
| Duan, M; Gu, Y; Li, B; Liu, D; Liu, Q; Liu, X; Liu, Z; Ma, Q; Wang, Y; Wei, Y | 1 |
| Chen, G; Gu, D; Huang, R; Jia, B; Liu, J; Liu, Y; Wang, J; Wu, C; Xiang, X; Yan, X; Yang, Y; Zhang, Z; Zhao, XA | 1 |
| Li, EM; Li, JQ; Lin, CS; Mei, YY; Mo, ZS; Xiao, LX; Xu, Z | 1 |
| Ahn, SH; Cho, YY; Kim, BK; Kim, DY; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Park, SY | 2 |
| Chen, FY; Cheng, Z; Huang, HH; Shi, KQ; Van Poucke, S; Zhang, MY; Zheng, JN; Zheng, MH; Zhu, GQ | 1 |
| Capobianchi, MR; D'Offizi, G; Menzo, S; Piselli, P; Solmone, M; Vincenti, D | 1 |
| Arends, P; Chen, L; Chi, H; de Knegt, RJ; Guo, Q; Guo, S; Hansen, BE; Janssen, HLA; Qi, X; Verhey, E; Wang, JY; Xie, Q; Zhang, NP | 1 |
| Cho, H; Kang, H; Lee, HH | 1 |
| An, J; Byun, KS; Choi, J; Gwak, GY; Kim, YJ; Kwon, SY; Lee, HC; Lee, YS; Lim, YS; Yoo, BC | 1 |
| Celià-Terrassa, T; Gregori, J; Kang, Y; Luedde, T; Ploss, A; Rodríguez-Frías, F; Shirvani-Dastgerdi, E; Tabernero, D; Tacke, F; Trautwein, C; Winer, BY; Yagmur, E | 1 |
| He, L; Jiang, Y; Liu, X; Wang, X; Yang, Z; Zhang, S; Zhao, Y | 1 |
| Huang, JR; Lian, JS; Liu, YY; Pan, LF; Yang, JL; Zhou, J | 1 |
| Karris, MY | 1 |
| Brouwer, WP | 1 |
| Acharya, SK; Agarwal, K; Chan, HL; Chen, CY; Chowdhury, A; Chuang, WL; Flaherty, JF; Fung, S; Gaggar, A; Gane, E; Hui, AJ; Janssen, HL; Kim, HJ; Kitrinos, KM; Lim, YS; Lin, L; Massetto, B; McHutchison, JG; Mehta, R; Seto, WK; Subramanian, GM; Tsang, TY | 1 |
| Acharya, SK; Brunetto, M; Buti, M; Cathcart, AL; Chan, HL; Chuang, WL; Flaherty, JF; Gaggar, A; Gane, E; Hui, AJ; Izumi, N; Janssen, HL; Kim, K; Lim, YS; Marcellin, P; Massetto, B; McHutchison, JG; Mehta, R; Pan, CQ; Seto, WK; Stepanova, T; Subramanian, GM | 1 |
| Perricone, G; Pungolino, E; Vinci, M | 1 |
| Ahn, SH; Han, KH; Hwang, SG; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Park, JY; Rim, KS | 1 |
| Chamroonkul, N; Piratvisuth, T | 1 |
| Cheon, GJ; Don Kim, Y; Jang, JY; Jeong, SW; Jun, BG; Jun, DW; Kim, BS; Kim, HS; Kim, SG; Kim, TY; Kim, YS; Lee, BS; Lee, SH; Sohn, JH | 1 |
| Byun, KS; Hyun, MH; Je, JH; Kim, JH; Lee, YS; Yeon, JE; Yoo, YJ | 1 |
| Abdul Basit, S; Dawood, A; Gish, R; Ryan, J | 1 |
| Choe, WH; Kim, JH; Ko, SY; Kwon, SY; Lee, HA; Seo, HY; Wang, JH | 1 |
| Chan, HLY; Scott, LJ | 1 |
| Liu, CJ; Su, TH | 1 |
| Abdul Hafidz, MI; Lee, YY; Tan, SS | 1 |
| Hu, C; Huang, H; Li, Y; Liu, J; Yang, D; Yuan, G; Zhang, YY; Zhou, F; Zhou, Y | 1 |
| Beuers, U; de Niet, A; Jansen, L; Koot, M; Kuiken, SD; Molenkamp, R; Reesink, HW; Stelma, F; Takkenberg, RB; van Nieuwkerk, CMJ; Verheij, J; Weijer, S; Willemse, SB; Zaaijer, HL | 1 |
| Berg, T; Buti, M; Calleja, JL; Chi, H; Colombo, M; Dalekos, GN; de la Revilla, J; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HLA; Keskın, O; Kourikou, A; Lampertico, P; Lehretz, M; Loglio, A; Manolakopoulos, S; Papatheodoridis, GV; Savvidou, S; Siakavellas, S; Sypsa, V; van Boemmel, F; Vlachogiannakos, I; Yurdaydin, C | 1 |
| Aberra, H; Berhe, N; Desalegn, H; Gundersen, SG; Johannessen, A; Medhin, G; Stene-Johansen, K | 1 |
| Ahn, SH; Han, KH; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Park, J; Park, JY | 1 |
| Heo, NY | 1 |
| Ahn, JS; Jeon, HJ; Jung, SW; Kim, HR; Lee, JH; Noh, JH; Park, NH; Shin, JW; Yang, Y | 1 |
| Cho, HJ; Yoo, EH | 1 |
| AlMattooq, M; Borman, MA; Burak, KW; Coffin, CS; Congly, SE; Lee, SS; Myers, RP; Shaheen, AA; Swain, MG; Yazdanfar, S | 1 |
| Chan, HL; Chan, RS; Chim, AM; Hui, AJ; Lo, AO; Wong, GL; Wong, VW | 1 |
| Aggeletopoulou, I; Anastassiou, ED; Assimakopoulos, S; Gogos, C; Kalafateli, M; Labropoulou-Karatza, C; Mandellou, M; Taprantzi, D; Thomopoulos, K; Triantos, C; Tselekouni, P; Tsiaoussis, G; Vourli, G | 1 |
| Akinci, E; Alpat, SN; Ari, A; Gunal, O; Guner, R; Kayaaslan, B; Tabak, F; Tosun, S; Tufan, ZK | 1 |
| Byun, KS; Hyun, MH; Kim, JH; Lee, YS; Yeon, JE | 1 |
| Ahir, BK; Li, LQ; Wu, GB; Zhang, CY; Zhong, JH | 1 |
| Chen, J; Huang, Y; Huang, ZB; Liu, XX; Zhao, SS | 1 |
| Bang, SJ; Du Jeong, I; Jung, SW; Kim, BG; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW | 1 |
| Al-Mattooq, M; Borman, MA; Burak, KW; Coffin, CS; Congly, SE; Lee, SS; Myers, RP; Shaheen, AA; Swain, MG; Yazdanfar, S | 1 |
| Huang, R; Wang, J; Wu, C; Xia, J; Yan, X | 1 |
| Cathcart, AL; Delaney, WE; Kitrinos, KM; Liu, Y | 1 |
| Lee, JH; Lee, YB | 1 |
| Hsu, YC; Nguyen, MH; Wei, MT | 1 |
| Ferrara, SM; Santantonio, T; Sica, S; Tartaglia, A | 1 |
| Chen, S; Huang, J; Huang, Y; Li, G; Qiu, C; Shen, C; Wang, B; Wang, J; Wang, X; Yu, Y; Zhang, J; Zhang, W; Zhao, C | 1 |
| Wang, Y; Zhao, LF | 1 |
| Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Park, JY; Song, JE | 1 |
| Chun, JM; Han, YS; Hur, K; Jang, SY; Kang, MK; Kweon, YO; Lee, HJ; Lee, HW; Lee, YR; Park, JG; Park, SY; Tak, WY | 1 |
| Antinori, S; Binda, F; Cannizzo, ES; Cazzaniga, FA; d'Arminio Monforte, A; Marchetti, G; Milazzo, L; Ronzi, P; Tincati, C | 1 |
| Cho, JH; Choi, SW; Chun, DI; Kwon, SH; Lee, HW; Nho, JH; Suh, YS; Won, SH | 1 |
| Blanco, MÁ; Bonet, ML; Calleja, JL; Casado, MÁ; Fraga, E; Fuentes, J; García-Buey, ML; González, JM; Jorquera, F; Molina, E; Pascasio, JM; Pons, JA; Prieto, M; Rodríguez, M; Salmerón, J; Sánchez-Antolín, G | 1 |
| Buti, M; Esteban, R; Riveiro-Barciela, M | 2 |
| Furusyo, N; Nguyen, MH; Ogawa, E | 1 |
| Jang, JW; Kim, H; Kim, YH; Kwon, JH; Lee, JY; Nam, SW | 1 |
| El-Serag, HB; Ho, HJ; Hsu, YC; Huang, YT; Lee, TY; Lin, JT; Wu, CY; Wu, MS | 1 |
| Choe, BH; Choe, JY; Kang, B; Kim, JE; Ko, JS; Lee, KJ; Yang, HR | 1 |
| Chen, CH; Hsu, YC; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH | 1 |
| Iio, E; Inoue, T; Kumada, T; Matsunami, K; Murakami, S; Nojima, M; Ogawa, S; Shinkai, N; Tanaka, Y; Toyoda, H | 1 |
| Chen, CL; Chen, DS; Chen, PJ; Kao, JH; Liou, JM; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC | 1 |
| Becht, E; Bertoletti, A; Cheng, Y; Foster, GR; Gill, US; Hansi, NK; Kao, JH; Kennedy, PT; Kunasegaran, K; Le Bert, N; Lim, SG; Newell, EW; Rivino, L; Su, TH; Tan, DZ; Tseng, TC | 1 |
| Angeli, P; Fasolato, S; Gambino, C; Mareso, S; Piano, S; Pilutti, C; Pontisso, P; Romano, A; Sartori, L; Stanco, M; Tonon, M | 1 |
| Ahn, H; Chang, Y; Cho, EJ; Cho, H; Cho, YY; Jung, YJ; Kim, YJ; Lee, DH; Lee, JH; Lee, JM; Nam, JY; Yoon, JH; Yu, SJ | 1 |
| Grossi, G; Lampertico, P; Loglio, A; Viganò, M | 2 |
| Buti-Ferret, M; Edwards, R; Gaggar, A; Gane, E; Jackson, K; Janssen, H; Kitrinos, K; Littlejohn, M; Locarnini, S; Marcellin, P; Revill, P; Subramanian, M; Thompson, A; Wong, D | 1 |
| Gadano, A; Marciano, S | 1 |
| Berg, T; Buti, M; Calleja, JL; Chi, H; Colombo, M; Dalekos, G; de la Revilla, J; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HLA; Keskın, O; Kourikou, A; Lampertico, P; Lehretz, M; Loglio, A; Manolakopoulos, S; Papatheodoridis, GV; Savvidou, S; Siakavellas, S; Sypsa, V; van Boemmel, F; Vlachogiannakos, I; Yurdaydin, C | 1 |
| Baymbajav, B; Cha, SW; Cho, YD; Jang, JY; Jeong, SW; Jung, WJ; Kim, BS; Kim, HS; Kim, SG; Kim, YS; Lee, HJ; Lee, SH; Park, S; Park, SJ; Park, WY | 1 |
| Chang, KC; Chen, CH; Chou, YP; Hu, TH; Hung, CH; Kuo, MT; Kuo, YH; Lu, SN; Tsai, MC; Tseng, PL; Wang, JH | 1 |
| El-Serag, HB; Ho, HJ; Hsu, YC; Huang, YT; Lee, TY; Lin, JT; Wong, GL; Wong, VW; Wu, CY; Wu, MS; Yip, TC | 1 |
| Dickson, I | 1 |
| Hu, YK; Huang, YX; Jin, JL; Ying, Y; Zhang, JM; Zhang, WH | 1 |
| Kang, MK; Park, JG | 1 |
| Li, YH; Wan, YM; Wu, HM; Wu, XN; Xu, Y; Xu, ZY; Yang, JH | 1 |
| Brahmania, M; Gomes, T; Janssen, HLA; Juurlink, DN; Knowles, S; Mamdani, MM; Martins, D; Tadrous, M | 1 |
| Chen, YL; Dai, L; Li, QH; Lin, JZ; Ma, JD; Mo, YQ; Wang, XY; Yan, T; Yang, ZH; Zheng, DH | 1 |
| Chan, HL; Lam, KL; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 2 |
| Agarwal, K; Ahn, SH; Andreone, P; Bulusu, A; Cathcart, AL; Chuang, WL; Elkhashab, M; Gaggar, A; Kim, HJ; Lau, AH; Nguyen, MH; Subramanian, GM; Tian, X; Woo, J | 1 |
| Calinas, F; Costa, MN; Germano, I; Loureiro, RV | 1 |
| Cornberg, M; Crabé, S; Gineste, P; Höner Zu Siederdissen, C; Hui, AJ; Manns, MP; Nieto, GEG; Nitcheu, J; Stepien, S; Su, WW; Sukeepaisarnjaroen, W; Tangkijvanich, P; Trépo, C; Wedemeyer, H | 1 |
| Harrison, L; Jourdain, G; Ngo-Giang-Huong, N | 1 |
| Feld, JJ; Lok, ASF; Terrault, NA | 1 |
| Gerlich, W; Glebe, D | 1 |
| Cheung, KW; Ng, EHY; Seto, MTY | 1 |
| Bae, SH; Chang, UI; Choi, JY; Jang, BH; Jang, JW; Jo, SH; Kim, CW; Kim, HJ; Kim, HY; Kim, JH; Kim, SJ; Kwon, JH; Lee, HL; Lee, HS; Lee, J; Lee, Y; Park, CH; Park, IY; Seo, KI; Sung, PS; Tekle, F; Yoon, SK | 1 |
| Asci, Z; Demir, LS; Demir, NA; Kolgelier, S; Ozcimen, S; Sumer, S; Ural, O | 1 |
| Kaplan, D | 1 |
| Henry, L; Le, A; Lee, MH; Nguyen, MH; Nguyen, N; Trinh, H; Wong, C; Yang, HI; Zhang, J | 1 |
| Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Lee, BU; Lee, H; Lee, SB; Park, JH; Park, NH; Shin, JW | 1 |
| Caviglia, GP; Ngatchou, D; Olivero, A; Saracco, GM; Smedile, A | 1 |
| Dalekos, GN; Gatselis, N; Hadziyannis, E; Manolakopoulos, S; Papatheodoridi, M; Papatheodoridis, GV; Rigopoulou, EI; Vlachogiannakos, J; Xourafas, V; Zachou, K | 1 |
| Jia, L; Li, W; Tang, H; Wu, X; Zhao, X | 1 |
| Chan, HL; Lam, KL; Lui, GC; Szeto, CC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Chang, ET; Cheung, R; Chung, M; Henry, L; Hoang, J; Jeong, D; Le, AK; Lee, MH; Nguyen, MH; Trinh, S; Wang, U | 1 |
| Ahn, SH; Buti, M; Caruntu, FA; Chan, A; Chan, HLY; Chuang, WL; Crans, G; Elkhashab, M; Flisiak, R; Fung, S; Gaeta, GB; Guyer, W; Hui, AJ; Jump, B; Ma, X; Marcellin, P; Mehta, R; Papatheodoridis, G; Petersen, J; Subramanian, M; Tabak, F; Tak, WY | 1 |
| Alam, S; Khanna, R; Lal, BB; Rawat, D; Sood, V; Verma, S | 1 |
| Chen, CL; Chen, NC; Chung, TL | 1 |
| Anong, DN; Bolimo, AF; Georges, TD; Kouanou, YS; Kwenti, TE; Maurice, M; Meriki, HD; Nkuo-Akenji, T; Tony, NJ; Tufon, KA; Wung, NH | 1 |
| Goyal, A; Romero-Severson, EO | 1 |
| Flemming, JA; Terrault, NA | 1 |
| Cho, S; Choi, J; Kim, HJ; Ko, MJ; Lee, J; Lim, YS | 1 |
| Achalapong, J; Chinwong, D; Cressey, TR; Decker, L; Harrison, L; Jourdain, G; Kanjanavikai, P; Liampongsabuddhi, P; Murphy, TV; Ngo-Giang-Huong, N; Patamasingh Na Ayudhaya, O; Putiyanun, C; Salvadori, N; Siberry, GK; Siriwachirachai, T; Suriyachai, P; Tawon, Y; Tierney, C | 1 |
| Balkan, A; Gülşen, MT; Karaoğlan, İ; Namıduru, M; Şahin, A | 1 |
| Aziz, H; Aziz, M; Gill, ML; Waheed, Y | 1 |
| Cui, F; Ding, Y; Dou, X; Duan, Z; Han, G; Hou, J; Jia, J; Li, J; Li, Z; Liu, Z; Mao, Q; Wei, L; Xie, Q; Yang, X; Zhang, H; Zhuang, H | 1 |
| Bai, G; Chen, D; Ding, G; Lin, Y; Liu, K; Liu, Y; Touqui, L; Wang, W; Wu, Y; Xu, N; Zhang, L | 1 |
| Ahmed, A; Kim, D; Kim, WR; Udompap, P | 1 |
| Li, YH; Wan, YM; Wu, HM; Wu, XN; Xu, Y; Xu, ZY | 1 |
| Ahn, SH; Han, KH; Jeon, MY; Kim, BK; Kim, DS; Kim, DY; Kim, SU; Lee, HW; Park, JY | 1 |
| Cabeza-Barrera, I; Cabezas-Fernández, MT; Cuenca-Gómez, JÁ; Estévez-Escobar, M; Lozano-Serrano, AB; Salas-Coronas, J; Soriano-Pérez, MJ; Vázquez-Villegas, J | 1 |
| Ahn, SH; Cho, YK; Choi, W; Han, KH; Hong, GY; Jang, JY; Jin, SY; Jung, YK; Kim, DJ; Kim, HS; Kim, JH; Kim, KH; Kim, MY; Kim, W; Kim, YJ; Kweon, YO; Lee, BS; Lee, JW; Lee, KS; Lee, WS; Lim, YS; Park, NH; Park, SJ; Sohn, JH; Um, SH; Yang, JM; Yim, HJ; Yoon, SK | 1 |
| Chang, CY; Chen, CC; Hsu, YC; Lin, JT; Mo, LR; Nguyen, MH; Tai, CM; Tanaka, Y; Tseng, CH; Wu, CY; Wu, MS; Yang, TH | 1 |
| Chen, CH; Hu, TH; Hung, CH; Kuo, MT; Lu, SN; Tsai, KL; Wang, JH | 1 |
| Szeto, CC; Wong, GL; Wong, VW | 1 |
| Ni, W; Wang, J; Wu, Z; Xin, H | 1 |
| Della Pepa, R; Di Perna, M; Giordano, A; Giordano, C; Lucignano, M; Mortaruolo, C; Pane, F; Picardi, M; Pugliese, N; Raimondo, M; Salvatore, C; Trastulli, F; Zacheo, I | 1 |
| Aberra, H; Berhe, N; Desalegn, H; Gundersen, SG; Johannessen, A; Krarup, H; Mekasha, B; Pereira, AP; Stene-Johansen, K | 1 |
| McCormick, CA; McCormick, PA | 1 |
| Ahn, A; Bae, HS; Chang, M; Fong, TL; Lee, BT; Lim, C; Tien, A | 1 |
| Cai, LR; Chen, FS; Huang, Q; Li, DL; Li, YH; Wu, HC; Wu, ZX; Zeng, ZY; Zhang, SA; Zhou, XL | 1 |
| Cai, D; Dang, S; Jiang, N; Li, J; Lin, F; Pan, C; Ren, H; Shen, B; Wang, M; Wu, S; Xin, S; Yang, Y; Yu, W; Zhang, Z | 1 |
| Ahn, SH; Han, KH; Kim, BK; Kim, CW; Kim, YS; Lee, HW; Lee, JI; Lee, JW; Paik, SK; Park, H; Park, JY; Yoon, KT | 1 |
| Lee, JW; Yu, JH | 1 |
| An, HY; Heo, NY; Jang, JW; Jin, YJ; Lee, JW; Suh, YJ; You, CR; Yu, JH | 1 |
| Bae, SH; Chang, UI; Cho, EY; Choi, JY; Choi, SW; Han, NI; Jang, JW; Kim, CW; Kim, HY; Kim, SG; Kim, SH; Kim, YS; Kwon, JH; Lee, BS; Lee, HL; Lee, SW; Lee, TH; Nam, SW; Song, DS; Song, MJ; Yang, JM; Yoon, SK; You, CR | 1 |
| Liang, LY; Wong, GL | 1 |
| Güner, R; Koçak Tufan, Z; Mehmet A, T; Yılmaz, GR | 1 |
| Chang, MS; Cheung, R; Hsu, H; Le, AK; Nguyen, MH; Nguyen, P; Wei, MT; Wong, C; Zhang, JQ | 1 |
| Ahn, SH; An, Y; Chae, HB; Choi, BS; Ha, YN; Jeong, N; Ju, YS; Kang, HS; Kim, DH; Kim, KH; Kim, YJ; Kwon, SY; Lee, AR; Lee, JH; Lee, YB; Park, ES; Park, S; Park, YK; Shin, GC; Sim, H; Won, J; Yoo, JJ; Yoon, JH; Yu, KS; Yu, SJ; Zoulim, F | 1 |
| Buti, M; Crans, G; Flaherty, J; Flisiak, R; Gaggar, A; Gane, E; Janssen, HLA; Jump, B; Kaita, K; Kitrinos, K; Manns, M; Marcellin, P; Op den Brouw, M; Wong, DK | 1 |
| Chan, HL; Wong, GL; Wong, VW | 1 |
| Huang, R; Wang, J; Wu, C; Wu, W; Yao, R | 1 |
| Chen, CH | 1 |
| Acerbi, G; Ahn, SH; Alfieri, A; Andreone, P; Barili, V; Boni, C; Brillo, F; Brunetto, MR; Cavallone, D; Coco, B; Cursaro, C; Ferrari, C; Fisicaro, P; Fung, S; Gaggar, A; Janssen, HLA; Joshi, A; Laccabue, D; Lau, AH; Ma, X; Mangia, A; Margotti, M; Massetto, B; Pedrazzi, G; Piazzolla, V; Rodell, TC; Rossi, M; Santoro, R; Subramanian, GM; Trinh, H; Vecchi, A; Woo, J; Yoon, SK; Yoshida, EM; Zhao, Y | 1 |
| Ahn, SH; Han, KH; Hwang, SG; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Kweon, YO; Lee, HA; Lee, HW; Lee, YR; Park, JY; Park, SY; Rim, KS; Seo, YS; Tak, WY; Um, SH | 1 |
| Atalay, S; Köse, Ş; Tatli Kiş, T | 1 |
| Aguilera, A; Barea, L; Corral, O; Gomez-Gallego, F; Gonzalez, R; Soriano, V; Treviño, M | 1 |
| Hiraoka, A; Izumoto, H; Kitahata, S; Kondoh, K; Michitaka, K; Ninomiya, T; Tsubouchi, E; Ueki, H; Yamago, H | 1 |
| Chen, C; Chen, S; Cheng, J; Gao, Z; Hou, J; Jia, J; Li, J; Liang, X; Mao, Q; Mao, Y; Ning, Q; Niu, J; Pan, C; Ren, H; Sheng, J; Tan, D; Tang, H; Wang, H; Wu, S; Xie, Q; Xiong, C; Xu, M; Zhang, J; Zhang, W; Zhang, X; Zhao, W | 1 |
| Allavena, C; Bani-Sadr, F; Cabié, A; Chéret, A; Cotte, L; Delobel, P; Duvivier, C; Gantner, P; Huleux, T; Jacomet, C; Joly, V; Pugliese, P; Rey, D; Valantin, MA | 1 |
| Jia, J; Kong, Y; Yang, HI | 1 |
| Choi, J; Ko, MJ; Lim, YS | 1 |
| Hou, J; Liu, Z; Sun, J | 1 |
| Zeng, W; Zhang, H | 1 |
| Gao, ZL; Hu, ZX; Liang, XJ; Peng, L; Wu, QW; Wu, WG; Xie, C; Ye, YN; Zhang, A; Zheng, XR | 1 |
| Chang, Y; Cho, EJ; Cho, H; Cho, YY; Kim, YJ; Lee, JH; Nam, JY; Yoon, JH; Yu, SJ | 1 |
| Belle, SH; Bzowej, NH; Chung, R; Khalili, M; Li, R; Smith, CI; Terrault, N; Tran, TT; Tsai, N | 1 |
| Aberra, H; Berhe, N; Desalegn, H; Gundersen, SG; Johannessen, A; Medhin, G; Mekasha, B | 1 |
| Abdurakhmanov, DT; Ibragimov, EK; Moiseev, SV; Nikulkina, EN; Odintsov, AV; Panevkina, SV; Rozina, TP; Tanaschuk, EL | 1 |
| Buggisch, P; Buti, M; Cathcart, AL; Crans, G; Flaherty, J; Flisiak, R; Gaggar, A; Jump, B; Kaita, K; Krastev, Z; Lee, SS; Manns, M; Marcellin, P; Op den Brouw, M; Petersen, J; Sievert, W; Wong, DK | 1 |
| Hu, K; Huang, Y; Yang, J; Zhang, Z; Zhou, Y | 1 |
| Chen, X; Liu, L; Wei, M; Xu, T; Xu, Z; Zhang, C; Zhang, X | 1 |
| Fujii, T; Kawasoe, K; Nitta, K; Ohta, A | 1 |
| Dang, Z; Jiang, Y; Liu, X; Wang, X; Yan, Z; Yu, L | 1 |
| Chang, SY; Chen, GJ; Cheng, A; Chuang, YC; Huang, SH; Huang, YC; Huang, YS; Hung, CC; Lin, KY; Liu, WC; Su, YC; Sun, HY | 1 |
| Hagiwara, S; Ida, H; Komeda, Y; Kudo, M; Minami, Y; Nishida, N; Takita, M; Ueshima, K | 1 |
| Lampertico, P; Wong, GL | 1 |
| Ji, J; Jia, Y; Shen, Y; Xun, P; Zhou, J | 1 |
| Andersson, M; Barnes, EJ; Burn, EAO; Goedhals, D; Matthews, PC; Mokaya, J; Pinedo-Villanueva, R; Tamandjou, CR | 1 |
| Ahn, SH; Han, KH; Hwang, SG; Kim, BK; Kim, DY; Kim, EH; Kim, HY; Kim, MN; Kim, SU; Kweon, YO; Lee, HA; Lee, HW; Lee, YR; Park, JY; Park, SY; Rim, KS; Seo, YS; Tak, WY; Um, SH | 1 |
| Wyles, DL | 1 |
| Lopatin, U | 1 |
| Kim, WR; Kwo, PY; Mannalithara, A; Sripongpun, P | 1 |
| Chan, TM; Fung, J; Lai, CL; Liu, SH; Mak, LY; Seto, WK; Wong, DK; Yap, DY; Yuen, MF | 1 |
| Bertoletti, A; Borghi, M; Ceriotti, F; Ferenci, P; Giovanelli, S; Greco, L; Holzmann, H; Lampertico, P; Loglio, A; Lunghi, G; Perbellini, R; Porretti, L; Prati, D; Tham, CYL; Trombetta, E; Uceda Renteria, SC; van Bömmel, F | 1 |
| Ceriotti, F; Colombo, M; Cortinovis, I; Facchetti, F; Iavarone, M; Lampertico, P; Loglio, A; Lunghi, G; Occhipinti, V; Orenti, A; Rumi, M; Sangiovanni, A; Viganò, M | 1 |
| Choi, J; Lim, YS | 1 |
| Huang, R; Wang, J; Wu, C; Wu, W; Yan, X | 1 |
| Cloherty, G; Deerain, J; Gaggar, A; Hammond, R; Kitrinos, K; Leary, T; Locarnini, S; O'Donnell, T; Subramanian, M; Walsh, R; Wong, D; Yuen, L | 1 |
| Fan, L; Fan, Y; Jing, H; Li, C; Ma, B; Zhou, S | 1 |
| Bzowej, N; Dinh, P; Flaherty, J; Martin, P; Poordad, F; Pungpapong, S; Rossi, S; Schiano, T; Spivey, J; Subramanian, GM; Teperman, LW | 1 |
| Bonino, F; Brunetto, MR; Caputo, A; Coco, B; Espinos, B; Iannazzo, S; Latour, A; Rossetti, F | 1 |
| Acurcio, Fde A; Almeida, AM; Andrade, EI; Araújo de Oliveira, GL; Brandão, CM; Carmo, RA; Cherchiglia, ML; Silva, AL | 1 |
| Amarapurkar, DN; Patel, N | 1 |
| Lee, WM; Tujios, SR | 2 |
| Acalovschi, M; Arama, V; Bjork, S; Kamar, D; Klauck, I; Leblebicioglu, H; Lescrauwaet, B; Marcellin, P; Mauss, S; Morais, E; Sieklucki, J; Simon, K; Usluer, G; Zarski, JP; Zeuzem, S | 1 |
| Costa, JB; Ferreira, AO; Marinho, RT; Velosa, J | 1 |
| Aguilera, A; Barreiro, P; del Romero, J; Mena, A; Pedreira, J; Plaza, Z; Poveda, E; Rodriguez, C; Sierra-Enguita, R; Soriano, V; Tomé, S; Vispo, E | 1 |
| Fontana, RJ; Kuo, YF; Salameh, H; Singal, AK | 1 |
| Al Hawajri, N; Borroto-Esoda, K; Dény, P; Kitrinos, K; Lavocat, F; Pichoud, C; Zoulim, F | 1 |
| Fung, J; Huang, FY; Hung, IF; Lai, CL; Liu, K; Seto, WK; Wong, DK; Yuen, MF | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Baxter, C; Tshabalala, P; Yende-Zuma, N | 1 |
| Gracey, DM; McKenzie, P; Snelling, P; Strasser, SI | 1 |
| Horváth, G | 1 |
| Braat, AE; Claas, EC; Coenraad, MJ; Knoester, M; van Hoek, B; Vossen, AC; Wesdorp, DJ | 1 |
| Asselah, T; Marcellin, P | 1 |
| Barreiro, P; Poveda, E; Soriano, V; Vispo, E | 1 |
| Šperl, J | 1 |
| Bailly, F; Brochier, C; Cotte, L; Le Pogam, MA; Maynard, M; Miailhes, P; Okon, JB; Pradat, P; Trolliet, P; Zoulim, F | 1 |
| Buğdacı, MS; Sayan, M | 1 |
| Dixit, VK; Jain, AK; Rungta, S; Shukla, SK; Singh, TB; Srivastava, M | 1 |
| Chi, X; Hu, X; Lian, Z; Lv, J; Niu, J; Pan, Y; Sun, H; Tu, Z; Xu, D; Yan, H | 1 |
| Akkoyunlu, Y; Ceylan, B; Eren, G; Fincanci, M; Muderrisoglu, C; Tozalgan, U; Yardimci, C | 1 |
| Hwang, SG; Yim, HJ | 1 |
| Lilly, LB; Renner, EL; Selzner, N; Tanaka, T; Therapondos, G | 1 |
| Berg, T; Chan, S; Dinh, P; Flaherty, JF; Kitrinos, KM; Manns, M; Marcellin, P; McHutchison, JG; Moeller, B; Trinh, H; Zoulim, F | 1 |
| Cholongitas, E; Papatheodoridis, G; Pipili, C | 1 |
| Arama, V; Bjork, S; Bludzin, W; Habersetzer, F; Jinga, M; Kamar, D; Klauck, I; Leblebicioglu, H; Lescrauwaet, B; Morais, E; Niederau, C; Simon, K; Ulusoy, S; Vermehren, J; Zarski, JP; Zeuzem, S | 1 |
| Acurcio, Fde A; Almeida, AM; Andrade, EI; Brandão, CM; Cherchiglia, ML; Oliveira, GL; Silva, AL | 1 |
| Caruntu, FA; Corsa, A; Dinh, P; Fabri, M; Flaherty, JF; Fung, S; Gane, E; Gurel, S; Hann, HW; Horban, A; Husa, P; Kwan, P; Massetto, B; McHutchison, JG; Pelemis, M; Subramanian, GM | 1 |
| Fung, J; Lai, CL; Seto, WK; Yuen, MF | 1 |
| Buti, M | 2 |
| Lampertico, P; Mangia, G; Viganò, M | 1 |
| Colombo, M; Della Corte, C; Triolo, M | 1 |
| Esteban, R; Pérez-Cameo, C; Pons, M | 1 |
| Gao, L; Li, J; Nguyen, MH; Trinh, HN | 3 |
| Boswell, S; Crane, HM; Eron, JJ; Geng, E; Kim, HN; Kitahata, MM; Martin, J; Mathews, WC; Moore, R; Mugavero, M; Overton, ET; Rodriguez, B; Rodriguez, CV; Saag, MS; Thio, CL; Van Rompaey, S | 1 |
| Byun, KS; Choe, WH; Kim, JH; Kim, YS; Kwon, SY; Lee, CH; Lee, CI; Yeon, JE; Yoon, EL | 1 |
| Akyüz, F; Badur, S; Baran, B; Bozdayi, AM; Idilman, R; Kabaçam, G; Karatayli, E; Karatayli, S; Kaymakoglu, S; Keskin, O; Onel, D; Ormeci, AC; Tüzün, A; Yurdaydin, C | 1 |
| Becker, C; Hamnvik, OP; Vaidya, A | 1 |
| Price, J | 1 |
| Bielawski, KP; Dreczewski, M; Rybicka, M; Smiatacz, T; Stalke, P; Stracewska, E; Wróblewska, A | 1 |
| Strasser, SI | 1 |
| Bae, H; Chan, S; Lou, L; Pan, CQ; Trinh, H; Yao, A | 2 |
| Boyd, A; Delaugerre, C; Girard, PM; Gozlan, J; Lacombe, K; Maylin, S; Simon, F | 1 |
| Gervain, J; Horváth, G; Hunyady, B; Lengyel, G; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I | 1 |
| Chatterjee, U; Davison, S; Glass, A; Greenup, AJ; Holdaway, S; Jackson, K; Levy, MT; Locarnini, SA; Nguyen, V; Samarasinghe, D; Strasser, SI; Tan, PK | 1 |
| Bradshaw, D; Danta, M | 1 |
| Chaikledkaew, U; Tantai, N; Tanwandee, T; Teerawattananon, Y; Werayingyong, P | 1 |
| Gupta, E; Hissar, SS; Sarin, SK; Sharma, MK; Singh, AK | 1 |
| Boyd, A; Delaugerre, C; Girard, PM; Gozlan, J; Lacombe, K; Maylin, S; Peytavin, G; Zoulim, F | 1 |
| Lee, SS; Sadler, MD | 1 |
| Chang, HY; Kim, HJ; Lee, HW; Yang, SY | 1 |
| Dinh, P; Flaherty, JF; Fung, S; Gane, EJ; Kitrinos, KM; Liu, Y; Miller, MD; Svarovskaia, ES | 1 |
| Cainelli, F; Comparcola, D; Della Corte, C; Nobili, V; Vento, S | 1 |
| Tang, CM; Yau, TO; Yu, J | 1 |
| Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F | 1 |
| De Vincentis, A; Dell'Unto, C; Galati, G; Gallo, P; Picardi, A; Solmone, MC; Vespasiani-Gentilucci, U; Vincenti, D | 1 |
| Cagatay, A; Ceylan, B; Erdem, L; Gokturk, K; Gunduz, A; Karaosmanoglu, H; Kocak, F; Mete, B; Ozaras, R; Ozgunes, N; Senates, E; Tabak, F | 1 |
| Gao, Y; Ke, W; Liu, L; Yang, Y; Ye, X; Zhang, C; Zhou, S | 1 |
| Akriviadis, E; Antoniadis, N; Cholongitas, E; Fouzas, I; Goulis, I; Imvrios, G; Papanikolaou, V | 1 |
| Kim, JH; Kim, KH; Park, ES; Park, YK | 1 |
| Corsa, AC; Flaherty, JF; Fung, SK; Gane, E; Kitrinos, KM; Liu, Y; Miller, MD; Mitchell, B | 1 |
| Ridruejo, E | 1 |
| Panda, C | 1 |
| Kekez, AJ | 1 |
| Dinçkan, A; Ersoy, F; Koçak, H; Ruhi, Ç; Süleymanlar, G; Süleymanlar, İ | 1 |
| Berg, T; van Bömmel, F | 1 |
| Gerlich, WH | 1 |
| Locarnini, S; Warner, N | 1 |
| Gürtler, LG | 1 |
| Beggel, B; Kaiser, R; Neumann-Fraune, M; Obermeier, M | 1 |
| Buti, M; de Man, RA; Dinh, P; Dusheiko, GM; Flaherty, JF; Flisiak, R; Gaggar, A; Gurel, S; Heathcote, EJ; Krastev, Z; Lin, L; Lou, L; Marcellin, P; Massetto, B; McHutchison, JG; Subramanian, GM; Zeuzem, S | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Mineta, R; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Watahiki, S | 1 |
| Afdhal, NH; Bonder, A; Lau, D; Patwardhan, VR; Sengupta, N | 1 |
| Shan, C; Wu, P; Yin, GQ | 1 |
| Ahn, H; Cho, EJ; Cho, H; Cho, Y; Cho, YY; Choi, WM; Kim, CY; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Yoo, JJ; Yoon, JH; Yu, SJ | 1 |
| Al-Shamma, S; Barr, DA; Burke, K; Foster, GR; Gill, US; Kallis, YN; Kennedy, PT; Kooner, P; Marley, RT; McPhail, MJ; Zissimopoulos, A | 1 |
| Ao, Y; Chong, Y; Huang, M; Jie, Y; Li, X; Lin, G; Pang, Y; Shi, H; Tao, L; Wu, Y; Yang, F; Zhang, M | 1 |
| Brunetto, M; Carosi, G; Greenbloom, S; Jeffers, L; Llamoso, C; Mazur, W; Nguyen, T; Yu, S; Zoulim, F | 1 |
| Buti, M; Chan, S; Charuworn, P; Dinh, P; Flaherty, JF; Gane, E; Kitrinos, KM; Lee, SS; Marcellin, P; Subramanian, GM; Trinh, H; Tsai, NC; Washington, MK | 1 |
| Arends, P; Buti, M; Colombo, M; Dalekos, GN; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HL; Keskın, O; Lampertico, P; Mangia, G; Manolakopoulos, S; Papaioannou, C; Papatheodoridis, GV; Savvidou, S; Sypsa, V; Yurdaydin, C | 1 |
| Chi, BH; Emge, D; Mulenga, L; Mweemba, A; Vinikoor, MJ; Wandeler, G; Zanolini, A | 1 |
| Bae, HS; Chan, LS; Chang, M; Fong, TL; Huh, B; Lee, S; Lim, C; Shinada, S; Tien, C; Xu, JJ | 1 |
| Chen, CW; Chen, SJ; Cheng, J; Dong, J; Gao, ZL; Hou, JL; Ji, Y; Jia, JD; Li, J; Mao, Q; Mao, YM; Ning, Q; Niu, JQ; Pan, C; Ren, H; Sheng, JF; Tan, DM; Tang, H; Wang, H; Wu, SM; Xie, Q; Xu, M; Zhang, JM; Zhang, XX; Zhao, W | 1 |
| Eliadi, I; Polyzos, A; Samarkos, M; Theofanis, V; Vlachogiannakos, J | 1 |
| Buti, M; Dinh, P; Dusheiko, G; Flaherty, JF; Flisiak, R; Fung, S; Gane, E; Gordon, SC; Horban, A; Jacobson, IM; Kitrinos, KM; Krastev, Z; Marcellin, P; Martins, EB; Petersen, J; Rustgi, VK; Sperl, J; Trinh, H; Yee, LJ | 1 |
| Arslan, F; Batirel, A; Guclu, E; Karabay, O; Kocak, F; Mert, A; Ozer, S; Turanli, M | 1 |
| Deng, ZZ; Li, ZJ; Liu, SK; Ma, YT; Song, LY; Wang, CJ; Zhang, HY; Zuo, SR; Zuo, XC | 1 |
| Desmet, VJ; Grizzi, F | 1 |
| Alcantara, L; Burak, KW; Coffin, CS; Klein, P; Myers, RP; Pang, JX; Rezaeeaval, M | 1 |
| Ahn, SH; Ahn, SS; Chon, YE; Han, KH; Kim, BK; Kim, DY; Kim, SU; Park, JY | 1 |
| Chan, S; Han, SH; Krishnan, G; Li, J; Lu, L; Nguyen, MH; Pan, CQ; Trinh, H; Wong, CC; Yip, B | 1 |
| Ahn, H; Cho, EJ; Cho, H; Cho, Y; Cho, YY; Choi, WM; Jung, EU; Kim, BH; Kim, CM; Kim, CY; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Lee, YJ; Park, JW; Park, SJ; Yoo, JJ; Yoon, JH; Yu, SJ | 1 |
| Kao, JH; Tseng, TC | 1 |
| Akarca, US; Elhan, AH; Gulsen, M; Gunsar, F; Idilman, R; Keskin, O; Koruk, M; Meral, CE; Yurdaydin, C | 1 |
| Enomoto, M; Hayakawa, M; Iwadate, M; Kawada, N; Murakami, Y; Tamori, A; Tanahashi, T; Umeyama, H; Yano, Y | 1 |
| Agarwal, K; Cheng, W; Flaherty, JF; Foster, GR; Fung, SK; Gane, EJ; Lawson, E; McHutchison, JG; Nguyen, TT; Ryder, SD; Sicard, E; Subramanian, GM; Zhao, S | 1 |
| Brocchieri, A; Castelli, F; Colombo, M; Facchetti, F; Fugazza, A; Lampertico, P; Mangia, G; Spinetti, A; Viganò, M; Zaltron, S | 1 |
| Corouge, M; Fontaine, H; Mallet, V; Pol, S; Schwarzinger, M; Sogni, P; Vallet-Pichard, A | 1 |
| Ozdogan, OC; Yegin, EG | 1 |
| Fan, H; Fan, Y; Ge, Y; Li, D; Liu, X; Liu, Z; Lyu, W; Yang, H; Zhou, B | 1 |
| Aguilar Schall, R; Charuworn, P; Corsa, A; Dinh, P; Ge, D; Hengen, PN; Kitrinos, KM; Reesink, HW; Zoulim, F | 1 |
| Papatheodoridis, GV; Vlachogiannakos, J | 1 |
| Invernizzi, F; Lampertico, P; Viganò, M | 1 |
| Borsa-Lebas, F; Cacoub, P; Carrat, F; Fillion, A; Lacombe, K; Lopes, A; Loustaud-Ratti, V; Miailhes, P; Piroth, L; Pol, S; Rosenthal, E; Salmon, D | 1 |
| An, J; Byun, KS; Kim, YJ; Kwon, SY; Lee, HC; Lee, YS; Lim, YS; Yoo, BC | 2 |
| Cheon, GJ; Choi, K; Jang, JY; Jeong, SW; Jun, BG; Kim, BS; Kim, HS; Kim, SG; Kim, YD; Kim, YS; Lee, HM; Lee, SH | 1 |
| Andrade, JR; Barros, LM; Bertolini, DA; Carrilho, FJ; Conde, SR; de Araújo, LV; Ferreira, AC; Ferreira, AS; Galvan, J; Gomes-Gouvêa, MS; Kliemann, DA; Kunyoshi, AS; Leite, AG; Lyra, AC; Mendes-Corrêa, MC; Nastri, AC; Oikawa, MK; Piccoli, LZ; Pinho, JR; Rezende, RE; Soares, MC; Teixeira, R | 1 |
| Hwang, HS; Park, CW; Song, MJ | 1 |
| Ha, FS; Han, T; Liu, H; Liu, L; Nie, CY; Zhang, Q | 1 |
| Cai, HD; Cao, YJ; Hu, YH; Liu, M; Yi, W | 1 |
| Caccuri, F; Caruso, A; Castelli, F; De Francesco, MA; Gargiulo, F; Giagulli, C; Spinetti, A; Zaltron, S | 1 |
| Arends, JE; Harkisoen, S; Hoepelman, AI; van Erpecum, KJ | 1 |
| Kim, CW | 1 |
| Chang, KC; Chen, CH; Chiu, YC; Hu, TH; Hung, CH; Kee, KM; Kuo, YH; Lee, CM; Lu, SN; Tsai, MC; Wang, JH | 1 |
| Afdhal, NH; Bornstein, JD; Buti, M; Dinh, P; Flaherty, JF; Flisiak, R; Fung, S; Gane, E; George, J; Gurel, S; Janssen, HL; Mani Subramanian, G; Marcellin, P; Martins, EB; Yee, LJ | 1 |
| Akyuz, F; Badur, S; Baran, B; Besisik, F; Demir, K; Evirgen, S; Gokturk, S; Gulluoglu, M; Karaca, C; Kaymakoglu, S; Onel, D; Ormeci, AC; Soyer, OM | 1 |
| Ayaz, C; Bayan, K; Çelen, MK; Dal, MS; Dal, T; Deveci, Ö; Kandemir, I; Mert, D; Oruç, E; Özcan, N | 1 |
| Chan, HL; Chan, HY; Lo, AO; Tse, YK; Wong, GL; Wong, VW | 1 |
| Huang, H; Li, M; Pan, H; Wu, W; Yang, D; Zhao, N | 1 |
| Durantel, D; Zoulim, F | 1 |
| Bae, WK; Ha, SY; Jung, SK; Jwa, YJ; Kim, JW; Kim, KA; Kim, NH; Kim, YD; Lee, BH; Lee, HK; Lee, JS; Paik, WH | 1 |
| Chan, KA; Chang, CH; Chang, MH; Chen, DS; Chen, HL; Chen, SM; Hsu, JJ; Hu, JJ; Lai, MW; Lee, CL; Lee, CN; Lin, HH; Lin, HM; Mu, SC; Ni, YH; Shyu, MK; Tsai, MS; Zhao, LL | 1 |
| Anglaret, X; Boyd, A; Danel, C; Delaugerre, C; Eholié, SP; Gabillard, D; Girard, PM; Lacombe, K; le Carrou, J; Maylin, S; Moh, R; Zoulim, F | 1 |
| Akın, MS; Doğan, ÜB; Öztürk, AB; Sayan, M; Yalaki, S | 1 |
| Arora, SK; Bhattacharyya, R; Chakraborti, A; Chawla, YK; Das, A; Dhiman, RK; Duseja, A; Kapil, S; Sharma, BK; Singla, B | 1 |
| Chaung, KT; Ha, NB; Kim, LH; Kin, KC; Nguyen, HA; Nguyen, MH; Trinh, HN; Vu, VD | 1 |
| Cheong, JY; Cho, HJ; Cho, SW; Kim, SS; Shin, SJ; Yoo, BM | 1 |
| Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Kim, CJ; Kim, MH; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW | 1 |
| Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Kim, CJ; Kim, EH; Kim, JH; Kim, MH; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW; Sung, SJ | 1 |
| Huits, RM; Koot, AW; Visscher, AP | 1 |
| Ha, NB; Nghiem, D; Nguyen, MH; Rosenblatt, L; Trinh, HN | 1 |
| Appiah, LT; Beloukas, A; Bhagani, S; Bonnett, L; Chadwick, D; Dusheiko, G; Geretti, AM; Phillips, RO; Sarfo, FS; Stockdale, AJ | 1 |
| Allegra, S; Boglione, L; D'Avolio, A; De Nicolò, A; Di Perri, G; Pensi, D; Simiele, M | 1 |
| Akıncı, H; Balık, İ; Başar, Ö; Çoban, Ş; Dökmeci, A; Güner, R; Kalkan, Ç; Örmeci, N; Özbaş, B; Özkan, H; Yalçı, A; Yüksel, İ; Yüksel, O | 1 |
| Coppolino, G; Fuiano, G; Postorino, MC; Rivoli, L; Simeoni, M; Strazzulla, A; Summaria, C; Torti, C | 1 |
| Chang, KC; Chen, CH; Chiu, KW; Chou, YP; Hu, TH; Hung, CH; Lee, CM; Lin, MT; Lu, SN; Tsai, MC; Tseng, PL; Wang, JH; Yen, YH | 1 |
| Buti, M; Casillas, R; Esteban, R; Homs, M; Riveiro-Barciela, M; Rodriguez-Frias, F; Salcedo, MT; Tabernero, D | 1 |
| Casazza, G; Colombo, M; de Franchis, R; Facchetti, F; Fraquelli, M; Iavarone, M; Invernizzi, F; Jovani, M; Lampertico, P; Loglio, A; Mangia, G; Primignani, M; Viganò, M | 1 |
| Cho, EJ; Cho, Y; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Yoo, JJ; Yoon, JH; Yu, SJ | 1 |
| Caroleo, B; Gallelli, L; Perticone, F; Staltari, O | 1 |
| Bae, HS; Chang, M; Cheung, E; Cho, YW; Chu, D; Cooper, SL; Fong, TL; Han, SB; Jo, KJ; LeDuc, VH; Mena, EA; Mohammed, W; Nguyen, N; Phan, QQ; Tien, A; Tong, MJ; Velasco, A; Yu, AS | 1 |
| Chan, HL; Charuworn, P; Chuang, WL; Dinh, P; Elkhashab, M; Foster, GR; Kim, YJ; Lin, L; Ma, X; Marcellin, P; Martins, EB; Tak, WY; Trinh, H | 1 |
| Georgiou, A; Hadziyannis, E; Manolakopoulos, S; Nikolopoulou, V; Papatheodoridis, G; Triantos, C; Vlachogiannakos, I; Voulgaris, T; Zisimopoulos, K | 1 |
| Boettler, T; Thimme, R | 1 |
| Cui, G; Diao, H; Xu, X | 1 |
| El Agheb, MO; Grange, JD | 1 |
| Aguilar Schall, RE; Berg, T; Buti, M; Dinh, PV; Flaherty, JF; Fung, S; Gurel, S; Jacobson, I; Kim, WR; Loomba, R; Marcellin, P; Martins, EB; Therneau, TM; Yee, LJ | 1 |
| Gross, JB; Kim, WR; Poterucha, JJ; Stadheim, LM; Wi, CI | 1 |
| Castillo, E; Coffin, CS; Lee, SS; Martin, SR; Myers, RP; Oshiomogho, JI; Osman, M; Samadi Kochaksaraei, G; Scott, AN; Simmonds, K | 1 |
| Cao, F; Chen, T; He, Y; Jin, L; Liu, J; Qi, C; Wang, J; Yan, T; Yang, Y; Zhang, S; Zhao, Y | 1 |
| Jansen, L; Kootstra, NA; Reesink, HW; Takkenberg, RB; van Dort, KA; Zaaijer, HL | 1 |
| Barreiro, P; Chagas, C; Magalhães-Costa, P; Matos, L | 1 |
| Behera, M; Dixit, VK; Ghosh, J; Goyal, SK; Gupta, N; Jain, AK; Ranjan, A; Shukla, SK; Tripathi, M | 1 |
| Warpakowski, A | 1 |
| Avihingsanon, A; Burger, D; Lewin, SR; Matthews, G; Punyawudho, B; Ruxrungtham, K; Thammajaruk, N; Thongpeang, P | 1 |
| Ahn, SH; Chong, Y; Kang, HS; Kim, BK; Kim, DH; Kim, KH; Lee, AR; Park, ES; Park, S; Park, YK; Rhee, JK; Shin, GC; Yang, SI | 1 |
| Boyd, A; Lacombe, K | 1 |
| Geretti, AM; Stockdale, AJ | 1 |
| Byun, SS; Jung, SW; Kim, CJ; Kim, JH; Kim, MH; Park, BR; Park, NH; Shin, JW | 1 |
| Amani, A; Niederau, C; Thiel, A | 1 |
| Ahn, SH; Buti, M; Caruntu, FA; Chan, HL; Charuworn, P; Chuang, WL; Corsa, A; Dinh, P; Elkashab, M; Flisiak, R; Foster, GR; Fung, S; Gaeta, GB; Hui, AJ; Lim, SG; Lin, L; Lou, L; Ma, X; Marcellin, P; Martins, EB; Mehta, R; Papatheodoridis, G; Petersen, J; Reesink, HW; Reiser, H; Strasser, SI; Subramanian, GM; Tabak, F; Tak, WY; Trinh, H | 1 |
| Yin, GQ; Zhong, B | 1 |
| Deshpande, S; Horne, K; Kiss, C; Ko, T; Lau, JS; Ratnam, D; Roberts, E; Williams, J; Woolley, I | 1 |
| Kosinska, AD; Liu, J; Lu, M; Roggendorf, M | 1 |
| Abe, H; Aikata, H; Akita, T; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Kan, H; Kawaoka, T; Masaki, K; Miki, D; Murakami, E; Nakahara, T; Ochi, H; Ono, A; Tanaka, J; Tsuge, M; Uchida, T | 1 |
| Park, JG; Park, SY | 1 |
| Hutton, DW; So, SK; Toy, M | 1 |
| Ahn, SH; Han, KH; Kim, BK; Kim, D Y; Kim, SU; Ku, HJ; Lee, S; Park, JY; Song, K | 1 |
| Boeker, K; Eisenbach, C; Felten, G; Hartmann, H; Heyne, R; Hueppe, D; John, C; Krause, W; Leuschner, M; Loehr, HF; Mauss, S; Petersen, J; Ruppert, S; Schiffelholz, W; Schlaak, J; Trautwein, C; Trein, A; Warger, T; Wiese, M | 1 |
| Halota, W; Kozielewicz, D; Wietlicka-Piszcz, M | 1 |
| McMahon, BJ | 1 |
| Lu, X; Ning, Q; Wang, HL; Yang, X | 1 |
| Chaung, KT; Ha, NB; Nguyen, MH; Nguyen, NH; O'Brien, C; Trinh, HN | 1 |
| Kittitrakul, C; Leowattana, W; Nontprasert, A; Phumratanaprapin, W; Poovorawan, K; Sriboonvorakul, N; Tangkijvanich, P; Thu, AM; Wilairatana, P | 1 |
| Menne, S; Paulsen, D; Ruebsamen-Schaeff, H; Tennant, BC; Weber, O | 1 |
| Arslan, F; Batırel, A; Ceylan, B; Fersan, E; Fincancı, M; Mert, A; Paşaoğlu, E; Yardımcı, C; Yılmaz, M | 1 |
| Buti, M; Calleja, JL; Chi, H; Colombo, M; Dalekos, G; de la Revilla, J; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HL; Keskin, O; Lampertico, P; Mangia, G; Manolakopoulos, S; Papatheodoridis, G; Savvidou, S; Sypsa, V; Vlachogiannakos, I; Yurdaydin, C | 1 |
| Chang, KC; Chen, CH; Hu, TH; Hung, CH; Kee, KM; Lee, CM; Lu, SN; Tseng, PL; Wang, HM; Wang, JH; Yen, YH | 1 |
| Béguelin, C; Moradpour, D; Rauch, A; Sahli, R; Suter, F; Vazquez, M; Wandeler, G | 1 |
| Ahn, SH; Bae, SH; Han, KH; Jung, KS; Kim, CW; Kim, HY; Park, JY; Yoon, SK | 1 |
| Anderson, PL; Kiser, JJ; Lan, A; Naggie, S; Patel, K; Tillman, H; Wong, TC | 1 |
| Bourlière, M; Cadranel, JF; Causse, X; Consoli, SM; Dumortier, J; Hézode, C; Larrey, D; Libert, O; Marcellin, P; Ouzan, D; Pageaux, GP; Pauwels, A; Pétour, P; Riachi, G; Roche, B; Stern, C; Tilliet, V; Truchi, R; Zarski, JP; Zoulim, F | 1 |
| Bair, MJ; Chang, CW; Chen, CJ; Chen, MJ; Chu, CH; Hu, KC; Lee, KH; Lin, CC; Lin, SC; Liou, TC; Liu, CY; Shih, SC; Wang, HY; Wang, TE | 1 |
| Chauhan, R; Kumar, M; Rooge, S; Sarin, SK; Singh, AK; Varshney, A | 1 |
| Cainelli, F; Vento, S | 1 |
| Audsley, J; Avihingsanon, A; Bayliss, J; Bent, SJ; Bowden, S; Fairley, CK; Lewin, SR; Littlejohn, M; Locarnini, S; Luciani, F; Matthews, G; Sasadeusz, J; Yuen, L | 1 |
| Cao, Y; Dai, CY; Hou, W; Jiang, B; Li, XM; Lu, W; Su, R; Xu, J | 1 |
| Andini, R; Durante-Mangoni, E; Falco, E; Iossa, D; Maiello, C; Parrella, A; Ragone, E; Utili, R; Vitrone, M; Zampino, R | 1 |
| Chong, Y; Huang, M; Jie, Y; Li, X; Lin, G; Shi, H; Wu, Y | 2 |
| Bae, MA; Chung, HS; Jung, SW; Lee, YI; Park, CH; Park, NH; Park, YT; Shin, JW | 1 |
| Aykın, N; Çevik, F; Demirtürk, N; Doğan, N; Koca, B; Köken, T | 1 |
| Almeida, PR; Dal-Pupo, BB; Grossmann, TK; Mattos, AA; Mirenda, H; Pereira, CV; Tovo, CV | 1 |
| Beraud, G; Chagneau-Derrode, C; Garcia, M; Godet, C; Le Moal, G; Roblot, F | 1 |
| Berg, T; Chan, HL; Janssen, HL; Lampertico, P; Schindler, R; Strasser, SI | 1 |
| Bendahmane, S; Białkowska-Warzecha, J; Diculescu, MM; Goldis, AE; Heyne, R; Janssen, HL; Klauck, I; Mach, T; Marcellin, P; Petersen, J; Simon, K; Wasiak, W; Zoulim, F | 1 |
| Atay, K; Canbakan, B; Durcan, E; Gültepe, İ; Hatemi, İ; Köroğlu, E; Özdemir, S; Sonsuz, A; Tuncer, M; Yurttaş, B | 1 |
| Boeijen, LL; Boonstra, A; de Knegt, RJ; Janssen, HL; Reijnders, JG; Tjwa, ET; van Campenhout, MJ; van Oord, GW; Woltman, AM; Zoutendijk, R | 1 |
| Defresne, F; Sokal, E | 1 |
| Gao, Y; Ke, W; Liu, L; Yang, Y; Yao, Z; Ye, X; Zhang, C; Zhou, S | 1 |
| Ahn, SH; Choe, WH; Kim, JH; Kim, KH; Ko, SY; Kwon, SY | 1 |
| Dai, E; Duan, Z; Han, G; Jiang, H; Pan, CQ; Wang, Y; Zhang, H; Zhang, S; Zhao, W; Zhu, B; Zou, H | 1 |
| Arenas Ruiz Tapiador, J; Bonet Vidal, ML; Buti, M; Calleja, JL; Castro, Á; Crespo, J; Del Pino-Montes, J; Delgado Blanco, M; Diago, M; Fernández-Rodríguez, C; Fraga, E; García-Samaniego, J; González Diéguez, L; Morillas, R; Núñez, O; Pascasio, JM; Praga, M; Prieto, M; Rodríguez-Nóvoa, S; Romero-Gómez, M; Solá, R | 1 |
| Chemin, I; Diop, M; Ghosh, S; Guillot, C; Jeng, A; Kane, CT; Lemoine, M; Mboup, S; Mendy, M; Ndow, G; Njie, R; Sow, A; Thursz, M; Toure, S; Zoulim, F | 1 |
| Yim, HJ | 1 |
| Cho, EJ; Cho, H; Cho, Y; Kim, YJ; Lee, JH; Lee, K; Mustika, S; Oh, KH; Yoon, JH; Yu, SJ | 1 |
| Chen, YC; Chien, RN; Hu, TH; Jeng, WJ; Liaw, YF; Lin, CL; Sheen, IS | 1 |
| Akyildiz, M; Balci, D; Cinar, K; Dayangac, M; Gungor, G; Hazinedaroglu, S; Idilman, R; Kalkan, C; Keskin, O; Tokat, Y; Yilmaz, TU | 1 |
| Akriviadis, E; Antoniadis, N; Cholongitas, E; Fouzas, I; Giakoustidis, D; Giouleme, O; Goulis, I; Imvrios, G; Papanikolaou, V; Vasiliadis, T | 1 |
| Chang, CY; Chen, TB; Hsu, YC; Lin, JT; Mo, LR; Tseng, CM | 1 |
| Chen, B; Ju, JC; Qi, JH; Xu, L; Zhang, NN | 1 |
| den Eynde, EV; Riveiro-Barciela, M | 1 |
| Brahmania, M; Brouwer, WP; Feld, J; Hansen, T; Janssen, HL; Kowgier, M; Mazzulli, T; Wong, D | 1 |
| Bayliss, J; Buti, M; Colledge, D; Edwards, R; Gaggar, A; Gane, E; Hammond, R; Jackson, K; Janssen, HLA; Kitrinos, KM; Littlejohn, M; Locarnini, S; Marcellin, P; Revill, PA; Rosenberg, G; Sozzi, V; Subramanian, GM; Thompson, A; Wong, D; Yuen, L | 1 |
| Berg, T; Caruntu, FA; Elkhashab, M; Fabri, M; Flaherty, JF; Fung, S; Gane, E; Gurel, S; Hann, HW; Horban, A; Husa, P; Jablkowski, MS; Kim, K; Kitrinos, KM; Kwan, P; Massetto, B; McHutchison, JG; Pelemis, M; Sporea, I; Subramanian, GM; Yee, LJ; Yurdaydin, C | 1 |
| Collado Borrell, R; Gutiérrez García, ML; López Centeno, B; Pérez Encinas, M; Sanmartin Fenollera, P | 1 |
| Chitturi, S; Farrell, GC; Kaye, G; Ooi, M; Shadbolt, B; Teoh, NC; Truong, J | 1 |
| Chen, J; Li, M; Xi, H; Xu, X; Zhang, R; Zhang, X; Zhang, Y | 1 |
| Agarwal, K; Ahn, SH; Buti, M; Caruntu, FA; Chan, HL; Charuworn, P; Chuang, WL; Elkhashab, M; Flisiak, R; Foster, GR; Fung, S; Gaeta, GB; Hui, AJ; Idilman, R; Lee, CM; Lim, SG; Lin, L; Ma, X; Marcellin, P; Martins, EB; Mehta, R; Morano, L; Papatheodoridis, G; Petersen, J; Samuel, D; Strasser, SI; Tabak, F; Tak, WY; Wu, G; Yee, LJ | 1 |
| Buti, M; Cathcart, AL; Corsa, AC; Flaherty, JF; Gane, EJ; Kitrinos, KM; Liu, Y; Marcellin, P; Miller, MD | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Mineta, R; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Tsai, MC; Wang, JH | 1 |
| Ahn, SH; Baatarkhuu, O; Han, K; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Ku, HJ; Lee, S; Park, JY | 1 |
| Altınel, Ç; Demirkoparan, Ü; Karasu, Z; Turan, İ | 1 |
| He, J; Li, K; Li, W; Ning, HB; Shang, J; Zeng, YL | 1 |
| Asano, M; Dohi, T; Enomoto, N; Gatanaga, H; Honda, M; Inoue, T; Kaneko, S; Kawamura, YI; Matsumoto, A; Mizokami, M; Murata, K; Nishida, N; Oka, S; Sakamoto, M; Shirasaki, T; Shuno, Y; Sugiyama, M; Tanaka, E; Yano, H | 1 |
| Buchanan, R; Khakoo, SI; Naftel, J | 1 |
| Chan, CC; Pagnoux, C; Wei, DW | 1 |
| Angus, P; Bowden, S; Desmond, P; George, J; Lee, A; Lim, L; Locarnini, S; Marion, K; Nicoll, A; Patterson, S; Roberts, S; Sievert, W; Strasser, S; Thompson, A | 1 |
| Chen, Y; Ding, H; Han, Y; Liao, H; Liu, Y; Zeng, A | 1 |
| Anania, FA; Pearlman, BL; Pillai, AA | 1 |
| Chinnaratha, MA; Fraser, RJ; Kaambwa, B; Wigg, AJ; Woodman, RJ | 1 |
| Adinolfi, LE; Andreana, L; Boemio, A; Guerrera, B; Marrone, A; Pasquale, G; Rainone, I; Rinaldi, L; Ruggiero, G; Zampino, R | 1 |
| Jung, YK; Kang, K; Kim, D; Kim, DH; Lee, J; Suh, SJ; Yim, HJ | 1 |
| Chen, GF; Lau, G; Wang, C | 1 |
| Acero, D; Aguirre, A; Buti, M; Calleja, JL; Comas, C; Crespo, J; de Cuenca, B; Esteban, R; Fernandez-Bermejo, M; García-Samaniego, J; Gutierrez, ML; Lens, S; Manzano, ML; Moreno, D; Moreno-Palomares, JJ; Pascasio, JM; Piqueras, B; Riveiro-Barciela, M; Rivero, M; Rodríguez, FG; Sánchez-Pobre, P; Suárez, E; Tabernero, D | 1 |
| Song, BC | 1 |
| Ahn, HJ; Bae, SH; Choi, JY; Jang, JW; Song, MJ; Yoon, SK | 1 |
| Dixit, VK; Jain, AK; Nath, G; Singh, N; Srivastava, M | 1 |
| Angarano, G; Fasano, M; Fiore, JR; Leone, A; Maggi, P; Santantonio, TA; Volpe, A | 1 |
| Lim, YS | 1 |
| Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH; Wu, IT | 1 |
| Cho, EJ; Cho, Y; Chung, GE; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Lee, M; Yoo, JJ; Yoon, JH; Yu, SJ; Zoulim, F | 1 |
| Basile, M; Cicchetti, A; Coretti, S; Drago, C; Ruggeri, M | 1 |
| Atkinson, A; Battegay, M; Béguelin, C; Bernasconi, E; Calmy, A; Cavassini, M; Friolet, N; Günthard, HF; Lüthi, A; Moradpour, D; Rauch, A; Sahli, R; Schmid, P; Suter-Riniker, F; Wandeler, G | 1 |
| Afdhal, N; Aguilar Schall, R; Akarca, US; Buti, M; Flaherty, JF; Flisiak, R; Jacobson, IM; Marcellin, P; McHutchison, JG; Myers, RP; Patel, K; Subramanian, GM; Tchernev, KG; Thompson, A; Washington, MK; Younossi, Z | 1 |
| Chen, J; Diao, H; Fan, J; Fu, X; Guo, R; Li, L; Li, Y; Yan, D; Yang, J; Yao, X | 1 |
| Jang, MK; Kim, DJ; Kim, HS; Kim, SE; Kwak, KM; Lee, MS; Park, CK; Park, JW; Park, SH; Suk, KT | 1 |
| Banerjee, P; Banerjee, S; Chakrabarti, S; Chakraborty, A; Chowdhury, A; Das, K; Datta, S; Ghosh, S; Khatun, M; Mondal, RK; Mukherjee, S; Pandit, P | 1 |
| Bläckberg, J; Duberg, AS; Fischler, B; Friman, S; Karlström, O; Lindh, M; Norkrans, G; Reichard, O; Sangfeldt, P; Söderström, A; Sönnerborg, A; Uhnoo, I; Weiland, O; Wejstål, R; Wiström, J | 1 |
| de Man, RA; Janssen, HL; Leemans, WF; Niesters, HG; Schalm, SW; van der Eijk, AA | 1 |
| Butler, SD; Cote, PJ; George, AL; Gerin, JL; Menne, S; Tennant, BC; Tochkov, IA; Xiong, S; Zhu, Y | 1 |
| Deterding, K; Manns, MP; Wedemeyer, H | 1 |
| Dieterich, DT; Han, SH; Jacobson, IM; Keeffe, EB; Martin, P; Schiff, ER; Tobias, H | 1 |
| Canbay, A; Gerken, G; Gerlich, WH; Jochum, C; Katsounas, A; Schlaak, J | 1 |
| Anderson, J; Buggisch, P; Buti, M; de Man, RA; Flisiak, R; Gane, E; Germanidis, G; Heathcote, EJ; Kaita, K; Kotzev, I; Krastev, Z; Kurdas, OO; Lee, SS; Manns, M; Marcellin, P; Mondou, E; Quinn, J; Rousseau, F; Shiffman, ML; Snow-Lampart, A; Sorbel, J; Tchernev, K; Trinh, H; Washington, MK; Weilert, F | 1 |
| Lai, CL; Yuen, MF | 1 |
| Amini-Bavil-Olyaee, S; Lutz, T; Sheldon, J; Tacke, F; Trautwein, C | 1 |
| Sarmento E Castro, R; Sheldon, J; Soriano, V | 1 |
| González-Diéguez, ML; Rodríguez, M | 1 |
| Buster, EH; Janssen, HL; Schalm, SW | 1 |
| Colombo, M; Lampertico, P | 1 |
| Lampertico, P | 1 |
| Zarski, JP | 1 |
| Moreno, V; Valencia, ME | 1 |
| Ham, MY; Holt, C; Saab, S; Stone, MA; Tong, M | 1 |
| Borroto-Esoda, K; Curtis, M; Miller, MD; Qi, X; Zhu, Y | 1 |
| Buffet, C | 1 |
| Brosa, M; Buti, M; Casado, MA; Esteban, R; Rueda, M | 1 |
| Brancaccio, G; Gaeta, GB; Nardiello, S; Precone, V; Sgrò, G; Stornaiuolo, G | 1 |
| Lok, AS; McMahon, BJ | 1 |
| Cheng, J; Liang, ZL; Liu, Y; Ren, XQ; Wang, CM; Xu, DP; Xu, ZH; Zhong, YW; Zoulim, F | 1 |
| Barreiro, P; Fernández, JV; Labarga, P; Medrano, J; Soriano, V; Tuma, P; Vispo, E | 1 |
| Jenh, AM; Pham, PA; Thio, CL | 1 |
| Perry, CM; Simpson, D | 1 |
| Lin, Q; Zhang, DZ | 1 |
| Adusumilli, S | 1 |
| Funk, A; Helm, M; Olotu, C; Rockstroh, JK; Schildgen, O; Sirma, H; Zöllner, B | 1 |
| Lau, GK | 1 |
| Marcellin, P; Piratvisuth, T; Sung, J | 1 |
| Marcellin, P; Perrillo, RP | 1 |
| Gómez Espín, R; Muñoz Bertrán, E; Ortega González, I; Pérez Ceballos, E | 1 |
| Chan, HL; Han, KH; Hou, JL; Kao, JH; Lui, YY; Mihm, U; Mohamed, R; Piratvisuth, T; Teo, EK; Tsoi, KK; Wong, GL; Wong, VW | 1 |
| Benhamou, Y; Izzedine, H; Peytavin, G; Schneider, L; Thibault, V; Valantin, MA | 1 |
| Colquitt, J; Cooper, K; Harris, P; Jones, J; Shepherd, J | 1 |
| Chien, RN | 1 |
| Berg, T; Borroto-Esoda, K; Chan, S; Frederick, D; Lavocat, F; Marcellin, P; Moller, B; Oldach, D; Rousseau, F; Snow-Lampart, A; Sorbel, J; Suarez, E; Trinh, H; Zoulim, F | 1 |
| Einarson, TR; Heathcote, EJ; Kowgier, M; Krahn, M; Nishikawa, Y; Pham, B; Sherman, M; Tomlinson, G; Ungar, WJ; Wong, DK; Woo, G | 1 |
| Chen, EQ; Tang, H | 1 |
| Cacoub, P; Carrat, F; Goderel, I; Lacombe, K; Loustau-Ratti, V; Miailhes, P; Morlat, P; Piroth, L; Pol, S; Rami, A; Rey, D; Rosenthal, E; Sene, D | 1 |
| de Man, RA; de Vries-Sluijs, TE; Hansen, BE; Hoepelman, AI; Janssen, HL; Mulder, JW; Pas, SD; Prins, JM; Reijnders, JG; Richter, C; Schutten, M; van der Ende, ME; Zaaijer, HL | 1 |
| Bentley, A; Dakin, H; Dusheiko, G | 1 |
| Dakin, H; Fidler, C; Harper, C | 1 |
| Belvisi, V; Cenfra, N; Cimino, G; Del Borgo, C; Lichtner, M; Marocco, R; Mastroianni, CM; Mecarocci, S; Rago, A | 1 |
| Avihingsanon, A; Bowden, S; Chang, JJ; Dore, GJ; Kerr, S; Lange, J; Lewin, SR; Matthews, GV; Napissanant, N; Piyawat, K; Ruxrungtham, K | 1 |
| Boroń-Kaczmarska, A; Cianciara, J; Flisiak, R; Gładysz, A; Halota, W; Juszczyk, J; Kryczka, W; Malkowski, P; Pawlowska, M; Simon, K | 1 |
| Einecke, D | 1 |
| Amini-Bavil-Olyaee, S; Herbers, U; Luedde, T; Tacke, F; Trautwein, C | 1 |
| Chotiyaputta, W; Ditah, FA; Goodwin, D; Lok, AS; Peterson, C | 1 |
| Jenh, AM; Pham, PA | 1 |
| Anderson, J; Borroto-Esoda, K; Buggisch, P; Buti, M; De Man, RA; Flisiak, R; Gane, E; Germanidis, G; Gurel, S; Heathcote, EJ; Kaita, K; Kotzev, I; Krastev, Z; Kurdas, OO; Lee, SS; Manns, M; Marcellin, P; Mondou, E; Rousseau, F; Shiffman, ML; Snow-Lampart, A; Sorbel, J; Tchernev, K; Trinh, H; Weilert, F | 1 |
| Bonacini, M | 1 |
| Angus, PW; Bowden, S; Desmond, PV; George, J; Lee, AU; Locarnini, S; Nicoll, AJ; Patterson, SJ; Roberts, SK; Sievert, W; Strasser, SI | 1 |
| Bonnard, P; Boyd, A; Girard, PM; Lacombe, K; Lascoux-Combe, C; Lasnier, E; Meynard, JL; Miailhes, P; Molina, JM; Wendum, D | 1 |
| Anglaret, X; Attia, A; Chenal, H; Danel, C; Eholié, S; Gabillard, D; Messou, E; N'Dri-Yoman, T; Polneau, S; Seyler, C; Toni, T; Wakasugi, N | 1 |
| Bourlière, M; Kahloun, A; Zoulim, F | 1 |
| Benhamou, Y; Pais, R | 1 |
| Marcellin, P | 1 |
| Borchert, K; Freund, M; Hilgendorf, I; Junghanss, C; Loebermann, M; Schmitt, M | 1 |
| Janssen, HL; Rijckborst, V; Sonneveld, MJ | 1 |
| Janssen, HL; Sonneveld, MJ | 1 |
| Leung, N | 1 |
| Zoulim, F | 1 |
| Mutimer, D | 1 |
| Bettocchi, D; Consales, G; Durval, A; Luzzio, MG; Zamidei, L | 1 |
| Akarca, US; Berg, T; Buti, M; Chang, TT; Frederick, D; Horban, A; Kitrinos, K; Kwan, P; Lee, CM; Liaw, YF; Mondou, E; Papatheodoridis, GV; Peschell, K; Prieto, M; Rousseau, F; Schiff, ER; Sheen, IS; Suet-Hing Wong, F; Wang, C | 1 |
| Alberti, A; Brunetto, M; Bruno, R; Cariti, G; Carosi, G; Colombo, M; Craxì, A; Di Marco, V; Ferrari, C; Filice, G; Gaeta, GB; Lampertico, P; Levrero, M; Marzano, A; Mazzotta, F; Pastore, G; Piccinino, F; Pollicino, T; Prati, D; Puoti, M; Raimondo, G; Rizzetto, M; Sagnelli, E; Santantonio, T; Smedile, A; Toti, M | 1 |
| Garg, H; Garg, V; Kumar, A; Kumar, M; Sarin, SK; Sharma, BC | 1 |
| Hissar, SS; Khanam, A; Kotillil, S; Mishra, SK; Sarin, SK; Shrivastava, S; Sukriti, S; TrehanPati, N | 1 |
| Hosaka, T; Kumada, H; Suzuki, F | 1 |
| Alric, L; Basse, G; Daudé, M; Esposito, L; Guitard, J; Izopet, J; Kamar, N; Lavayssière, L; Rostaing, L; Sauné, K | 1 |
| Beadsworth, MB; Pennell, A; Phillips, M; Ratcliffe, L; Vilar, FJ | 1 |
| Liu, T; Wang, Y; Zhang, C | 1 |
| Borroto-Esoda, K; Chappell, B; Curtis, M; Heathcote, J; Kitrinos, K; Marcellin, P; Miller, MD; Myrick, F; Schawalder, J; Snow-Lampart, A; Sorbel, J; Svarovskaia, ES; Zhu, Y | 1 |
| Chen, LZ; Dai, XH; Fan, XG; Tang, LH; Wang, W; Zhao, SS; Zhou, RR | 1 |
| Desire, N; Katlama, C; Stitou, H; Thibault, V; Tubiana, R; Valantin, MA | 1 |
| Tornai, I | 1 |
| Andreoni, M; Bertoli, A; Ceccarelli, L; Perno, CF; Salpini, R; Sarrecchia, C; Sordillo, P; Svicher, V; Volpi, A | 1 |
| Benetti, S; Cassino, L; Fay, F; Quarleri, J; Tanno, H | 1 |
| Athmann, C; Berger, F; Filmann, N; Hegener, P; Henke, J; Herrmann, E; Hueppe, D; Mauss, S; Schmutz, G | 1 |
| Boucher, CA; Hansen, BE; Janssen, HL; van Vuuren, AJ; Zoutendijk, R | 1 |
| Chan, HL; Chan, HY; Locarnini, SA; Tse, CH; Wong, GL; Wong, VW; Yuen, LK | 1 |
| Bailly, F; Buti, M; Cruiziat, C; Deterding, K; Dumortier, J; Esteban, R; Janssen, HL; Mallet, V; Pradat, P; Si-Ahmed, SN; Wedemeyer, H; Zoulim, F; Zoutendijk, R | 1 |
| Giles, M; Sasadeusz, J; Visvanathan, K | 1 |
| Borroto-Esoda, K; Curtis, M; Zhu, Y | 1 |
| Chan, HL; Chan, HY; Ong, A; Tse, CH; Wong, GL; Wong, VW | 1 |
| da Silva, AC; Gianini, RJ; Gomes-Gouvea, MS; Guastini, CF; Leite, AG; Martins, LG; Mendes-Correa, MC; Pinho, JR; Silva, MH; Uip, DE | 1 |
| Berg, T; Brown, A; Buggisch, P; Buti, M; Janssen, HL; Lampertico, P; Lutgehetmann, M; Petersen, J; Ratziu, V; Sarrazin, C; Schollmeyer, J; Sterneck, M; Wedemeyer, H; Zoulim, F | 1 |
| Lee, SS; Sherman, M | 1 |
| Bentley, A; Dakin, H; Fidler, C; Fung, S; Sherman, M | 1 |
| Suzuki, F | 2 |
| Campanale, F; D'Addiego, G; Fazio, V; Giammario, A; Scotto, G | 1 |
| Brunetto, MR; Janssen, HL; Sonneveld, MJ | 1 |
| Arasli, M; Buyukuysal, C; Delikanli, B; Harmandar, F; Ustundag, Y | 1 |
| Cox, N; Tillmann, H | 1 |
| Fontana, RJ; Singal, AK | 1 |
| Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Lada, O; Leclerc, L; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B | 1 |
| Bunchorntavakul, C; Chen, W; Hu, KQ; Pan, CQ; Reddy, KR; Yu, AS | 1 |
| Boyd, A; Delaugerre, C; Girard, PM; Gozlan, J; Lacombe, K; Lascoux-Combe, C; Lassel, L; Lavocat, F; Maylin, S; Miailhes, P; Zoulim, F | 1 |
| Ridruejo, E; Silva, MO | 1 |
| Lampertico, P; Liaw, YF | 1 |
| Chong, WH; Collins, MT; Gara, N; Ghany, MG; Hoofnagle, JH; Jake Liang, T; Kleiner, DE; Zhao, X | 1 |
| Baqai, S; Clark, MD; Gish, RG; Kane, SD; Mangahas, MF; Shaw, RE | 1 |
| Fernandes, CA; Gomes, Sde A; Mello, FC | 1 |
| Corsa, AC; Dinh, P; Luminos, LM; McHutchison, J; Mizerski, J; Murray, KF; Pang, PS; Pawlowska, M; Rossi, S; Szenborn, L; Wysocki, J | 1 |
| Lampertico, P; Pol, S | 1 |
| Hadziyannis, SJ | 1 |
| Das, P; Ford, M; Holt, S; Kingdon, E; Vivek, V | 1 |
| Rosenthal, P | 1 |
| Almasio, PL; Bertino, G; Brandolino, N; Bruno, S; Caroleo, B; Cosco, L; Di Marco, V; Foti, G; Frugiuele, P; Galdieri, A; Madonia, S; Montalto, G; Portelli, V; Russello, M; Sapienza, M; Scifo, G; Siciliano, R; Spadaro, A; Stroffolini, T; Surace, L | 1 |
| Ducos, J; Kania, D; Kuster, N; Lozano, C; Mondain, AM; Nagot, N; Pageaux, GP; Poinso, A; Reynes, J; Tuaillon, E; Van de Perre, P | 1 |
| Alfieri, A; Boni, C; Brancaccio, G; Colombo, M; Ferrari, C; Gaeta, GB; Giuberti, T; Laccabue, D; Lampertico, P; Missale, G; Pesci, M; Schivazappa, S; Viganò, M | 1 |
| Akin, MS; Doğan, ÜB; Gümürdülü, Y; Kara, B; Soylu, A | 1 |
| Bruzzone, B; Caligiuri, P; Di Biagio, A; Giacobbe, DR; Mikulska, M; Taramasso, L; Viscoli, C | 1 |
| Bozdayi, AM; Cevik, E; Idilman, R; Kabaçam, G; Karatayli, E; Karatayli, SC; Seven, G; Yakut, M; Yurdaydin, C | 1 |
| Buti, M; Homs, M | 1 |
| Ahmed, A; Chaung, K; Cheung, R; Nguyen, HA; Nguyen, MH; Trinh, HN; Wong, CR; Yip, B | 1 |
| Akbal, E; Akin, E; Alkan, E; Ataseven, H; Aygün, C; Başar, O; Baykal, O; Coban, S; Demir, M; Gülşen, MT; Ibiş, M; Koçkar, MC; Köklü, S; Köksal, AŞ; Küçükazman, M; Nadir, I; Ozdil, K; Pürnak, T; Tuna, Y; Yildirim, B; Yüksel, I; Yüksel, O | 1 |
| Baak, BC; Bakker, CM; Beuers, UH; Brouwer, JT; Buster, EH; Drenth, JP; Honkoop, P; Janssen, HL; Kerbert-Dreteler, MJ; Koek, GH; Tan, AC; van der Spek, BW; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, KM; van Soest, H; Vrolijk, JM | 1 |
| Hu, KQ; Pan, CQ; Tsai, N | 1 |
| Bahrami, S; Chevaliez, S; Grare, M; Hézode, C; Pawlotsky, JM | 1 |
| Afdhal, N; Aguilar Schall, R; Bornstein, JD; Buti, M; Flaherty, JF; Gane, E; Germanidis, G; Heathcote, EJ; Jacobson, IM; Kitrinos, KM; Marcellin, P; McHutchison, JG; Sievert, W; Subramanian, GM; Washington, MK | 1 |
| Hoofnagle, JH; Tana, MM | 1 |
| Buti, M; Petersen, J | 1 |
| Coffin, CS; Fung, SK; Ma, MM | 1 |
| Colle, I; Gamil, M; Horsmans, Y; Hulstaert, F; Nevens, F; Schwierz, C; Thiry, N; Van de Sande, S | 1 |
| Berg, T; Borroto-Esoda, K; Curtis, M; Kitrinos, KM; Lavocat, F; Miller, MD; Svarovskaia, ES; Zhu, Y; Zoulim, F | 1 |
| Baietto, L; Boglione, L; Burdino, E; Cariti, G; Cusato, J; D'Avolio, A; De Rosa, FG; Di Perri, G; Ghisetti, V; Gregori, G | 1 |
| Avihingsanon, A; Bowden, S; Dore, GJ; Finlayson, R; Hoy, JF; Lewin, SR; Littlejohn, M; Locarnini, S; Matthews, GV; Revill, PA; Ruxrungtham, K; Sasadeusz, J; Saulynas, M; Seaberg, EC; Thio, CL | 1 |
| Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC | 1 |
| Cui, YJ; Song, ZL; Teng, DH; Zheng, H; Zheng, WP | 1 |
| Buti, M; Casado, MA; Lozano, V; Oyagüez, I | 1 |
| Fadda, V; Maratea, D; Messori, A; Trippoli, S | 1 |
| Akyuz, F; Badur, S; Baran, B; Besisik, F; Bozbey, HU; Demir, K; Evirgen, S; Gokturk, S; Gulluoglu, M; Karaca, C; Kaymakoglu, S; Onel, D; Ormeci, AC; Soyer, OM | 1 |
| Bessone, F; Chan, HL; Cheinquer, H; Daruich, J; Dong, Y; Fassio, E; Komolmit, P; Ono, SK; Pathan, R; Pessôa, MG; Piratvisuth, T; Sukeepaisarnjaroen, W; Tanwandee, T; Trylesinski, A; Zeuzem, S | 1 |
| Díaz, B; González-Lahoz, J; Núñez, M; Pérez-Olmeda, M; Ríos, P; Soriano, V | 1 |
| Aberg, JA; Crippin, J; Kessels, L; Lisker-Melman, M; Powderly, WG; Ristig, MB; Tebas, P | 1 |
| Atkins, M; Barr, A; Bower, M; Fisher, M; Gazzard, B; Matthews, G; Nelson, M; Pillay, D; Portsmouth, S; Stebbing, J | 1 |
| Bruno, R; Ciappina, V; Filice, G; Puoti, M; Sacchi, P; Zocchetti, C | 1 |
| Crippin, J; Drechsler, H; Lisker-Melman, M; Ristig, M; Tebas, P | 1 |
| Camino, N; Núñez, M; Puoti, M; Soriano, V | 1 |
| Benhamou, Y; Poynard, T | 1 |
| Chung, RT; Dienstag, JL; Kuo, A | 1 |
| Cheng, AK; Cooper, DA; DeJesus, E; Dore, GJ; Lu, B; Miller, MD; Pozniak, AL; Zhong, L | 1 |
| Thio, CL | 1 |
| Ala, A; Dieterich, DT | 1 |
| Avci, A; Erhardt, A; Häussinger, D; Heintges, T; Lörke, J; Sagir, A | 1 |
| Lok, AS | 1 |
| Berger, A; Brodt, HR; Lennemann, TS; Lutz, T; Mösch, M; Staszewski, S; Stephan, C; Stürmer, M | 1 |
| Harangozo, CS; Korman, TM; Moyle, M; Veitch, AJ; Woolley, IJ | 1 |
| Benhamou, Y; Bonyhay, L | 1 |
| Duncan, R; Lau, DT; Madariaga, JR; Montalbano, M; Muslu, H; Neff, GW; Nery, C; Nery, J; O'Brien, CB; Ruiz, P; Safdar, K; Schiff, ER; Shire, NJ; Tzakis, AG | 1 |
| Berg, T; Bergk, A; Mauss, S; Reinke, P; Schürmann, D; van Bömmel, F; Wiedenmann, B; Wünsche, T | 1 |
| Benhamou, Y; Bonacini, M; Brook, G; Cargnel, A; Puoti, M; Rockstroh, J; Soriano, V; Thio, C | 1 |
| Del Poggio, P; Jamoletti, C; Zaccanelli, M | 1 |
| Boelle, PY; Girard, PM; Gozlan, J; Lacombe, K; Serfaty, L; Valleron, AJ; Zoulim, F | 1 |
| Butler, SD; Cote, PJ; Delaney, WE; George, AL; Gerin, JL; Korba, BE; Menne, S; Tennant, BC; Tochkov, IA; Xiong, S | 1 |
| de Man, RA; Hansen, BE; Janssen, HL; Niesters, HG; Schalm, SW; van de Ende, M; van der Eijk, AA | 1 |
| Berger, A; Bickel, M; Carlebach, A; Klauke, S; Lutz, T; Staszewski, S; Stephan, C; Stuermer, M | 1 |
| Gerlich, WH; Hartmann, H; Schildgen, O | 1 |
| Roche, B; Samuel, D | 1 |
| Sherman, M | 1 |
| Butt, AA | 1 |
| Funk, A; Gerlich, WH; Hartmann, H; Helm, M; Olotu, C; Rockstroh, JK; Schildgen, O; Sirma, H; Wend, UC; Will, H; Willems, WR | 1 |
| Lee, WA; Martin, JC | 1 |
| Berg, T; Berger, F; Bruno, R; Carlebach, A; Hoffmann, C; Jaeger, H; Lutz, T; Mauss, S; Nelson, M; Rockstroh, J; Schmutz, G; Schürmann, D; Schwarze-Zander, C; Sheldon, J; Soriano, V; Stoehr, A; von Boemmel, F; Wolf, E | 1 |
| Barreiro, P; Camino, N; Díaz-Pollán, B; González-Lahoz, J; Martín-Carbonero, L; Núñez, M; Ramos, B; Soriano, V | 1 |
| Alston-Smith, B; Andersen, J; Brosgart, CL; Jacobson, JM; Johnson, VA; Liu, T; Lynch, P; Peters, MG; Pollard, RB; Polsky, B; Rooney, JF; Sherman, KE; Swindells, S | 1 |
| Benhamou, Y | 1 |
| Durantel, S; Girard, PM; Gozlan, J; Lacombe, K; Ollivet, A; Tran, N; Zoulim, F | 1 |
| Carriero, D; Dieterich, DT; Jaffe, D; Lucas, J; Park, JS; Santos, SA; Uriel, AJ | 1 |
| Berger, A; Faust, D; Stuermer, M; Teuber, G; Trojan, J | 1 |
| Chaix, ML; Correas, JM; Dhalluin-Venier, V; Mallet, VO; Pol, S; Verkarre, V; Viard, JP | 1 |
| Garcia-Gasco, P; Sheldon, J; Soriano, V | 1 |
| Daniels, E; Gaglio, PJ; Sterling, R; Tedaldi, E | 1 |
| Bozdayi, AM; Karaaslan, H; Karatayli, E; Karayalçin, S; Kayhan, H; Sahin, F; Türkyilmaz, AR; Yurdaydin, C | 1 |
| Ananworanich, J; Chetchotisakd, P; Hirschel, B; Jupimai, T; Klinbuayam, W; Mahanontharit, A; Nüesch, R; Prasithsirikul, W; Ruxrungtham, K; Srasuebkul, P | 1 |
| Guillemi, S; Gutiérrez, S; Harrigan, PR; Jahnke, N; Montaner, JS; Montessori, V | 1 |
| de Man, RA; Janssen, HL; Leemans, WF; Niesters, HG | 1 |
| Janssen, HL; Reijnders, JG | 1 |
| Degertekin, B; Husain, M; Lok, AS; Oberhelman, K; Tan, J; Wong, SN | 1 |
| Byun, KS; Choe, WH; Kim, BK; Kim, GH; Ko, SY; Kwon, SY; Lee, CH; Yeon, JE | 1 |
| Goto, T; Kato, N; Omata, M | 1 |
| Mauss, S | 1 |
| Ayoub, WS; Keeffe, EB | 1 |
164 review(s) available for tenofovir and Hepatitis B, Chronic
| Article | Year |
|---|---|
Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Tenofovir; Treatment Outcome | 2022 |
Low-level viremia in nucleoside analog-treated chronic hepatitis B patients.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Nucleosides; Tenofovir; Treatment Outcome; Viremia | 2021 |
Clinical management of chronic hepatitis B: A concise overview.
Topics: Aged; Antiviral Agents; Asymptomatic Diseases; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Esophageal and Gastric Varices; Hepatic Encephalopathy; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Failure; Liver Neoplasms; Male; Seroconversion; Tenofovir; Withholding Treatment | 2022 |
Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Thailand; Treatment Outcome | 2022 |
Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data.
Topics: Adenine; Aged; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Safety of current antiviral drugs for chronic hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir; Treatment Outcome | 2022 |
Current Trend in Antiviral Therapy for Chronic Hepatitis B.
Topics: Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Randomized Controlled Trials as Topic; Symptom Flare Up; Tenofovir; Treatment Outcome | 2022 |
Finite nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B: From an "option" to an "active recommendation".
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Tenofovir; Treatment Outcome | 2022 |
Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Tenofovir; Treatment Outcome | 2022 |
Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Tenofovir | 2022 |
Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B.
Topics: Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Pre-Exposure Prophylaxis; Risk Assessment; Tenofovir | 2022 |
Comparison of renal safety and bone mineral density of tenofovir and entecavir in patients with chronic hepatitis B: a systematic review and meta-analysis.
Topics: Antiviral Agents; Bone Density; Bone Diseases, Metabolic; Hepatitis B, Chronic; Humans; Kidney; Osteoporosis; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Assessment of Adherence to Clinical Guidelines in Patients with Chronic Hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Hepatitis C; HIV Infections; Humans; Liver Neoplasms; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Two-drug regimens for HIV treatment.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Tenofovir | 2022 |
Tenofovir versus entecavir for tertiary prevention of hepatocellular carcinoma in chronic hepatitis B infection after curative therapy: A systematic review and meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir; Tertiary Prevention; Treatment Outcome | 2023 |
The Different Prognoses of Hepatocellular Carcinoma with Previous Tenofovir versus Entecavir Treatment for Chronic Hepatitis B Virus: Analysis Based on 15 Propensity Score-Matched Studies.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Prognosis; Propensity Score; Retrospective Studies; Tenofovir; Treatment Outcome | 2023 |
Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2023 |
The Use of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide for Preventing Vertical Transmission of Hepatitis B.
Topics: Adenine; Antiviral Agents; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Infant; Infectious Disease Transmission, Vertical; Tenofovir | 2023 |
Lower risk of hepatocellular carcinoma with tenofovir than entecavir in antiviral treatment-naïve chronic hepatitis B patients: a systematic review and meta-analysis involving 90,897 participants.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Liver Neoplasms; Retrospective Studies; Tenofovir; Treatment Outcome | 2023 |
Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir; Treatment Outcome | 2023 |
Possible biological mechanisms of entecavir versus tenofovir disoproxil fumarate on reducing the risk of hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interleukin-10; Leukocytes, Mononuclear; Liver Neoplasms; Nucleosides; Proto-Oncogene Proteins c-akt; Tenofovir; TOR Serine-Threonine Kinases; Treatment Outcome | 2023 |
Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis.
Topics: Adenine; Alanine; Cholesterol; Cholesterol, LDL; Dyslipidemias; Hepatitis B; Hepatitis B, Chronic; Humans; Tenofovir; Triglycerides | 2023 |
HCC prediction models in chronic hepatitis B patients receiving entecavir or tenofovir: a systematic review and meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2023 |
Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2023 |
Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Topics: Adenine; Alanine; Antiviral Agents; Bone and Bones; Creatinine; Fumarates; Hepatitis B; Hepatitis B, Chronic; Humans; Kidney; Network Meta-Analysis; Tenofovir; Treatment Outcome | 2023 |
Efficacy and safety of tenofovir disoproxil fumarate versus entecavir in the treatment of acute-on-chronic liver failure with hepatitis B: a systematic review and meta-analysis.
Topics: Acute-On-Chronic Liver Failure; Antiviral Agents; End Stage Liver Disease; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospective Studies; Retrospective Studies; Severity of Illness Index; Tenofovir; Treatment Outcome | 2023 |
[Research progress on the effect of tenofovir disoproxil fumarate on blood lipid profile].
Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipids; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2023 |
Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift.
Topics: Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Tenofovir; Treatment Outcome | 2019 |
Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2019 |
[Long Term Efficacy of Antiviral Therapy: Mortality and Incidence of Hepatocellular Carcinoma].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Proportional Hazards Models; Tenofovir; Treatment Outcome | 2019 |
Effects of IFN monotherapy versus combined therapy on HBeAg seroconversion or seroclearance in HBeAg-positive chronic hepatitis B patients: A meta-analysis.
Topics: Antibodies, Viral; Antiviral Agents; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleosides; Randomized Controlled Trials as Topic; Seroconversion; Tenofovir; Treatment Outcome | 2020 |
Role of tenofovir disoproxil fumarate in prevention of perinatal transmission of hepatitis B virus from mother to child: a systematic review and meta-analysis.
Topics: Antiviral Agents; Child; DNA, Viral; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Mothers; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome; Viral Load | 2021 |
Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2020 |
New approaches in viraemic organ transplantation and antiviral therapies.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Neoplasms; Liver Transplantation; Macrocyclic Compounds; Proline; Quinoxalines; Salvage Therapy; Sofosbuvir; Sulfonamides; Tenofovir; Transplants | 2020 |
Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Tenofovir | 2020 |
Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Observational Studies as Topic; Randomized Controlled Trials as Topic; Risk; Tenofovir | 2021 |
Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis.
Topics: Adult; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Network Meta-Analysis; Randomized Controlled Trials as Topic; Telbivudine; Tenofovir; Treatment Outcome | 2020 |
Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Comorbidity; Female; Forecasting; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Risk; Tenofovir | 2020 |
Hepatocellular carcinoma and multiple myeloma with elevated globulin: a case report and literature review.
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Hepatocellular; Diagnosis, Differential; DNA, Viral; Fatal Outcome; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Radiofrequency Ablation; Tenofovir; Ultrasonography | 2020 |
Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir; Treatment Outcome | 2021 |
An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia.
Topics: Alanine; Antiviral Agents; Asia; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Randomized Controlled Trials as Topic; Tenofovir | 2020 |
Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis.
Topics: Adult; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Tenofovir | 2021 |
The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Duration of Therapy; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Public Health Practice; Tenofovir; Treatment Outcome; Viral Load; Withholding Treatment | 2020 |
Comparison of 48-week efficacy of tenofovir vs entecavir for patients with chronic hepatitis B: A network meta-analysis.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Network Meta-Analysis; Tenofovir | 2021 |
Efficacy and Safety of Tenofovir in the Prevention of Perinatal Transmission of Hepatitis B, a Meta-Analysis.
Topics: Antiviral Agents; Confidence Intervals; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Observational Studies as Topic; Pregnancy; Pregnancy Complications, Infectious; Publication Bias; Randomized Controlled Trials as Topic; Tenofovir | 2020 |
Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Tenofovir | 2020 |
Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Observational Studies as Topic; Risk Assessment; Tenofovir; Treatment Outcome | 2020 |
No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Risk Factors; Tenofovir | 2021 |
Differential Effectiveness of Tenofovir and Entecavir for Prophylaxis of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Depending on Coexisting Cirrhosis and Prior Exposure to Antiviral Therapy: A Systematic Review and Meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Tenofovir; Treatment Outcome | 2021 |
What would be the impact of COVID-19 on liver function of a patient with chronic hepatitis B? About a case and literature review.
Topics: Adult; Antiviral Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; Hepatitis B, Chronic; Hospitals, University; Humans; Hydroxychloroquine; Liver Function Tests; Male; Morocco; Tenofovir | 2021 |
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir; Treatment Outcome | 2021 |
Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
Topics: Adenine; Antiviral Agents; Controlled Clinical Trials as Topic; Guanine; Hematologic Neoplasms; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompromised Host; Lamivudine; Organophosphonates; Survival Analysis; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Activation | 2017 |
Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Organophosphonates; Retrospective Studies; Survival Analysis; Telbivudine; Tenofovir; Thymidine | 2017 |
Hepatitis B During Pregnancy in Endemic Areas: Screening, Treatment, and Prevention of Mother-to-Child Transmission.
Topics: Antiviral Agents; Endemic Diseases; Female; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunization; Immunoglobulins; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Telbivudine; Tenofovir; Thymidine; Viral Load | 2017 |
Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus.
Topics: Combined Modality Therapy; Female; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infectious Disease Transmission, Vertical; Mothers; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection.
Topics: Adenine; Alanine; Animals; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir; Time Factors | 2017 |
Tenofovir Alafenamide: A Review in Chronic Hepatitis B.
Topics: Adenine; Adolescent; Adult; Alanine; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Randomized Controlled Trials as Topic; Tenofovir | 2017 |
Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleic Acid Synthesis Inhibitors; Organophosphonates; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Viral Load | 2017 |
Comparison of the Efficacy of Tenofovir Versus Tenofovir plus Entecavir in the Treatment of Chronic Hepatitis B in Patients With Poor Efficacy of Entecavir: A Systematic Review and Meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2017 |
Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.
Topics: Adenine; Age Factors; Alanine; Antiviral Agents; Bone Density; Clinical Decision-Making; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney; Male; Osteoporosis; Patient Safety; Pregnancy; Renal Insufficiency; Risk Factors; Tenofovir; Treatment Outcome | 2017 |
Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy.
Topics: Adenine; Alanine; Antiviral Agents; Clinical Trials as Topic; Hepatitis B, Chronic; Humans; Molecular Conformation; Tenofovir | 2017 |
Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Dose-Response Relationship, Drug; Hepatitis B, Chronic; Humans; Prodrugs; Renal Insufficiency; Tenofovir | 2018 |
Why not to stop antiviral treatment in patients with chronic hepatitis B.
Topics: Alanine Transaminase; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Recurrence; Tenofovir; Treatment Outcome | 2018 |
Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B.
Topics: Adenine; Administration, Oral; Alanine; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Guanine; Hepatitis B, Chronic; Humans; Nucleosides; Randomized Controlled Trials as Topic; Tenofovir; Time Factors; Treatment Outcome | 2018 |
Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries.
Topics: Alanine Transaminase; Antiviral Agents; Creatine Kinase; Creatinine; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Viral Load | 2018 |
Management Algorithm for Interrupting Mother-to-Child Transmission of Hepatitis B Virus.
Topics: Algorithms; Antiviral Agents; Breast Feeding; Female; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulins; Immunologic Factors; Infant, Newborn; Infectious Disease Transmission, Vertical; Mass Screening; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Vaccination; Viral Load | 2019 |
Unmet need in chronic hepatitis B management.
Topics: Alanine Transaminase; Antiviral Agents; Drug Resistance, Viral; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Prognosis; Renal Insufficiency, Chronic; Tenofovir | 2019 |
The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis.
Topics: Adult; Carcinoma, Hepatocellular; Controlled Clinical Trials as Topic; Female; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Retrospective Studies; Tenofovir | 2019 |
Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Nucleotides; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2020 |
Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs.
Topics: Adenine; Antiviral Agents; Bayes Theorem; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Network Meta-Analysis; Organophosphonates; Prospective Studies; Telbivudine; Tenofovir | 2019 |
Antiretroviral Effects on HBV/HIV Co-infection and the Natural History of Liver Disease.
Topics: Anti-Retroviral Agents; Coinfection; Disease Progression; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Prevalence; Prognosis; Risk Assessment; Survival Analysis; Tenofovir; Treatment Outcome | 2019 |
Drugs in the Pipeline for HBV.
Topics: Adenine; Antiviral Agents; DNA, Viral; Female; Forecasting; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Assessment; Tenofovir; Treatment Outcome; Virus Replication | 2019 |
Update in the management of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Monitoring; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon Type I; Organophosphonates; Practice Guidelines as Topic; Tenofovir | 2013 |
Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.
Topics: Adenine; Administration, Oral; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2013 |
[Interdisciplinary aspects of and new drugs for chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Comorbidity; Drug Interactions; Drug Therapy, Combination; Female; Gastroenterology; Guanine; Hematology; Hepatitis B, Chronic; Humans; Hungary; Infant, Newborn; Infant, Newborn, Diseases; Infectious Disease Transmission, Vertical; Interdisciplinary Communication; Interferons; Lamivudine; Medical Oncology; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Rheumatology; Tenofovir | 2013 |
Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Treatment Outcome; Virus Replication | 2013 |
Hepatitis B in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Resistance, Viral; Hepatitis B Vaccines; Hepatitis B, Chronic; Hepatitis D; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir | 2013 |
[Reactivation of chronic hepatitis B].
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antiviral Agents; Biomarkers; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Inflammation; Lamivudine; Organophosphonates; Rituximab; Tenofovir; Virus Activation | 2013 |
Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Mutation; Nucleosides; Organophosphonates; Tenofovir; Virus Replication | 2013 |
Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Renal Insufficiency, Chronic; Telbivudine; Tenofovir; Thymidine | 2014 |
Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment.
Topics: Acidosis, Lactic; Adenine; Administration, Oral; Antiviral Agents; Arabinofuranosyluracil; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Kidney Diseases; Male; Muscular Diseases; Nervous System Diseases; Nucleosides; Nucleotides; Organophosphonates; Pharmacovigilance; Pregnancy; Telbivudine; Tenofovir; Thymidine | 2014 |
HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?
Topics: Adenine; Age Factors; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Sex Factors; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2014 |
HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
Topics: Adenine; Age Factors; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Nucleosides; Organophosphonates; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Sex Factors; Tenofovir; Treatment Outcome | 2014 |
Impact of HBV therapy on the incidence of hepatocellular carcinoma.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Organophosphonates; Tenofovir | 2014 |
New therapeutic perspectives in HBV: when to stop NAs.
Topics: Adenine; Algorithms; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine | 2014 |
An update on hepatitis B, D, and E viruses.
Topics: Adenine; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Hepatitis D, Chronic; Hepatitis E; Humans; Interferon-alpha; Liver Cirrhosis; Liver Failure; Organophosphonates; Tenofovir; Treatment Outcome | 2014 |
Managing hepatitis B to prevent liver cancer: recent advances.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2014 |
Management of chronic hepatitis B in children: an unresolved issue.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Carrier State; Child; Databases, Bibliographic; Guanine; Hepatitis B, Chronic; Humans; Immune Tolerance; Incidence; Interferons; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Organophosphonates; Risk; Tenofovir | 2014 |
Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments.
Topics: Adenine; Antiviral Agents; Disease Management; DNA, Viral; Drug Delivery Systems; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B, Chronic; Humans; Interferons; Organophosphonates; Polyethylene Glycols; Practice Guidelines as Topic; Tenofovir; Viral Load | 2014 |
Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Safety; Tenofovir | 2014 |
Molecular diagnosis and treatment of drug-resistant hepatitis B virus.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Molecular Diagnostic Techniques; Mutation; Nucleic Acid Hybridization; Organophosphonates; Phenotype; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Tenofovir; Treatment Outcome | 2014 |
Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Treatment Outcome | 2014 |
[Treatment of viral hepatitis in children].
Topics: Adenine; Adolescent; Antiviral Agents; Child; Child Welfare; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tenofovir | 2013 |
A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection.
Topics: Antiviral Agents; Chi-Square Distribution; Clinical Trials as Topic; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Odds Ratio; Patient Selection; Risk Factors; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Treating Immune-tolerant Hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Therapy; Hepatitis B, Chronic; Humans; Interferons; Nucleotides; Organophosphonates; Tenofovir | 2015 |
Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Long-Term Care; Organophosphonates; Tenofovir; Treatment Outcome | 2015 |
Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Long-Term Care; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome; Virus Replication | 2015 |
Antiviral therapies and prospects for a cure of chronic hepatitis B.
Topics: Animals; Antiviral Agents; Disease Management; Disease Models, Animal; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Mice; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2015 |
The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists.
Topics: Antiviral Agents; Glomerular Filtration Rate; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Patient Safety; Renal Elimination; Risk Assessment; Tenofovir; Treatment Outcome; Virus Replication | 2015 |
Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B.
Topics: Antiviral Agents; Databases, Factual; Drug Administration Schedule; Emtricitabine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Odds Ratio; Tenofovir | 2015 |
The Woodchuck, a Nonprimate Model for Immunopathogenesis and Therapeutic Immunomodulation in Chronic Hepatitis B Virus Infection.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Guanine; Hepatitis B Virus, Woodchuck; Hepatitis B, Chronic; Humans; Immunization Schedule; Marmota; T-Lymphocytes; Tenofovir; Vaccines, DNA; Virus Replication | 2015 |
Efficacy of tenofovir-based rescue therapy in patients with lamivudine-resistant hepatitis B virus: A systematic review and meta-analysis.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Tenofovir | 2016 |
Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients.
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Tenofovir; Treatment Outcome | 2016 |
Chronic hepatitis B in children: Therapeutic challenges and perspectives.
Topics: Adenine; Alanine Transaminase; Antigens, Viral; Antiviral Agents; Child; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Tolerance; Interferon-alpha; Lamivudine; Molecular Targeted Therapy; Organophosphonates; Practice Guidelines as Topic; Seroconversion; Telbivudine; Tenofovir; Thymidine; Viral Envelope Proteins | 2017 |
[Management and treatment of patients with hepatitis B].
Topics: Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2016 |
The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis.
Topics: Acute Kidney Injury; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Hypophosphatemia; Liver Cirrhosis; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs).
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Safety; Sustained Virologic Response; Tenofovir | 2017 |
Treatment of chronic hepatitis B infection-2017.
Topics: Antiviral Agents; Biomarkers; Clinical Trials as Topic; Drug Design; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Tenofovir | 2017 |
Management of Antiviral Resistance in Chronic Hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Tenofovir | 2017 |
Treatment of chronic hepatitis B infection: an update of Swedish recommendations.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Transplantation; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Sweden; Tenofovir | 2008 |
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update.
Topics: Adenine; Antiviral Agents; Case Management; DNA, Viral; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome; United States | 2008 |
[Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Multicenter Studies as Topic; Nucleosides; Organophosphonates; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Replication | 2008 |
[Resistance in hepatitis B virus].
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Gene Products, pol; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Models, Molecular; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Virus Replication | 2008 |
[Clinical management of patients with chronic hepatitis B virus infection].
Topics: Adenine; Antiviral Agents; Biopsy; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genotype; Guanine; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver; Liver Transplantation; Male; Nucleosides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2008 |
Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Polyethylene Glycols; Practice Guidelines as Topic; Pyrimidinones; Randomized Controlled Trials as Topic; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2008 |
HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2009 |
[Chronic hepatitis B: current therapy].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Guanine; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Humans; Immunotherapy, Active; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2008 |
Tenofovir for the treatment of hepatitis B virus.
Topics: Adenine; Antiviral Agents; Drug Approval; Drug Interactions; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; United States; United States Food and Drug Administration | 2009 |
Tenofovir disoproxil fumarate: in chronic hepatitis B.
Topics: Adenine; Administration, Oral; Adult; Hepatitis B, Chronic; Humans; Organophosphonates; Prodrugs; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion.
Topics: Adenine; Adjuvants, Immunologic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Randomized Controlled Trials as Topic; Risk Assessment; Serologic Tests; Severity of Illness Index; Tenofovir; Treatment Outcome | 2010 |
Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2010 |
Effect of newer oral antiviral agents on future therapy of chronic hepatitis B.
Topics: Adenine; Administration, Oral; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2010 |
[Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab].
Topics: Adenine; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Cyclophosphamide; Fatal Outcome; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunologic Factors; Immunotherapy; Liver Failure; Lymphoma, B-Cell, Marginal Zone; Male; Organophosphonates; Prednisone; Recurrence; Rituximab; Tenofovir; Vincristine; Virus Activation | 2010 |
Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Models, Economic; Organophosphonates; Quality of Life; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; United Kingdom | 2010 |
On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.
Topics: Adenine; Antiviral Agents; Asia; Biomarkers; DNA, Viral; Drug Monitoring; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Time Factors; Treatment Outcome; Viral Load; Virus Replication | 2010 |
Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Tenofovir | 2010 |
Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Nucleotides; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2010 |
Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Clinical Trials, Phase III as Topic; Double-Blind Method; Hepatitis B virus; Hepatitis B, Chronic; Humans; Multicenter Studies as Topic; Organophosphonates; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2010 |
Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?
Topics: Adenine; Antiviral Agents; Decision Making; Guanine; Hepatitis B, Chronic; Humans; Immunomodulation; Interferon alpha-2; Interferon-alpha; Nucleosides; Organophosphonates; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Tenofovir; Treatment Outcome | 2011 |
Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2011 |
Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2011 |
Hepatitis B virus resistance to antiviral drugs: where are we going?
Topics: Adenine; Antiviral Agents; Capsid; Clinical Protocols; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Virus Internalization; Virus Replication | 2011 |
Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Italy; Liver Cirrhosis; Liver Neoplasms; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review.
Topics: Adenine; Antiviral Agents; Controlled Clinical Trials as Topic; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Treatment Outcome | 2011 |
[Interferon-based versus direct antiviral therapy in patients with chronic hepatitis B].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Nucleotides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2011 |
Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding.
Topics: Adenine; Antiviral Agents; Breast Feeding; Female; Guanine; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2011 |
Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
Topics: Adenine; Antiviral Agents; Biomarkers; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Viral Load | 2012 |
Emerging pipeline drugs for hepatitis B infection.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Design; Drugs, Investigational; Guanine; Hepatitis B Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Treatment Outcome; Virus Replication | 2011 |
Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Nucleosides; Organophosphonates; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Time Factors; Treatment Outcome; Viral Load | 2012 |
New advances in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Coinfection; Disease Progression; Drug Resistance, Viral; Female; Guanine; Guidelines as Topic; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; HIV Infections; Humans; Interferons; Liver Cirrhosis; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; Tenofovir | 2012 |
New perspectives in the therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Monitoring; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferons; Interleukins; Organophosphonates; Polymorphism, Genetic; Prognosis; Tenofovir | 2012 |
[New drugs of treatment of patients with chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Emtricitabine; Hepatitis B, Chronic; Humans; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2012 |
First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Guanine; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2012 |
Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
Topics: Adenine; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients.
Topics: Adenine; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Organophosphonates; Tenofovir; Treatment Outcome | 2013 |
Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs.
Topics: Adenine; Age Factors; Antiviral Agents; Comorbidity; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Life Style; Organophosphonates; Severity of Illness Index; Telbivudine; Tenofovir; Thymidine; Time Factors | 2012 |
Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Transplantation; Mutation; Nucleosides; Nucleotides; Organophosphonates; Prognosis; Tenofovir; Viral Load | 2012 |
Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Guanine; Health Care Costs; Hepatitis B, Chronic; Humans; Models, Economic; Organophosphonates; Reproducibility of Results; Tenofovir | 2013 |
Letter: First-line monotherapies for chronic hepatitis B - indirect comparison between entecavir and tenofovir.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2013 |
Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Organophosphorus Compounds; Prodrugs; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
Management of chronic hepatitis B in the HIV-infected patient.
Topics: Adenine; Algorithms; Antiviral Agents; Clinical Trials as Topic; Decision Trees; Drug Therapy, Combination; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Editorial comment: HIV and HBV coinfection--a coming-of-age in treatment strategies.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
[New approaches in the treatment of hepatitis B].
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Contraindications; Deoxycytidine; Emtricitabine; Famciclovir; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Organophosphorus Compounds; Polyethylene Glycols; Prodrugs; Prognosis; Recombinant Proteins; Tenofovir; Zalcitabine | 2004 |
New treatment of chronic hepatitis B.
Topics: Adenine; Animals; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Organophosphorus Compounds; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2004 |
Treatment of hepatitis B virus infection in patients coinfected with HIV.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Disease Progression; Drug Monitoring; Emtricitabine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Tenofovir | 2005 |
[Liver transplantation for complications of hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; Guanine; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Cirrhosis; Liver Transplantation; Mutation; Organophosphonates; Recurrence; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Vaccination; Viral Load; Virus Replication | 2006 |
Personal view: the management of chronic hepatitis B infection.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Organophosphonates; Tenofovir | 2006 |
Perspectives on the development of acyclic nucleotide analogs as antiviral drugs.
Topics: Adenine; Animals; Antiviral Agents; Dogs; Drug Design; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Nucleotides; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir | 2006 |
[Treating chronic lamivudine-resistant hepatitis B in HIV co-infected patients].
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2006 |
Treatment of chronic hepatitis B in HIV-infected patients in 2007.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2007 |
Clinical implications of resistance patterns against HBV-polymerase inhibitors for the treatment of chronic hepatitis B.
Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine | 2007 |
Review article: current antiviral therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Nucleosides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2008 |
136 trial(s) available for tenofovir and Hepatitis B, Chronic
| Article | Year |
|---|---|
Pradefovir Treatment in Patients With Chronic Hepatitis B: Week 24 Results From a Multicenter, Double-Blind, Randomized, Noninferiority, Phase 2 Trial.
Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphorus Compounds; Prodrugs; Tenofovir; Treatment Outcome; Viral Load | 2022 |
Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based Therapy.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Cross-Over Studies; DNA, Circular; Drug Therapy, Combination; Female; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Male; Nucleic Acids; Polymers; RNA, Viral; Seroconversion; Tenofovir; Treatment Outcome; Virus Inactivation | 2021 |
Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome; Viral Load | 2021 |
Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver f
Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Multicenter Studies as Topic; Polyethylene Glycols; Prospective Studies; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2021 |
Randomized Controlled Study of Tenofovir versus Lamivudine Followed by Tenofovir in Severe Exacerbation of Hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Tenofovir; Treatment Outcome | 2022 |
Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations With Implications on Host Gene Dysregulation.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; RNA; Tenofovir; Treatment Outcome; Viral Load; Viremia; Virus Integration; Virus Replication | 2022 |
Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Dyslipidemias; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipids; Male; Middle Aged; Tenofovir | 2022 |
A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV 'cure'.
Topics: Antiviral Agents; DNA, Viral; Hepatic Insufficiency; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Failure; Male; Middle Aged; Nucleosides; Tenofovir | 2022 |
Pegylated interferon-α-2b combined with tenofovir disoproxil fumarate, granulocyte-macrophage colony-stimulating factor, and hepatitis B vaccine treatment for naïve HBeAg-positive chronic hepatitis B patients: A prospective, multicenter, randomized contro
Topics: Antiviral Agents; Granulocyte-Macrophage Colony-Stimulating Factor; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Tenofovir; Treatment Outcome | 2022 |
Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients.
Topics: Adenine; Antiviral Agents; Creatinine; DNA, Viral; Fumarates; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2022 |
Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study.
Topics: Adenine; Alanine; Antiviral Agents; DNA, Viral; Female; Fumarates; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome | 2022 |
A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; RNA; Tenofovir; Treatment Outcome | 2023 |
Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Polyethylene Glycols; Tenofovir; Treatment Outcome | 2023 |
Tenofovir versus entecavir on the prognosis of hepatitis B-related hepatocellular carcinoma after surgical resection: a randomised controlled trial.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis B, Chronic; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Prognosis; Tenofovir; Treatment Outcome | 2023 |
Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study.
Topics: Antiviral Agents; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospective Studies; Rituximab; Symptom Flare Up; Tenofovir | 2023 |
The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Tenofovir; Treatment Outcome | 2023 |
A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B: First-stage results at week 48.
Topics: Adolescent; Adult; Aged; Antiviral Agents; China; Double-Blind Method; Drug Administration Schedule; Drug Compounding; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Young Adult | 2019 |
RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection.
Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Combinations; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; RNA, Small Interfering; RNAi Therapeutics; Tenofovir; Time Factors; Young Adult | 2020 |
Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Prodrugs; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Mitochondrial toxicity and body shape changes during nucleos(t)ide analogues administration in patients with chronic hepatitis B.
Topics: Adenine; Adiposity; Antiviral Agents; Cross-Sectional Studies; DNA, Mitochondrial; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Mitochondria; Organophosphonates; RNA, Mitochondrial; Tenofovir | 2020 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Double-Blind Method; Drug Substitution; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Nasopharyngitis; Renal Insufficiency; Respiratory Tract Infections; Sustained Virologic Response; Tenofovir | 2020 |
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
Topics: Adult; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Moldova; Nucleic Acids; Polyethylene Glycols; Polymers; Recombinant Proteins; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2020 |
Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Male; Nucleosides; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Recurrence; Tenofovir; Treatment Outcome; Withholding Treatment | 2020 |
Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial.
Topics: Adult; Antiviral Agents; Bone Density; Double-Blind Method; Drug Administration Schedule; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Republic of Korea; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Consolidation period of 18 months no better at promoting off-treatment durability in HBeAg-positive chronic hepatitis B patients with tenofovir disoproxil fumarate treatment than a 12-month period: A prospective randomized cohort study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Administration Schedule; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Recurrence; Seroconversion; Sustained Virologic Response; Tenofovir; Time Factors | 2020 |
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Sustained Virologic Response; Telbivudine; Tenofovir | 2020 |
Comparison of Tenofovir Disoproxil Fumarate and Entecavir in the Prophylaxis of HBV Reactivation.
Topics: Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Middle Aged; Tenofovir; Viral Load | 2021 |
A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study.
Topics: Antiviral Agents; DNA, Viral; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Iran; Polyethylene Glycols; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Comparison of viral control between two tenofovir dose reduction regimens (300 mg every 48 hours versus 300 mg every 72 hours) in chronic hepatitis B patients with moderate renal impairment from tenofovir-induced renal dysfunction.
Topics: Antiviral Agents; Drug Tapering; Female; Hepatitis B, Chronic; Humans; Infant, Newborn; Kidney Diseases; Male; Tenofovir; Thailand | 2021 |
Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Risk Factors; Tenofovir; Time Factors | 2021 |
Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prospective Studies; Tenofovir; Treatment Outcome | 2021 |
Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2021 |
Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial.
Topics: Adult; Aged; Alanine Transaminase; Biomarkers; Double-Blind Method; Female; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Placebo Effect; Taiwan; Tenofovir; Treatment Outcome | 2021 |
Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China.
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infectious Disease Transmission, Vertical; Male; Mothers; Pregnancy; Tenofovir; Treatment Outcome; Viral Load | 2022 |
Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate.
Topics: Alanine; Antiviral Agents; Hepatitis B; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2022 |
Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.
Topics: Adolescent; Adult; Alanine; Antiviral Agents; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2021 |
Bone loss in hepatitis B virus-infected patients can be associated with greater osteoclastic activity independently of the retroviral use.
Topics: Absorptiometry, Photon; Adult; Anti-Retroviral Agents; Body Composition; Bone Density; Bone Resorption; Cross-Sectional Studies; Female; Femur Neck; Fibroblast Growth Factor-23; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hip; Humans; Lamivudine; Lumbar Vertebrae; Male; Middle Aged; Osteoclasts; Tenofovir | 2021 |
Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B.
Topics: Alanine Transaminase; Antiviral Agents; Bilirubin; China; Cohort Studies; DNA, Viral; Fatty Liver; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Tenofovir; Treatment Outcome; Viremia | 2021 |
Hepatitis B virus genome diversity in adolescents: Tenofovir disoproxil fumarate treatment effect and HBeAg serocon version.
Topics: Adolescent; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome; Viral Load | 2021 |
Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
Topics: Acute-On-Chronic Liver Failure; Adenine; Adult; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome | 2021 |
Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg-positive chronic hepatitis B naïve patients.
Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Prospective Studies; Tenofovir; Treatment Outcome | 2021 |
Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.
Topics: Alanine; Antiviral Agents; Female; Fumarates; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infectious Disease Transmission, Vertical; Pregnancy; Tenofovir; Treatment Outcome; Viral Load | 2021 |
Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
Topics: Adult; Antiviral Agents; China; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Netherlands; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2017 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2016 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Biomarkers; Double-Blind Method; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2016 |
Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2018 |
Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Real-Time Polymerase Chain Reaction; Tenofovir; Treatment Outcome; Young Adult | 2017 |
Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Intention to Treat Analysis; Interferon-alpha; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Tenofovir; Viral Load; Young Adult | 2017 |
Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Alanine Transaminase; Antiviral Agents; Biomarkers; Cohort Studies; Coinfection; Ethiopia; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Viral Load; Young Adult | 2017 |
Four-year Outcomes After Cessation of Tenofovir in Immune-tolerant Chronic Hepatitis B Patients.
Topics: Adult; Antiviral Agents; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Hepatitis B, Chronic; Hong Kong; Humans; Immunocompetence; Male; Middle Aged; Recurrence; Tenofovir; Young Adult | 2018 |
Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Nucleosides; Sustained Virologic Response; Tenofovir; Treatment Outcome | 2018 |
Unconventional T cells in chronic hepatitis B patients on long-term suppressive therapy with tenofovir followed by a Peg-IFN add-on strategy: A randomized study.
Topics: Adult; Aged; Antiviral Agents; Flow Cytometry; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Sustained Virologic Response; T-Lymphocyte Subsets; Tenofovir; Treatment Outcome | 2018 |
Tenofovir
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hospital Costs; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Failure; Viral Load | 2017 |
ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Tenofovir; Young Adult | 2018 |
Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment.
Topics: Adult; Aged; Antiviral Agents; Cytokines; DNA, Viral; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pteridines; Seroconversion; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2018 |
Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative Patients.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Recurrence; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.
Topics: Adult; Antiviral Agents; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Sustained Virologic Response; Tenofovir; Time Factors; Treatment Outcome | 2018 |
Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus.
Topics: Administration, Oral; Adult; Antiviral Agents; Area Under Curve; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Postpartum Period; Pregnancy; Tenofovir; Viral Load | 2018 |
Efficacy of tenofovir in preventing perinatal transmission of HBV infection in pregnant women with high viral loads.
Topics: Adult; Case-Control Studies; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Postpartum Period; Pregnancy; Tenofovir; Treatment Outcome; Viral Load | 2018 |
Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection.
Topics: Absorptiometry, Photon; Adult; Alanine Transaminase; Antiviral Agents; Bone Density; Bone Diseases, Metabolic; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Female; Glomerular Filtration Rate; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Hip; Humans; Lumbar Vertebrae; Male; Maleates; Middle Aged; Organophosphonates; Osteoporosis; Renal Insufficiency; Sustained Virologic Response; Tenofovir; Treatment Outcome | 2019 |
Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia.
Topics: Adolescent; Adult; Antiviral Agents; Biomarkers; Ethiopia; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Tenofovir; Treatment Adherence and Compliance; Treatment Outcome; Viral Load; Young Adult | 2018 |
Tenofovir and telbivudine combination therapy rapidly decreases viral loads in immune-tolerant chronic hepatitis B patients awaiting assisted reproduction: an open-label, randomized, controlled study.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Immune Tolerance; Male; Preconception Care; Reproductive Techniques, Assisted; Seroconversion; Telbivudine; Tenofovir; Viral Load | 2019 |
Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBeAg-positive patients with chronic hepatitis B: A large, multicentre, randomized controlled trials.
Topics: Adult; Antiviral Agents; China; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Tenofovir; Treatment Outcome | 2019 |
Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials.
Topics: Adult; Alanine Transaminase; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipase; Liver; Male; Middle Aged; Nucleotides; Reverse Transcriptase Inhibitors; Symptom Flare Up; Tenofovir; Withholding Treatment | 2019 |
Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; CD8-Positive T-Lymphocytes; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Tolerance; Interferon-gamma; Interleukin-2; Male; Middle Aged; Tenofovir; Trans-Activators; Tumor Necrosis Factor-alpha; Viral Load; Viral Regulatory and Accessory Proteins; Young Adult | 2019 |
Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Asian People; China; Double-Blind Method; Female; Hepatitis B, Chronic; Humans; Longitudinal Studies; Male; Middle Aged; Tenofovir; Viral Load; Young Adult | 2019 |
Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.
Topics: Adult; Anti-HIV Agents; Coinfection; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir | 2019 |
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Internationality; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2019 |
Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.
Topics: Adenine; Adult; Aged; Alanine; Antiviral Agents; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir | 2019 |
Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Double-Blind Method; Epitope Mapping; Epitopes; Female; Genotype; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Seroconversion; Tenofovir; Viral Load | 2019 |
Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation.
Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B, Chronic; Humans; Immunoglobulins; Liver Transplantation; Male; Middle Aged; Organophosphonates; Prospective Studies; Recurrence; Tenofovir; Treatment Outcome; United States | 2013 |
Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Evolution, Molecular; Female; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Phylogeny; RNA-Directed DNA Polymerase; Tenofovir; Time Factors; Treatment Failure; Young Adult | 2013 |
Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: results from the CAPRISA 004 trial.
Topics: Adenine; Adult; Anti-Infective Agents, Local; Antiviral Agents; Carrier State; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Vaginal Creams, Foams, and Jellies | 2013 |
Antiviral treatment improves disrupted peripheral B lymphocyte homeostasis in chronic hepatitis B virus-infected patients.
Topics: Adenine; Adult; Antiviral Agents; B-Lymphocytes; Female; Flow Cytometry; Hepatitis B, Chronic; Homeostasis; Humans; Liver Diseases; Male; Organophosphonates; Tenofovir; Viral Load; Virus Replication | 2013 |
Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients.
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B Antibodies; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load; Viremia | 2014 |
Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Europe; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; New Zealand; North America; Organophosphonates; Prospective Studies; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings.
Topics: Adenine; Adolescent; Adult; Asian; Creatinine; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Residence Characteristics; Tenofovir; Treatment Outcome; Young Adult | 2014 |
Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
Topics: Adenine; Adult; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Viremia; Virus Replication | 2014 |
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; Drug Carriers; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome; Viral Load | 2014 |
First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Young Adult | 2014 |
No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Point Mutation; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Tenofovir | 2014 |
Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Double-Blind Method; Female; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Regression Analysis; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; Young Adult | 2014 |
Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.
Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir | 2015 |
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.
Topics: Adenine; DNA, Viral; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Intention to Treat Analysis; Liver Cirrhosis; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2015 |
Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Asian People; China; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml).
Topics: Adenine; Adult; Asian People; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Native Hawaiian or Other Pacific Islander; Organophosphonates; Statistics, Nonparametric; Tenofovir; Viral Load | 2015 |
Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Creatinine; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Prospective Studies; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.
Topics: Adenine; Adult; Alanine; Antiviral Agents; DNA, Viral; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Time Factors; Treatment Outcome; Young Adult | 2015 |
Baseline interpatient hepatitis B viral diversity differentiates HBsAg outcomes in patients treated with tenofovir disoproxil fumarate.
Topics: Adult; Antiviral Agents; Disease Transmission, Infectious; DNA, Viral; Female; Genetic Variation; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Tenofovir | 2015 |
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Tenofovir; Treatment Failure | 2016 |
Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation.
Topics: Adult; Antiviral Agents; Creatinine; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome | 2015 |
Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Retrospective Studies; Tenofovir; Time Factors; Viral Load | 2015 |
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Republic of Korea; Tenofovir; Treatment Outcome | 2016 |
Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus.
Topics: Adenine; Adult; DNA, Viral; Female; Follow-Up Studies; Gestational Age; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Maternal Age; Multivariate Analysis; Organophosphonates; Patient Selection; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prospective Studies; Reference Values; Risk Assessment; Taiwan; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
Topics: Adult; Alanine Transaminase; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aspartate Aminotransferases; Coinfection; Cote d'Ivoire; DNA, Viral; Drug Resistance, Viral; Emtricitabine; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; HIV-2; Humans; Lamivudine; Male; Prospective Studies; Tenofovir; Viral Load | 2015 |
Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Time Factors; Treatment Outcome; Vitamin B Deficiency; Vitamin D; Vitamins; Young Adult | 2015 |
Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Double-Blind Method; Drug Administration Schedule; Female; Hepatitis B, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Risk Assessment; Tenofovir | 2015 |
Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
Topics: Adenine; Adult; Amantadine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hep G2 Cells; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Reproducibility of Results; RNA, Viral; Tenofovir; Virion | 2016 |
[Therapy discontinuation after many years of virus suppression is possible].
Topics: Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Recurrence; Tenofovir | 2015 |
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.
Topics: Administration, Oral; Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Internationality; Kaplan-Meier Estimate; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Risk Assessment; Severity of Illness Index; Survival Rate; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2016 |
Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; Young Adult | 2016 |
Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Republic of Korea; Tenofovir; Treatment Outcome | 2016 |
Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load | 2016 |
Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load.
Topics: Adult; Alanine Transaminase; Antiviral Agents; China; Congenital Abnormalities; Creatine Kinase; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Intention to Treat Analysis; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Tenofovir; Viral Load; Young Adult | 2016 |
Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
Topics: Adult; Antiviral Agents; Biomarkers; DNA, Viral; Double-Blind Method; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Promoter Regions, Genetic; Sequence Analysis, DNA; Seroconversion; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
Topics: Adult; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.
Topics: Administration, Oral; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Tenofovir; Treatment Outcome | 2016 |
Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Biopsy; Clinical Trials, Phase III as Topic; Fatty Liver; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Histocytochemistry; Humans; Liver; Male; Middle Aged; Tenofovir; Young Adult | 2017 |
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load | 2008 |
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Medication Adherence; Middle Aged; Mutation; Organophosphonates; Tenofovir | 2010 |
Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Kaplan-Meier Estimate; Kidney; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Time Factors; Virus Replication | 2010 |
Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Hepatitis B, Chronic; HIV Infections; Humans; Male; Organophosphonates; Prospective Studies; Tenofovir; Thailand | 2010 |
Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
Topics: Adenine; Adult; Aged; Aged, 80 and over; DNA, Viral; Drug Resistance, Viral; Epidemiologic Methods; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Salvage Therapy; Tenofovir; Treatment Failure; Treatment Outcome; Viral Load; Young Adult | 2011 |
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.
Topics: Adenine; Adolescent; Adult; Aged; Creatinine; Deoxycytidine; DNA, Viral; Drug Combinations; Emtricitabine; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load | 2011 |
Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; India; Liver Failure, Acute; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2011 |
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.
Topics: Adenine; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Gene Products, pol; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; RNA-Directed DNA Polymerase; Tenofovir | 2011 |
Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study.
Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Europe; Follow-Up Studies; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2011 |
Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B.
Topics: Adenine; Adolescent; Alanine Transaminase; Antiviral Agents; Bone Density; Child; DNA, Viral; Double-Blind Method; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir; Viral Load | 2012 |
Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genome, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Tenofovir; Treatment Outcome; Young Adult | 2013 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Topics: Adenine; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunohistochemistry; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Safety Management; Severity of Illness Index; Tenofovir; Time Factors; Treatment Outcome | 2013 |
Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Drug Tolerance; Female; Genotype; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Phenotype; Phosphorus; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2012 |
52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Replication | 2013 |
Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2002 |
Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Middle Aged; Organophosphonates; Organophosphorus Compounds; Pilot Projects; Tenofovir; Time Factors; Viral Load | 2002 |
An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lymphocyte Count; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2003 |
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Mutation; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.
Topics: Adenine; Adult; Drug Resistance, Viral; Female; Hepatitis B, Chronic; HIV Infections; Humans; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Tenofovir in chronic hepatitis B.
Topics: Adenine; Adult; Aged; Hepatitis B, Chronic; Humans; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Epidemiologic Methods; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load; Virus Replication | 2005 |
Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Models, Biological; Organophosphonates; Tenofovir; Viral Load; Virus Replication | 2005 |
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
Topics: Adenine; Anti-HIV Agents; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; Tenofovir; Treatment Failure | 2006 |
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2006 |
Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2006 |
Second tenofovir phase III study for the chronic HBV reaches primary endpoint.
Topics: Adenine; Anti-HIV Agents; Double-Blind Method; Hepatitis B, Chronic; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2007 |
Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
Topics: Adenine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Male; Organophosphonates; Tenofovir; Thailand; Transaminases; Treatment Outcome; Viral Load | 2008 |
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.
Topics: Adenine; Adult; Aged; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load | 2008 |
700 other study(ies) available for tenofovir and Hepatitis B, Chronic
| Article | Year |
|---|---|
In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
Topics: Adenine; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Multiple, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Microbial Sensitivity Tests; Mutation; Organophosphonates; Pyrimidine Nucleosides; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2007 |
Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV/HBV-coinfected patients: a multicentre prospective cohort study.
Topics: Coinfection; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Prospective Studies; Tenofovir | 2021 |
Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B.
Topics: Antiviral Agents; Fibrosis; Guanine; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2022 |
Concentration of LDLR, degree of hepatic fibrosis and hepatic steatosis in patients with chronic hepatitis B infection treated with tenofovir disoproxil fumarate.
Topics: Adult; Aged; Antiviral Agents; Fatty Liver; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipoproteins, HDL; Liver Cirrhosis; Male; Middle Aged; Receptors, LDL; Tenofovir; Triglycerides | 2021 |
Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Meta-Analysis as Topic; Proportional Hazards Models; Research Design; Risk Assessment; Tenofovir; Treatment Outcome | 2022 |
Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Tenofovir | 2021 |
Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs.
Topics: Aged; Cohort Studies; Female; Hepatitis B, Chronic; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Nucleosides; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Artificial Intelligence; Asian People; Carcinoma, Hepatocellular; Cohort Studies; Computer Simulation; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Republic of Korea; Tenofovir; White People | 2022 |
Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Case-Control Studies; Cohort Studies; COVID-19; Databases, Factual; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Odds Ratio; Republic of Korea; Risk; Severity of Illness Index; Tenofovir; Young Adult | 2021 |
Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide
Topics: Adenine; Alanine; Body Weight; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir | 2022 |
Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy.
Topics: Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Tenofovir; Treatment Outcome | 2022 |
Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Topics: Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Immunomodulation and RNA interference alter hepatitis B virus-specific CD8 T-cell recognition of infected HepG2-NTCP.
Topics: CD8-Positive T-Lymphocytes; Culture Media, Conditioned; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunomodulation; Interferon Type I; RNA Interference; Tenofovir; Toll-Like Receptor 7; Toll-Like Receptor 8 | 2022 |
Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study).
Topics: Adult; Age Factors; Antiviral Agents; Asian People; Cohort Studies; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Nucleosides; Race Factors; Recurrence; Retreatment; Tenofovir; White People | 2022 |
Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients.
Topics: Aged; Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Tenofovir; Treatment Outcome | 2021 |
Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study.
Topics: Adult; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Kidney; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Letter to the editor: Reactivation of HBV triggered by SARS-CoV-2 in a patient with cirrhosis.
Topics: Acute-On-Chronic Liver Failure; Adult; Antiviral Agents; COVID-19; DNA, Viral; Fatal Outcome; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; SARS-CoV-2; Tenofovir; Treatment Outcome | 2022 |
Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Middle Aged; Tenofovir; Treatment Failure; Treatment Outcome; Young Adult | 2022 |
Earlier and Higher Rate of Hepatitis B Virus Relapse After Discontinuing Tenofovir Versus Entecavir in Hepatitis B e Antigen-Positive Patients.
Topics: Antiviral Agents; DNA, Viral; Guanine; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Tenofovir; Treatment Outcome | 2022 |
Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study.
Topics: Adenine; Adult; Antiviral Agents; China; Cleft Lip; Cleft Palate; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Infant, Newborn; Pregnancy; Pregnant Women; Prospective Studies; Tenofovir | 2022 |
Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapies.
Topics: Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Retrospective Studies; Symptom Flare Up; Tenofovir; Treatment Outcome | 2022 |
Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Retrospective Studies; Tenofovir | 2021 |
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis.
Topics: Adenine; Alanine; Cholesterol; Hepatitis B, Chronic; Humans; Propensity Score; Tenofovir | 2022 |
Effects of Long-Term Tenofovir and Entecavir Treatment on Bone Mineral Density in Patients with Chronic Hepatitis B.
Topics: Adenine; Antiviral Agents; Bone Density; Guanine; Hepatitis B, Chronic; Humans; Prospective Studies; Tenofovir; Treatment Outcome | 2022 |
[Clinical significance and management strategies of low-level viremia during the treatment of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome; Viremia | 2021 |
Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Fumarates; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Renal Insufficiency, Chronic; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Renal Outcomes With Tenofovir Alafenamide in Liver Transplant Recipients.
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Kidney; Liver Transplantation; Tenofovir; Treatment Outcome | 2023 |
Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Retrospective Studies; Tenofovir; Treatment Outcome; United States | 2022 |
Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
Topics: Aged; Alanine; Antiviral Agents; Drug Substitution; Female; Follow-Up Studies; Fumarates; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Nucleosides; Prospective Studies; Tenofovir; Treatment Outcome | 2022 |
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles.
Topics: Adenine; Alanine; Dyslipidemias; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
The Risk of Hepatocellular Carcinoma in Entecavir Versus Tenofovir Treated US Cohort With Chronic Hepatitis B Virus.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Retrospective Studies; Tenofovir; Treatment Outcome | 2023 |
Validation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment.
Topics: Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Risk Factors; Tenofovir | 2022 |
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B.
Topics: Adenine; Alanine; Carcinoma, Hepatocellular; Female; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Tenofovir | 2022 |
First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide.
Topics: Alanine; Antiviral Agents; Hepatitis B; Hepatitis B, Chronic; Humans; Prospective Studies; Retrospective Studies; Tenofovir; United States | 2022 |
Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Radiofrequency Ablation; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Renal safety of tenofovir disoproxil fumarate and entecavir in liver transplant patients: a nationwide Korean registry study.
Topics: Adult; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Kidney Diseases; Liver Transplantation; Registries; Republic of Korea; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Prognosis Comparison Between Chronic Hepatitis B Patients Receiving a Finite Course of Tenofovir and Entecavir Treatment: A Nationwide Cohort Study in Taiwan.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Prognosis; Taiwan; Tenofovir; Treatment Outcome | 2022 |
Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Mutation; Organophosphonates; RNA-Directed DNA Polymerase; Tenofovir; Viremia | 2022 |
Prophylactic effect of tenofovir on viral reactivation in immunocompromised pregnant women living with hepatitis B virus.
Topics: Antiviral Agents; Female; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Pregnancy; Pregnant Women; Symptom Flare Up; Tenofovir; Viral Load | 2022 |
Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome; Viral Load | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Female; Hepatitis B; Hepatitis B, Chronic; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Milk, Human; Pregnancy; Tenofovir | 2022 |
Characterization of the tenofovir resistance-associated mutations in the hepatitis B virus isolates across genotypes A to D.
Topics: DNA, Viral; Drug Resistance, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Mutation; Tenofovir | 2022 |
Primary partial response with tenofovir monotherapy: two adults and one child.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Effectiveness and Safety of Low Dose of Tenofovir Disoproxil Fumarate in Malagasy Patients with Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Comparable outcomes of decompensated chronic hepatitis B patients treated with entecavir or tenofovir: an 8-year cohort study.
Topics: Antiviral Agents; Cohort Studies; End Stage Liver Disease; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Tenofovir; Treatment Outcome | 2022 |
Long-term follow-up of treatment-naïve HBeAg-negative patients with chronic hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2023 |
Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Topics: Adenine; Adult; Alanine; Antiviral Agents; DNA, Viral; Hepatitis B, Chronic; Humans; Renal Insufficiency, Chronic; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks.
Topics: Adenine; Adult; Alanine; Hepatitis B, Chronic; HIV Infections; Humans; Phosphates; Prospective Studies; Tenofovir | 2022 |
Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse.
Topics: Antiviral Agents; DNA, Viral; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Recurrence; Tenofovir; Treatment Outcome | 2022 |
One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study.
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2022 |
Treatment of chronic hepatitis B: virological and pharmacological aspects
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Real-life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose, and uric acid in chronic hepatitis B patients.
Topics: Antiviral Agents; Glucose; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipids; Retrospective Studies; Tenofovir; Treatment Outcome; Uric Acid | 2022 |
Tenofovir Alafenamide use in pregnant women with chronic hepatitis B virus infection: more data needed.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Pregnancy; Pregnant Women; Tenofovir | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide of mothers with chronic hepatitis B infection-Authors' reply.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Milk, Human; Mothers; Tenofovir | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B, Chronic; HIV Infections; Humans; Milk, Human; Mothers; Tenofovir | 2022 |
Comparison of tenofovir disoproxil fumarate and telbivudine in preventing hepatitis B transmission in mothers with high viral load.
Topics: Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Mothers; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Telbivudine; Tenofovir; Viral Load | 2023 |
Association of tenofovir and entecavir use with prognosis after surgical resection for hepatitis B virus-related hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Tenofovir; Treatment Outcome | 2022 |
Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis.
Topics: Adenine; Alanine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Retrospective Studies; Tenofovir | 2022 |
Efficacy and safety of tenofovir disoproxil fumarate or telbivudine used throughout pregnancy for the prevention of mother-to-child transmission of hepatitis B virus: A cohort study.
Topics: Antiviral Agents; Cohort Studies; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Telbivudine; Tenofovir; Viral Load | 2022 |
Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Tenofovir; Treatment Outcome | 2023 |
Switching from Tenofovir-Based Combination Therapy to Tenofovir Monotherapy in Multidrug-Experienced Chronic Hepatitis B Patients: a 5-Year Experience at Two Centers.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off-therapy relapse: An observational study.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Symptom Flare Up; Tenofovir; Treatment Outcome; Withholding Treatment | 2022 |
Does Hepatic Steatosis Influence the Virological Response with Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir Disoproxil Fumarate?
Topics: Adult; Antiviral Agents; DNA, Viral; Fatty Liver; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Awareness and treatment of chronic hepatitis B in Malaysia-findings from a community-based screening campaign.
Topics: Adult; Antiviral Agents; DNA, Viral; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Malaysia; Tenofovir | 2022 |
Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients-author's reply.
Topics: Adenine; Alanine; Bone Density; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir | 2022 |
Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B.
Topics: Adenine; Alanine; Bone Density; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir | 2022 |
Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Kidney; Longitudinal Studies; Maleates; Organophosphonates; Renal Insufficiency, Chronic; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
Topics: Adenine; Alanine; Antiviral Agents; DNA, Viral; Hepatitis B, Chronic; Humans; Recurrence; Retreatment; Retrospective Studies; Tenofovir; Treatment Outcome | 2023 |
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B.
Topics: Adenine; Alanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B - author's reply.
Topics: Adenine; Alanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort.
Topics: Antiviral Agents; Cohort Studies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection.
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis A; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnant Women; Tenofovir; Viral Load | 2023 |
Hepatitis B Virus (HBV) Replication During Tenofovir Therapy Is Frequent in Human Immunodeficiency Virus/HBV Coinfection.
Topics: Cohort Studies; Coinfection; DNA, Viral; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Tenofovir; Viral Load | 2023 |
Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Fumarates; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir; Treatment Outcome | 2022 |
Efficacy and Safety of Peginterferon
Topics: Antiviral Agents; Genotype; Guanine; Hepatitis B, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2022 |
Treating Hepatitis B Virus in Times of COVID-19: The Case for Clinical Pharmacogenomics Research in Tenofovir-Induced Kidney Toxicity.
Topics: Antiviral Agents; COVID-19; DNA, Viral; Ecosystem; Ghana; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Pharmacogenetics; SARS-CoV-2; Tenofovir | 2022 |
Prospective cohort study of prevention of mother to child transmission of hepatitis B infection and 9 months follow-up of hepatitis B-exposed infants at Ile-Ife, Nigeria.
Topics: Adult; DNA, Viral; Female; Follow-Up Studies; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Nigeria; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Tenofovir | 2022 |
Pembrolizumab-induced acute exacerbation of hepatitis D.
Topics: Antiviral Agents; Carcinoma, Non-Small-Cell Lung; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; Humans; Interferon-alpha; Lung Neoplasms; Male; Middle Aged; RNA; Tenofovir | 2023 |
Long-Acting Treatments for Hepatitis B.
Topics: Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg-positive chronic hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Genotype; Haplotypes; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Tenofovir | 2023 |
Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Tenofovir; Treatment Outcome; Withholding Treatment | 2023 |
Effect of nucleos(t)ide analogues on blood lipid profiles in patients with chronic hepatitis B: A cross-sectional survey.
Topics: Adenine; Antiviral Agents; Cross-Sectional Studies; Hepatitis B, Chronic; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lipids; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Efficacy and safety of long-term postpartum antiviral therapy in hepatitis B virus-infected mothers receiving prophylactic tenofovir disoproxil fumarate treatment.
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Postpartum Period; Pregnancy; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2023 |
Prevalence and Associated Factors of Low-Level Viremia in Chronic Hepatitis B Patients After Long-Term Therapy with Nucleos(t)ide Analogs.
Topics: Antiviral Agents; China; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prevalence; Tenofovir; Treatment Outcome; Viremia | 2023 |
Tenofovir Alafenamide for Multiple Drug-Resistant Chronic Hepatitis B: A 3-Year Clinical Trial.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Tenofovir; Treatment Outcome | 2023 |
Profiling of Peripheral TRBV and CD4+CD25+ Treg in CHB Patients with HBeAg SC during TDF Treatment.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; T-Lymphocytes, Regulatory; Tenofovir; Treatment Outcome; Viral Load | 2023 |
A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Topics: Alanine Transaminase; Antiviral Agents; Cyclophosphamide; DNA, Viral; Doxorubicin; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lymphoma, Large B-Cell, Diffuse; Prednisone; Prospective Studies; Rituximab; Tenofovir; Vincristine | 2023 |
Effects of viral load on tenofovir vs. entecavir efficacy in recurrence prevention of hepatitis B virus-related hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir; Treatment Outcome; Viral Load | 2023 |
Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; COVID-19; Hepatitis B, Chronic; Humans; Retrospective Studies; SARS-CoV-2; Tenofovir; Treatment Outcome | 2023 |
Diabetes Mellitus Impacts on the Performance of Hepatocellular Carcinoma Risk Scores in Chronic Hepatitis B Patients.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Diabetes Mellitus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Risk Factors; Tenofovir | 2023 |
Resistant mutations within the hepatitis B virus reverse transcriptase sequence in treatment failure patients with chronic HBV infection in Vietnam.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Mutation; RNA-Directed DNA Polymerase; Telbivudine; Tenofovir; Treatment Failure; Vietnam | 2023 |
Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-gamma; Interleukin-18; Interleukin-7; Recurrence; Tenofovir; Treatment Outcome | 2023 |
Personalized Antiviral Drug Selection in Patients With Chronic Hepatitis B Using a Machine Learning Model: A Multinational Study.
Topics: Antiviral Agents; Artificial Intelligence; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Machine Learning; Male; Retrospective Studies; Tenofovir; Treatment Outcome | 2023 |
Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Tenofovir; Treatment Outcome | 2023 |
Viral hepatitis in persons living with HIV in the post-COVID era.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; COVID-19; Drug Users; Hepatitis A; Hepatitis B; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Sexual and Gender Minorities; Substance Abuse, Intravenous; Tenofovir | 2023 |
Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation.
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Transplantation; Retrospective Studies; Tenofovir | 2023 |
Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy.
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Kidney; Retrospective Studies; Tenofovir; Treatment Outcome | 2023 |
The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; DNA, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Interleukin-1beta; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Prospective Studies; Tenofovir; Treatment Outcome | 2023 |
Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Retrospective Studies; Tenofovir; Treatment Outcome | 2023 |
Association of Alanine Aminotransferase Flares to Hepatitis B Surface Decline During Tenofovir Alone or With Pegylated Interferon Alfa.
Topics: Alanine Transaminase; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Tenofovir | 2023 |
Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study.
Topics: Antiviral Agents; DNA, Viral; Elasticity Imaging Techniques; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome | 2023 |
Aldo-keto reductase family 1 member B10 is regulated by nucleos(t)ide analogues for chronic hepatitis B.
Topics: Aldo-Keto Reductase Family 1 member B10; Aldo-Keto Reductases; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Tenofovir | 2023 |
A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir | 2023 |
Entecavir versus tenofovir on the recurrence of hepatitis B-related HCC after liver transplantation: A multicenter observational study.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Tenofovir; Treatment Outcome | 2023 |
Five-year on-treatment variables-based PPACS model predicts subsequent hepatocellular carcinoma in entecavir/tenofovir-treated patients.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Retrospective Studies; Risk Factors; Tenofovir; Treatment Outcome | 2023 |
Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: A nationwide claims study in South Korea.
Topics: Adenine; Adult; Alanine; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Osteoporotic Fractures; Retrospective Studies; Tenofovir | 2023 |
Study of the Molecular Dynamics Stability in the Inhibitory Interaction of Tenofovir Disoproxil Fumarate against CTLA-4 in Chronic Hepatitis B Patients.
Topics: CTLA-4 Antigen; Hepatitis B, Chronic; Humans; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Tenofovir | 2023 |
Severe skeletal damage suggesting neoplastic disease as a manifestation of tenofovir-induced Fanconi syndrome in chronic hepatitis B.
Topics: Antiviral Agents; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Neoplasms; Tenofovir | 2023 |
Letter: Entecavir versus tenofovir on serum lipoprotein levels of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy-Author's reply.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipoproteins; Liver Neoplasms; Tenofovir; Treatment Outcome | 2023 |
Letter: Entecavir versus tenofovir on serum lipoprotein levels of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipoproteins; Liver Neoplasms; Tenofovir; Treatment Outcome | 2023 |
Five-year results of a treatment program for chronic hepatitis B in Ethiopia.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Ethiopia; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Tenofovir | 2023 |
Symptoms of Liver Disease During Tenofovir Therapy With or Without Peginterferon: Results from the Hepatitis B Research Network Immune Active Trial.
Topics: Adult; Antiviral Agents; Biomarkers; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Tenofovir; Treatment Outcome | 2023 |
Successful results of early nucleos(t)ide analogue treatment for liver transplantation candidates with severe acute hepatitis B infection.
Topics: Antiviral Agents; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Failure, Acute; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2024 |
The relationship between the use of nucleos(t)ide analogs and metabolic parameters in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Glycated Hemoglobin; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Tenofovir; Treatment Outcome | 2023 |
Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV/HIV during antiretroviral therapy in Guangdong, China.
Topics: Adult; Coinfection; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Incidence; Lamivudine; Male; Retrospective Studies; Tenofovir | 2023 |
Antenatal hepatitis B virus sero-prevalence, risk factors, pregnancy outcomes and vertical transmission rate within 24 months after birth in a high HIV prevalence setting.
Topics: Child; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Mothers; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prevalence; Risk Factors; Seroepidemiologic Studies; Tenofovir | 2023 |
Effects of entecavir and tenofovir disoproxil fumarate on the incidence and severity of COVID-19 in patients with chronic hepatitis B.
Topics: Antiviral Agents; COVID-19; Hepatitis B, Chronic; Humans; Incidence; Retrospective Studies; Tenofovir; Treatment Outcome | 2023 |
Investigation of hepatitis B virus (HBV) rtS78T/sC69* mutation in a large cohort of chronic HBV-infected patients with nucleoside/nucleotide analogue treatment.
Topics: Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Multiple, Viral; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Nucleosides; RNA-Directed DNA Polymerase; Tenofovir; Viral Proteins | 2019 |
Effectiveness of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A protocol for systematic review and meta-analysis.
Topics: Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Meta-Analysis as Topic; Systematic Reviews as Topic; Tenofovir | 2019 |
Clinical factors leading to a change in management in chronic hepatitis B patients managed in a tertiary setting.
Topics: Adult; Antiviral Agents; Costs and Cost Analysis; Disease Management; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Tenofovir | 2020 |
Editorial: tenofovir disoproxil fumarate and prevention of mother-to-child transmission of hepatitis B virus-authors' reply.
Topics: Child; Female; Hemochromatosis; Hepatitis B virus; Hepatitis B, Chronic; Herpesvirus 1, Cercopithecine; Humans; Infectious Disease Transmission, Vertical; Mothers; Tenofovir; Viremia | 2019 |
Editorial: tenofovir disoproxil fumarate and prevention of mother-to-child transmission of hepatitis B virus.
Topics: Child; Female; Hemochromatosis; Hepatitis B virus; Hepatitis B, Chronic; Herpesvirus 1, Cercopithecine; Humans; Infectious Disease Transmission, Vertical; Mothers; Tenofovir; Viremia | 2019 |
Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Middle Aged; Mutation; RNA-Directed DNA Polymerase; Tenofovir; Viral Proteins | 2020 |
Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Survival Analysis; Tenofovir; Treatment Outcome | 2019 |
Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection.
Topics: Adenine; Adult; Aged; Antiviral Agents; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunomodulation; Interferon-alpha; Interleukin-10; Interleukin-12; Lamivudine; Leukocytes, Mononuclear; Lipopolysaccharides; Male; Nucleosides; Organophosphonates; Proto-Oncogene Proteins c-akt; Tenofovir | 2020 |
Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations.
Topics: Adult; DNA Mutational Analysis; DNA Probes; DNA, Viral; Drug Resistance, Viral; Feasibility Studies; Female; Gene Products, pol; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Oligonucleotides; Real-Time Polymerase Chain Reaction; Retrospective Studies; Tenofovir | 2019 |
In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.
Topics: Adenine; Hepatitis B, Chronic; Humans; Mutation; Organophosphonates; Tenofovir | 2019 |
First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China.
Topics: Antiviral Agents; Cost-Benefit Analysis; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Markov Chains; Tenofovir | 2019 |
Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China.
Topics: Adult; Aftercare; Antiviral Agents; Carcinoma, Hepatocellular; China; Disease Progression; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment.
Topics: Adult; Antiviral Agents; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Prospective Studies; Recurrence; Retreatment; Retrospective Studies; Taiwan; Tenofovir; Treatment Outcome; Withholding Treatment | 2019 |
Reply to: "In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients."
Topics: Adenine; Hepatitis B, Chronic; Humans; Mutation; Organophosphonates; Tenofovir | 2019 |
Letter: decreased neonatal hepatitis B virus (HBV) viremia by maternal tenofovir treatment predicts reduced chronic HBV infection in children born to highly viremic mothers.
Topics: Child; Female; Hemochromatosis; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Herpesvirus 1, Cercopithecine; Humans; Mothers; Tenofovir; Viremia | 2019 |
Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Creatinine; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; Young Adult | 2020 |
Efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B virus infection: A 2-year prospective study.
Topics: Adult; Antiviral Agents; China; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Male; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2019 |
Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; China; Cohort Studies; Disease Progression; Female; Guanine; Hepatitis B, Chronic; Hong Kong; Humans; International Cooperation; Japan; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Taiwan; Tenofovir; Treatment Outcome; United States | 2020 |
Reply to: "Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis".
Topics: Carcinoma, Hepatocellular; Delayed Diagnosis; Hepatitis B, Chronic; Humans; Liver Neoplasms; Mutation; Tenofovir | 2019 |
Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cause of Death; Female; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Propensity Score; Republic of Korea; Risk; Tenofovir | 2020 |
Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada.
Topics: Antiviral Agents; Canada; Cost-Benefit Analysis; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Probability; Quality-Adjusted Life Years; Tenofovir; Treatment Outcome | 2020 |
Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Female; Guanine; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Nucleosides; Predictive Value of Tests; Retrospective Studies; RNA; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2020 |
Comments on 'Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance'.
Topics: Guanine; Hepatitis B, Chronic; Humans; Mutation; Tenofovir | 2020 |
Is Tenofovir Superior to Entecavir in Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B? The Controversy Continues.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; China; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2020 |
Reply to: "Comment on - A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea".
Topics: Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prognosis; Republic of Korea; Tenofovir | 2020 |
Comment on - A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea.
Topics: Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Republic of Korea; Tenofovir | 2020 |
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
Topics: Adenine; Aged; Alanine; Antibodies, Viral; Antiviral Agents; Female; Fumarates; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Japan; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Surveys and Questionnaires; Tenofovir; Transaminases; Treatment Outcome | 2020 |
Response to comments on: Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance.
Topics: Guanine; Hepatitis B, Chronic; Humans; Mutation; Tenofovir | 2020 |
Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Propensity Score; Republic of Korea; Tenofovir | 2020 |
Tenofovir for the Prevention of HCC in Patients With Cirrhosis.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Tenofovir | 2020 |
Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate.
Topics: Adult; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Hypophosphatemia; Male; Middle Aged; Republic of Korea; Retrospective Studies; Risk Factors; Tenofovir; Treatment Outcome | 2019 |
Placental infection of hepatitis B virus among Thai pregnant women: Clinical risk factors and its association with fetal infection.
Topics: Adult; Cohort Studies; Female; Fetal Diseases; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Placenta Diseases; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prospective Studies; Risk Factors; Tenofovir; Thailand; Viral Load | 2020 |
Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hong Kong; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Prognosis; Research Design; Retrospective Studies; Risk Assessment; Risk Factors; Serologic Tests; Tenofovir | 2020 |
Model for End-Stage Liver Disease With Additional Criteria to Predict Short-Term Mortality in Severe Flares of Chronic Hepatitis B.
Topics: Acute-On-Chronic Liver Failure; Antiviral Agents; End Stage Liver Disease; Female; Guanine; Hepatitis B, Chronic; Hong Kong; Humans; Liver Function Tests; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Severity of Illness Index; Tenofovir | 2020 |
Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B?
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Humans; Liver Cirrhosis; Liver Neoplasms; Tenofovir; Virus Replication | 2020 |
Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B? Authors' reply.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Humans; Liver Cirrhosis; Liver Neoplasms; Tenofovir; Virus Replication | 2020 |
Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Risk; Tenofovir; Treatment Outcome | 2020 |
The safety and efficacy of tenofovir disoproxil fumarate used throughout pregnancy for mothers with chronic hepatitis B.
Topics: Antiviral Agents; Cesarean Section; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Mothers; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Tenofovir; Viral Load | 2020 |
Inhibitory Effect of Nucleos(t)ide Analogs on Telomerase Activity and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Telomerase; Tenofovir | 2020 |
The Administration of Tenofovir Disoproxil Fumarate for Pregnant Japanese Women with Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; Child; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Japan; Male; Mothers; Pregnancy; Pregnancy Complications; Prenatal Care; Tenofovir; Viral Load | 2020 |
Kinetics of Hepatitis B Core-Related Antigen and Anti-Hepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus-Hepatitis B Coinfection.
Topics: Adult; Antiviral Agents; Coinfection; Female; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Tenofovir | 2020 |
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
Topics: Adenine; Adult; Alanine; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Nucleotides; Platelet Count; Research Design; Risk; Tenofovir; Time Factors | 2020 |
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Risk Factors; Tenofovir; Treatment Outcome; White People; Young Adult | 2020 |
Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver; Liver Neoplasms; Male; Middle Aged; Molecular Typing; Republic of Korea; Risk Adjustment; Risk Factors; Tenofovir; Time Factors | 2020 |
Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B.
Topics: Antiviral Agents; Drug Substitution; Guanine; Hepatitis B, Chronic; Humans; Medication Adherence; Patient Satisfaction; Retrospective Studies; Surveys and Questionnaires; Tenofovir | 2020 |
Does regression in treatment-induced liver fibrosis reflect noninvasive tests? Assessing treatment results of hepatitis B patients who took potent antiviral drugs for 5 years.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Biopsy; Blood Platelets; Female; Guanine; Hepatitis B, Chronic; Humans; Liver; Liver Cirrhosis; Male; Mean Platelet Volume; Middle Aged; Platelet Count; Retrospective Studies; RNA, Viral; Tenofovir; Treatment Outcome | 2020 |
Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B.
Topics: Age Factors; Aged; Alanine Transaminase; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Failure; Male; Middle Aged; Research Design; Retrospective Studies; Serum Albumin; Survival Rate; Tenofovir; Treatment Outcome | 2020 |
Tenofovir versus entecavir in prevention of hepatocellular carcinoma and mortality in patients with chronic hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Propensity Score; Republic of Korea; Tenofovir | 2020 |
Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment.
Topics: Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome; Viral Load | 2020 |
[Evaluation of Histological Response in Chronic Hepatitis B Patients with Tenofovir or Entecavir Therapy].
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver; Retrospective Studies; Tenofovir; Treatment Outcome; Turkey | 2020 |
Hepatitis B core antibody and liver stiffness measurements predict HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with minimally elevated alanine aminotransferase (ALT) levels.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Elasticity Imaging Techniques; Female; Guanine; Hepatitis B Antibodies; Hepatitis B, Chronic; Humans; Liver; Male; Prospective Studies; Seroconversion; Telbivudine; Tenofovir | 2020 |
Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients.
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Tenofovir | 2020 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide: perhaps not as simple as we thought.
Topics: Adenine; Alanine; Antiviral Agents; Cholesterol, LDL; Drug Monitoring; Drug Substitution; Glomerular Filtration Rate; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipid Metabolism; Risk Assessment; Tenofovir | 2020 |
Approach to women who become pregnant while on tenofovir disoproxil fumarate for chronic B hepatitis: A report of two cases.
Topics: Adult; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Pregnancy; Tenofovir | 2020 |
No Difference in Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection Treated With Entecavir vs Tenofovir.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Long-Term Effects of Tenofovir on Liver Histopathology in Patients with Chronic Viral Hepatitis B Infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Liver; Male; Middle Aged; Seroconversion; Tenofovir; Time; Young Adult | 2020 |
Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Propensity Score; Retrospective Studies; Risk; Tenofovir | 2020 |
Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; China; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2020 |
Is Tenofovir Associated with a Lower Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Compared With Entecavir?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; China; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2020 |
Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Sustained Virologic Response; Tenofovir | 2020 |
No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Tenofovir | 2021 |
Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels.
Topics: Alanine; Antiviral Agents; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2021 |
Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients.
Topics: Antiviral Agents; Guanine; Hepatitis Antibodies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Transplantation; Tenofovir; Treatment Outcome | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir; Young Adult | 2020 |
Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
Topics: Aged; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Follow-Up Studies; Guanine; Hepatectomy; Hepatitis B, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Tenofovir | 2021 |
Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy.
Topics: Antiviral Agents; DNA, Viral; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Neoplasm Recurrence, Local; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL.
Topics: Antigens, Surface; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Recurrence; Tenofovir; Treatment Outcome | 2020 |
Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Creatinine; Female; Glomerular Filtration Rate; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Kidney Function Tests; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Comparison of tenofovir and entecavir in the development of acute kidney injury in cirrhotic chronic hepatitis B patients with refractory ascites.
Topics: Acute Kidney Injury; Antiviral Agents; Ascites; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Tenofovir | 2020 |
High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antiviral Agents; DNA, Viral; Female; Guanine; Hematologic Neoplasms; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Failure; Male; Middle Aged; Recurrence; Retrospective Studies; Risk Factors; Rituximab; Tenofovir; Viral Load; Virus Activation; Withholding Treatment; Young Adult | 2020 |
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Elasticity Imaging Techniques; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Risk Assessment; Tenofovir; White People | 2020 |
High body mass index hinders fibrosis improvement in patients receiving long-term tenofovir therapy in hepatitis B virus-related cirrhosis.
Topics: Antiviral Agents; Body Mass Index; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Tenofovir; Treatment Outcome | 2020 |
Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Renal Insufficiency; Retrospective Studies; Tenofovir; Treatment Outcome; Young Adult | 2020 |
Letter to the Editor: Re: Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Tenofovir | 2021 |
Nucleoside analogs assisted with Chinese compound prescription in treating hepatic fibrosis of chronic hepatitis B patients: A protocol of systematic review and meta-analysis.
Topics: Antiviral Agents; China; Databases, Factual; DNA Viruses; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Function Tests; Male; Meta-Analysis as Topic; Nucleosides; Quality of Life; Randomized Controlled Trials as Topic; Systematic Review as Topic; Tenofovir | 2020 |
Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
Topics: Adenine; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Telbivudine; Tenofovir | 2020 |
Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adults.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; South Africa; Tenofovir; Treatment Outcome | 2020 |
Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Japan; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Tenofovir | 2020 |
Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?
Topics: Anti-HIV Agents; Australia; Coinfection; DNA, Viral; Drug Administration Schedule; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; RNA, Viral; Tenofovir; Thailand | 2020 |
Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Comorbidity; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Practice Guidelines as Topic; Retrospective Studies; Tenofovir | 2020 |
Tenofovir-based combination therapy or monotherapy for multidrug-resistant chronic hepatitis B: Long-term data from a multicenter cohort study.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospective Studies; Tenofovir; Treatment Outcome | 2020 |
Single center analysis of therapy and outcomes of hepatocellular carcinoma in Sub-Saharan Africa.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Doxorubicin; End Stage Liver Disease; Ethiodized Oil; Ethiopia; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Palliative Care; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Rate; Tenofovir; Treatment Outcome | 2020 |
Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; China; Cohort Studies; Female; Hepatectomy; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Survival Rate; Tenofovir; Treatment Outcome | 2020 |
Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Survival Rate; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2020 |
Tooth loss associated with the use of tenofovir disoproxil fumarate.
Topics: Adult; Antiviral Agents; Asian People; Hepatitis B, Chronic; Humans; Male; Tenofovir; Tooth Loss | 2020 |
Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study.
Topics: Abnormalities, Drug-Induced; Adenine; Adult; Alanine; Chemoprevention; China; Cohort Studies; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infectious Disease Transmission, Vertical; Male; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Editorial: tenofovir disoproxil fumarate vs entecavir in patients with chronic hepatitis B and renal impairment-still an open issue.
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Retrospective Studies; Tenofovir | 2020 |
Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment: Methodological issues.
Topics: Guanine; Hepatitis B, Chronic; Humans; Pharmaceutical Preparations; Tenofovir | 2020 |
Rely to: 'Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment: Methodological issues'.
Topics: Guanine; Hepatitis B, Chronic; Humans; Pharmaceutical Preparations; Tenofovir | 2021 |
Maintained virological suppression and renal function with reduced dose tenofovir disoproxil fumarate in renally impaired chronic hepatitis B patients.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B, Chronic; Humans; Kidney; Longitudinal Studies; Renal Dialysis; Tenofovir; Treatment Outcome | 2021 |
Prevention of mother-to-child transmission of hepatitis B virus: protocol for a one-arm, open-label intervention study to estimate the optimal timing of tenofovir in pregnancy.
Topics: Antiviral Agents; Child; DNA, Viral; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Myanmar; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Thailand; Viral Load | 2020 |
Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B".
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Hepatocellular carcinoma risk with antivirals for chronic hepatitis B: no longer confounding.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Tenofovir | 2020 |
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Letter to the Editor: Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Tenofovir | 2021 |
Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Infant, Newborn; Liver Neoplasms; Male; Retrospective Studies; Tenofovir | 2021 |
HCC risk reduction with oral nucleos(t)ide analogues in patients with chronic hepatitis B: Not perfect, not good enough.
Topics: Adenine; Administration, Oral; Alanine; Carcinoma, Hepatocellular; DNA, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Nucleotides; Tenofovir | 2020 |
Real-world clinical and virological outcomes in a retrospective multiethnic cohort study of 341 untreated and tenofovir disoproxil fumarate-treated chronic hepatitis B pregnant patients in North America.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Male; North America; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Tenofovir | 2020 |
Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.
Topics: Adult; Aged; alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Taiwan; Tenofovir | 2020 |
Is urinary β2-microglobulin a reliable marker for assessment of renal tubular dysfunction in chronic hepatitis B patients receiving tenofovir therapy?
Topics: Adult; Antiviral Agents; Biomarkers; Creatinine; Glomerular Filtration Rate; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Kidney Diseases; Male; Tenofovir | 2021 |
Melatonin protects against tenofovir-induced nephrotoxicity in rats by targeting multiple cellular pathways.
Topics: Animals; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Male; Melatonin; Metabolic Networks and Pathways; Models, Animal; Rats; Renal Insufficiency; Tenofovir | 2021 |
HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy.
Topics: Adult; Antiviral Agents; Biomarkers; Female; Guanine; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hong Kong; Humans; Male; Middle Aged; RNA, Viral; Tenofovir; Treatment Outcome | 2021 |
Optimization of the algorithm diagnosis chronic hepatitis B markers in patients with newly diagnosed HIV infection.
Topics: Algorithms; DNA, Viral; Genotype; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Mutation; Tenofovir | 2020 |
Additional more factors should be included in predicting risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients.
Topics: Adult; Alanine; Anti-HIV Agents; Cobicistat; Cohort Studies; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolones; Taiwan; Tenofovir | 2021 |
Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients With Chronic Hepatitis B.
Topics: Alanine; Alanine Transaminase; Antiviral Agents; Diabetes Mellitus; Hepatitis B, Chronic; Humans; Tenofovir | 2022 |
Authors' response: Additional more factors should be included in predicting risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study.
Topics: Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Tenofovir; Viral Load | 2021 |
Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospective Studies; Tenofovir; Treatment Outcome; Viremia | 2021 |
The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study.
Topics: Acute-On-Chronic Liver Failure; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospective Studies; Tenofovir; Treatment Outcome | 2021 |
Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Tenofovir | 2021 |
Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B - Authors' reply.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Tenofovir | 2021 |
Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience.
Topics: Antiviral Agents; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Tenofovir; Treatment Outcome | 2021 |
Debate settled for elevated alanine aminotransferase in hepatitis B?
Topics: Alanine Transaminase; Double-Blind Method; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir | 2021 |
Distinctive HBV Replication Capacity and Susceptibility to Tenofovir Induced by a Polymerase Point Mutation in Hepatoma Cell Lines and Primary Human Hepatocytes.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Drug Resistance, Viral; Female; Genes, Viral; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Humans; Liver Neoplasms; Middle Aged; Point Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir; Viral Proteins; Virus Replication | 2021 |
Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors' reply.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Europe; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Editorial: similar risk of hepatocellar carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Europe; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Organophosphonates; RNA-Directed DNA Polymerase; Tenofovir; Viral Load; Virus Replication | 2021 |
Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study.
Topics: Adult; Antiviral Agents; Female; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2021 |
Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Antiviral Therapy Reduces Risk of Cirrhosis in Noncirrhotic HBV Patients Among 4 Urban Safety-Net Health Systems.
Topics: Adult; Aged; Alanine; Antiviral Agents; Asian; Black or African American; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Mortality; Propensity Score; Proportional Hazards Models; Retrospective Studies; Safety-net Providers; Tenofovir; United States; Urban Population; White People | 2021 |
Another oral antiviral treatment, but still far away from hepatitis B virus cure.
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Maleates; Organophosphonates; Tenofovir | 2021 |
Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.
Topics: Adult; Aged; Alanine; Alanine Transaminase; DNA, Viral; Drug Substitution; Female; Glomerular Filtration Rate; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Liver; Liver Function Tests; Male; Middle Aged; Prodrugs; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Tenofovir | 2021 |
Analysis of long-term safety and efficacy of nucleos(t)ide analogue therapy for chronic hepatitis B throughout pregnancy.
Topics: Adult; Antiviral Agents; Bone Density; Child, Preschool; Cohort Studies; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Male; Nucleosides; Pregnancy; Retrospective Studies; Telbivudine; Tenofovir | 2021 |
A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Liver; Male; Middle Aged; North America; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Young Adult | 2021 |
Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study.
Topics: Alanine; Canada; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir | 2021 |
Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog.
Topics: Adult; Aged; Alanine; Antiviral Agents; Aspirin; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Guanine; Hepatitis B, Chronic; Hong Kong; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir | 2021 |
The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
The partial virological response to Tenofovir monotherapy in naive patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome | 2021 |
Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients-authors' reply.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Taiwan; Tenofovir | 2021 |
Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis-authors' reply.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Taiwan; Tenofovir | 2021 |
Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Databases, Factual; Female; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Tenofovir; Young Adult | 2021 |
Tenofovir disoproxil fumarate on the risk of hepatocellular carcinoma in chronic hepatitis B patients with failure to preceding treatments: A nationwide cohort study.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir; Treatment Outcome | 2021 |
Ponder of concern and long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil.
Topics: Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infectious Disease Transmission, Vertical; Mothers; Tenofovir | 2022 |
Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Tenofovir is Associated With Higher Risk of Kidney Function Decline Than Entecavir in Patients With Chronic Hepatitis B.
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Tenofovir-induced osteomalacia with hypophosphataemia.
Topics: Antiviral Agents; Fanconi Syndrome; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Hypophosphatemia; Middle Aged; Osteomalacia; Tenofovir | 2021 |
Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir.
Topics: Antiviral Agents; Biomarkers; Comorbidity; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Retrospective Studies; Tenofovir | 2021 |
Peginterferon alfa-2b combined with tenofovir disoproxil fumarate induced high clinical cure rate in inactive chronic hepatitis B virus carriers.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2021 |
Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide.
Topics: Adenine; Aged; Alanine; Antiviral Agents; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2021 |
Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Pharmaceutical Preparations; Tenofovir; Treatment Outcome | 2021 |
Fibrosis in patients with chronic hepatitis B and minimally raised ALT during tenofovir therapy.
Topics: Antiviral Agents; Fibrosis; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir | 2021 |
Fibrosis in patients with chronic hepatitis B and minimally raised ALT during tenofovir therapy - Authors' reply.
Topics: Fibrosis; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Tenofovir | 2021 |
Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Elasticity Imaging Techniques; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Liver; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; United Kingdom; Viral Load; Young Adult | 2021 |
Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China.
Topics: Antiviral Agents; Cost-Benefit Analysis; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2022 |
Comparison of the Efficacy of Entecavir and Tenofovir in Reducing Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients: A Real-Life Study in Turkey.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Risk Factors; Tenofovir; Turkey | 2021 |
Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir.
Topics: Antiviral Agents; DNA, Viral; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Tenofovir; Treatment Outcome | 2022 |
Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Pharmaceutical Preparations; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
Hepatitis B reactivation after tenofovir withdrawal in an HIV-infected patient with history of cured hepatitis B virus infection and poor immunological status.
Topics: Antiviral Agents; Hepatitis B; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Tenofovir | 2021 |
Plasma and Breast Milk Pharmacokinetics of Tenofovir Disoproxil Fumarate in Nursing Mother with Chronic Hepatitis B-Infant Pairs.
Topics: Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Infant; Milk, Human; Mothers; Pharmaceutical Preparations; Pregnancy; Tenofovir; Viral Load | 2021 |
Baseline serum hepatitis B core antibody level predicts HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B after antiviral treatment.
Topics: Adult; Antiviral Agents; Biomarkers; Female; Guanine; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Logistic Models; Male; Multivariate Analysis; Retrospective Studies; ROC Curve; Tenofovir | 2021 |
Factors associated with non-compliance with breastfeeding recommendation: a retrospective survey in hepatitis B virus-infected mothers who had taken Nucleos(t)ide analogs during pregnancy.
Topics: Adult; Antiviral Agents; Breast Feeding; China; Female; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Nucleosides; Patient Compliance; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Risk Factors; Telbivudine; Tenofovir | 2021 |
Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.
Topics: Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B.
Topics: Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Tenofovir | 2021 |
Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.
Topics: Adenine; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Evolution, Molecular; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Polymorphism, Genetic; RNA-Directed DNA Polymerase; Sequence Analysis; Tenofovir; Treatment Failure | 2017 |
Recovery of NK(CD56+CD3-) Cells after One Year of Tenofovir Therapy for Chronic Hepatitis B Infection.
Topics: Adult; Aged; Antiviral Agents; CD3 Complex; CD56 Antigen; Cell Count; DNA, Viral; Female; GPI-Linked Proteins; Hepatitis B, Chronic; Humans; Killer Cells, Natural; Male; Middle Aged; NK Cell Lectin-Like Receptor Subfamily C; Receptors, IgG; Tenofovir; Time Factors | 2017 |
Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial.
Topics: Adult; Aged; Analysis of Variance; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Patient Safety; Randomized Controlled Trials as Topic; Republic of Korea; Severity of Illness Index; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2017 |
Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy.
Topics: Adult; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Gene Products, pol; Genes, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Mutation; RNA-Directed DNA Polymerase; Selection, Genetic; Sequence Analysis, DNA; Tenofovir; Virus Replication | 2017 |
Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study.
Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Tenofovir | 2017 |
Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.
Topics: Adenine; Alanine; Anti-HIV Agents; Coinfection; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome | 2017 |
Tenofovir alafenamide for hepatitis B: evolution or revolution?
Topics: Anti-HIV Agents; Antiviral Agents; Hepatitis B; Hepatitis B, Chronic; HIV Infections; Humans; Tenofovir | 2016 |
Occult hepatitis B infection reactivation after ruxolitinib therapy.
Topics: Aged; Antiviral Agents; Drug Resistance; Enzyme Inhibitors; Guanine; Hepatitis B, Chronic; Humans; Hydroxyurea; Janus Kinase Inhibitors; Male; Middle Aged; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Tenofovir; Virus Activation | 2017 |
Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir.
Topics: Adult; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Models, Theoretical; Risk Assessment; Tenofovir | 2017 |
Is tenofovir the answer to further preventing mother-to-child transmission of hepatitis B?
Topics: Antiviral Agents; Child; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Mothers; Tenofovir | 2016 |
A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Practice Guidelines as Topic; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2017 |
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Europe; Female; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Risk Factors; Tenofovir; White People | 2017 |
Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis.
Topics: Antiviral Agents; Female; Glomerular Filtration Rate; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Seoul; Tenofovir; Treatment Outcome | 2017 |
Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?
Topics: Alanine; Alanine Transaminase; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir | 2017 |
Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir.
Topics: Adult; Aged; Antiviral Agents; Area Under Curve; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; ROC Curve; Tenofovir; Treatment Outcome | 2017 |
Clinical response to long-term tenofovir monotherapy in Korean chronic hepatitis B patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Republic of Korea; Tenofovir; Time Factors; Young Adult | 2017 |
Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers.
Topics: Aged; Antiviral Agents; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Lipoproteins; Male; Middle Aged; Propensity Score; Retrospective Studies; Tenofovir; Treatment Outcome | 2017 |
Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis.
Topics: Acidosis, Lactic; Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Lactic Acid; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Prospective Studies; Risk Factors; Sex Factors; Tenofovir; Time Factors; Treatment Outcome; Up-Regulation; Young Adult | 2017 |
A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Middle Aged; Nucleosides; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; Young Adult | 2018 |
Letter: role of tenofovir to prevent mother-to-child transmission of hepatitis B virus-authors' reply.
Topics: Child; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Tenofovir | 2017 |
Letter: role of tenofovir to prevent mother-to-child transmission of hepatitis B virus.
Topics: Child; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy Complications, Infectious; Tenofovir | 2017 |
Clinical Course of Partial Virologic Response with Prolonged Tenofovir Therapy in Nuclos(t)ides-Naïve Patients with Chronic Hepatitis B.
Topics: Adult; Biomarkers; DNA, Viral; Drug Administration Schedule; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2017 |
Letter: lipid-lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B-more evidence is needed. Authors' reply.
Topics: Adenine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lipids; Organophosphonates; Tenofovir | 2017 |
Letter: lipid-lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B-more evidence is needed.
Topics: Adenine; Antiviral Agents; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lipids; Organophosphonates; Tenofovir | 2017 |
Development of a digital droplet PCR assay to measure HBV DNA in patients receiving long-term TDF treatment.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; DNA, Viral; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Limit of Detection; Polymerase Chain Reaction; Sensitivity and Specificity; Seroconversion; Tenofovir; Viral Load; Virus Replication | 2017 |
Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?
Topics: Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Tenofovir | 2017 |
Successful treatment with tenofovir alafenamide of a HIV/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis.
Topics: Adenine; Adult; Alanine; Antiviral Agents; Coinfection; Drug Resistance, Viral; Female; Hepatitis B, Chronic; HIV Infections; Humans; Kidney Failure, Chronic; Renal Dialysis; Tenofovir; Treatment Outcome | 2017 |
Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication?
Topics: Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir | 2018 |
[Effect of clinical first-line Antiviral Agents on outcome of chronic hepatitis B treatment].
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Liver Cirrhosis; Liver Neoplasms; Tenofovir; Treatment Outcome | 2017 |
Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B.
Topics: Adult; Antiviral Agents; Disease Progression; DNA, Viral; Drug Resistance, Viral; End Stage Liver Disease; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Republic of Korea; ROC Curve; Severity of Illness Index; Tenofovir; Treatment Outcome | 2018 |
Pathologic femoral fracture due to tenofovir-induced Fanconi syndrome in patient with chronic hepatitis B: A case report.
Topics: Antiviral Agents; Fanconi Syndrome; Femoral Fractures; Fractures, Spontaneous; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir | 2017 |
Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Young Adult | 2017 |
Favorable effect of corticosteroids in treating acute-on-chronic liver failure underlying chronic hepatitis B.
Topics: Acute-On-Chronic Liver Failure; Adrenal Cortex Hormones; Antiviral Agents; Elasticity Imaging Techniques; Female; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Middle Aged; Tenofovir; Tomography, X-Ray Computed | 2018 |
Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir.
Topics: Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Comorbidity; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Risk Assessment; Sex Factors; Taiwan; Tenofovir | 2018 |
Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B.
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Child; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Remission Induction; Retrospective Studies; Tenofovir | 2018 |
The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients.
Topics: Adult; Aged; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Recurrence; Retrospective Studies; Risk Assessment; Tenofovir | 2018 |
High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
Topics: Adult; alpha-Fetoproteins; Antigens, Neoplasm; Antiviral Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Carrier Proteins; Female; Follow-Up Studies; Glycoproteins; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Research Design; Retrospective Studies; Sex Factors; Tenofovir | 2018 |
Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Recurrence; Risk Factors; Tenofovir | 2018 |
Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Separation; Cohort Studies; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; T-Lymphocytes; Tenofovir | 2018 |
Assessment of bone mineral density in patients with cirrhosis treated with third-generation nucleos(t)ide analogues: comparison between tenofovir and entecavir.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Antiviral Agents; Bone Density; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Parathyroid Hormone; Prospective Studies; Risk Assessment; Tenofovir; Vitamin D Deficiency; Young Adult | 2018 |
Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Secondary Prevention; Tenofovir; Treatment Outcome | 2018 |
Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients.
Topics: Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Tenofovir | 2018 |
Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Tenofovir | 2018 |
Effect of tenofovir on renal function in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Bilirubin; Cohort Studies; Creatinine; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Male; Middle Aged; Renal Insufficiency; Tenofovir | 2018 |
Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy.
Topics: Adult; Aged; Biomarkers; Female; Follow-Up Studies; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasms; Predictive Value of Tests; Recurrence; Secondary Prevention; Tenofovir; Time Factors | 2018 |
Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Data Accuracy; Female; Guanine; Hepatitis B, Chronic; Hong Kong; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Research Design; Risk Assessment; Risk Factors; Taiwan; Tenofovir | 2018 |
Viral hepatitis: Maternal tenofovir use does not improve prevention of perinatal HBV transmission.
Topics: Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Pregnancy; Tenofovir | 2018 |
Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B.
Topics: Acidosis, Lactic; Antiviral Agents; DNA Polymerase gamma; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Male; Middle Aged; Rhabdomyolysis; Telbivudine; Tenofovir; Thymidine | 2018 |
Tenofovir disoproxil fumarate-induced severe liver injury in a patient with chronic hepatitis B virus infection.
Topics: Aged; Antiviral Agents; Chemical and Drug Induced Liver Injury; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver; Liver Cirrhosis; Tenofovir; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Tenofovir Versus Entecavir for the Treatment of Acute-on-Chronic Liver Failure due to Reactivation of Chronic Hepatitis B With Genotypes B and C.
Topics: Acute-On-Chronic Liver Failure; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Virus Activation; Young Adult | 2019 |
Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study.
Topics: Administration, Oral; Antiviral Agents; Cross-Sectional Studies; Drug Costs; Financing, Government; Hepatitis B, Chronic; Humans; Ontario; Reimbursement Mechanisms; Tenofovir | 2018 |
Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study.
Topics: Adult; Antirheumatic Agents; Antiviral Agents; Arthritis, Rheumatoid; Case-Control Studies; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Logistic Models; Male; Middle Aged; Outcome Assessment, Health Care; Remission Induction; Retrospective Studies; Severity of Illness Index; Tenofovir | 2018 |
Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir | 2018 |
Pseudoresistance of hepatitis B virus to tenofovir with emtricitabine.
Topics: Anti-HIV Agents; Coinfection; Drug Resistance, Viral; Emtricitabine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Tenofovir | 2018 |
Tenofovir to Prevent Perinatal Transmission of Hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2018 |
Tenofovir to Prevent Perinatal Transmission of Hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2018 |
Tenofovir to Prevent Perinatal Transmission of Hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2018 |
Tenofovir to Prevent Perinatal Transmission of Hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2018 |
Effect of antiviral therapy in reducing perinatal transmission of hepatitis B virus and maternal outcomes after discontinuing them.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Postpartum Period; Pregnancy; Retrospective Studies; Telbivudine; Tenofovir; Young Adult | 2018 |
Monitoring and treatment results of 88 HBsAg-positive pregnant women.
Topics: Adult; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Retrospective Studies; Tenofovir; Young Adult | 2016 |
Causal Inference for Observational Studies.
Topics: Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Propensity Score; Tenofovir | 2019 |
Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Retrospective Studies; Taiwan; Tenofovir | 2019 |
Mortality, liver transplantation and hepatic complications in patients with treatment-naïve chronic hepatitis B treated with entecavir vs tenofovir.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Korea; Liver Failure; Liver Transplantation; Longitudinal Studies; Male; Middle Aged; Survival Analysis; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Long-term results of chronic hepatitis B antiviral treatment with nucleos(t)ide analogues: a single center experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Telbivudine; Tenofovir; Young Adult | 2019 |
DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
Topics: Adult; Aged; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Proportional Hazards Models; Recurrence; Retreatment; Tenofovir; Treatment Outcome; Viral Load | 2018 |
Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Disease Progression; Female; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Middle Aged; Registries; Renal Insufficiency, Chronic; Tenofovir; Treatment Outcome | 2018 |
Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Biostatistics; Creatinine; Female; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Longitudinal Studies; Male; Middle Aged; Renal Insufficiency; Retrospective Studies; Tenofovir | 2019 |
Pegylated interferon-based sequential therapy for treatment of HBeAg reactive pediatric chronic hepatitis B-First study in children.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Nucleosides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Seroconversion; Tenofovir | 2018 |
Severe hypophosphatemia induced by denosumab in a patient with osteomalacia and tenofovir disoproxil fumarate-related acquired Fanconi syndrome.
Topics: Antiviral Agents; Bone Density Conservation Agents; Denosumab; Fanconi Syndrome; Fractures, Stress; Hepatitis B, Chronic; Humans; Hypophosphatemia; Male; Middle Aged; Osteomalacia; Radiography; Radionuclide Imaging; Tenofovir; Tibial Fractures; Tomography, X-Ray Computed | 2019 |
Characterization and assessment of HBV chronically infected patients: Identification of those eligible for treatment in the South West region of Cameroon.
Topics: Adolescent; Adult; Antiviral Agents; Biomarkers; Cameroon; Female; Hepatitis B, Chronic; Humans; Longitudinal Studies; Male; Middle Aged; Patient Selection; Practice Guidelines as Topic; Tenofovir; Viral Load; Young Adult | 2018 |
Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil.
Topics: Antiviral Agents; Brazil; Coinfection; Disease Transmission, Infectious; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; Humans; Interferons; Male; Models, Theoretical; Tenofovir; Viral Load | 2018 |
Tenofovir vs Entecavir for Hepatocellular Carcinoma Prevention in Patients With Chronic Hepatitis B: One of These Things Is Not Like the Other.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Republic of Korea; Tenofovir | 2019 |
Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cause of Death; Databases, Factual; Female; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Protective Factors; Republic of Korea; Risk Factors; Tenofovir; Time Factors; Treatment Outcome | 2019 |
Assessment of histopathological alterations in patients with chronic hepatitis B infection following long-term oral antiviral therapy.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Tenofovir | 2018 |
Predictors of Therapeutic Outcome to Nucleotide Reverse Transcriptase Inhibitor in Hepatitis B Patients.
Topics: Adult; Biomarkers; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2018 |
HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hong Kong; Humans; Liver Neoplasms; Male; Middle Aged; Outcome and Process Assessment, Health Care; Retrospective Studies; Risk Assessment; Seroepidemiologic Studies; Sustained Virologic Response; Tenofovir | 2019 |
Longitudinal trends in renal function in chronic hepatitis B patients receiving oral antiviral treatment.
Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney; Longitudinal Studies; Male; Middle Aged; Nutrition Surveys; Organophosphonates; Retrospective Studies; Tenofovir | 2018 |
Genotype Matters in Patients with Acute-on-chronic Liver Failure Due to Reactivation of Chronic Hepatitis B.
Topics: Acute-On-Chronic Liver Failure; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Tenofovir; Viral Load; Virus Activation; Young Adult | 2018 |
Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir.
Topics: Adult; Antiviral Agents; Fatty Liver; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Sustained Virologic Response; Tenofovir; Treatment Outcome | 2019 |
Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice.
Topics: Adult; Africa South of the Sahara; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Nucleosides; Nucleotides; Practice Patterns, Physicians'; Spain; Tenofovir; Transients and Migrants; Treatment Outcome; Viral Load | 2018 |
Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk.
Topics: Adult; Antiviral Agents; Biomarkers; DNA, Viral; Female; Guanine; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Prospective Studies; Recurrence; Tenofovir; Withholding Treatment | 2019 |
Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir.
Topics: Adult; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Recurrence; Retrospective Studies; Tenofovir; Viral Load; Young Adult | 2019 |
Letter: chronic kidney disease risk in patients with chronic hepatitis B-authors' reply.
Topics: Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Renal Insufficiency, Chronic; Tenofovir | 2018 |
Letter: chronic kidney disease risk in patients with chronic hepatitis B.
Topics: Guanine; Hepatitis B, Chronic; Humans; Renal Insufficiency, Chronic; Tenofovir | 2018 |
Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Tenofovir; Virus Activation; Young Adult | 2019 |
Prevention of Mother-to-Child Transmission in Patients with Chronic Hepatitis B Virus Infection and High Viral Loads
Topics: Antiviral Agents; Female; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Viral Load | 2018 |
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Bone Density; Drug Substitution; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Pelvic Bones; Phosphorous Acids; Prospective Studies; Spine; Tenofovir; Treatment Outcome; Young Adult | 2019 |
Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection.
Topics: Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2019 |
How does hepatic steatosis affect the outcome of patients with chronic hepatitis B?
Topics: Fatty Liver; Guanine; Hepatitis B, Chronic; Humans; Tenofovir | 2019 |
Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir.
Topics: Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Reproducibility of Results; Risk Assessment; Serum Albumin; Sex Factors; Tenofovir | 2019 |
Efficacy and Safety of Tenofovir Disoproxil Fumarate in Treatment-Naïve Patients with Chronic Hepatitis B in Korea.
Topics: Adult; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Patient Safety; Prospective Studies; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sustained Virologic Response; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2019 |
Tenofovir disoproxil fumarate may not cause renal and bone toxicity in chronic hepatitis B patients: a retrospective cross-sectional study
Topics: Antiviral Agents; Bone Density; Calcium; Cross-Sectional Studies; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Hypocalcemia; Hypophosphatemia; Phosphates; Retrospective Studies; Tenofovir | 2019 |
Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Asian People; Bone Diseases, Metabolic; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Osteoporosis; Proportional Hazards Models; Retrospective Studies; Tenofovir; Treatment Outcome; United States | 2019 |
Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.
Topics: Aged; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir | 2019 |
Towards finite oral antiviral treatment for chronic hepatitis B.
Topics: Antiviral Agents; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir | 2019 |
Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients.
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Tenofovir | 2019 |
Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients-author's reply.
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Tenofovir | 2019 |
A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Prognosis; Propensity Score; Republic of Korea; Retrospective Studies; Tenofovir; Treatment Outcome | 2019 |
Efficacy of tenofovir and entecavir in patients who relapsed after pegylated interferon therapy.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Occult hepatitis B and HIV infection.
Topics: Anti-Retroviral Agents; Coinfection; DNA, Viral; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir; Virus Activation | 2019 |
[Marked improvement in renal tubular markers after switching from adefovir to tenofovir alafenamide in a case of Fanconi syndrome diagnosed through high ALP levels].
Topics: Adenine; Alanine; Alkaline Phosphatase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Fanconi Syndrome; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Middle Aged; Organophosphonates; Tenofovir; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Republic of Korea; Tenofovir | 2019 |
Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B-in Reply.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Republic of Korea; Tenofovir | 2019 |
Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Republic of Korea; Tenofovir | 2019 |
Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Republic of Korea; Tenofovir | 2019 |
Real-Life State of Anti-Hepatitis B Virus Drug Choice in Child-Bearing Age Male Patients and Effect on Fertility and Fetal Safety.
Topics: Adult; Antiviral Agents; Fathers; Fertility; Fetus; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Male; Surveys and Questionnaires; Tenofovir; Viral Load | 2019 |
Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Chemical and Drug Induced Liver Injury; Female; Glomerular Filtration Rate; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Nucleotides; Organophosphonates; Proportional Hazards Models; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome | 2020 |
Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study.
Topics: Alanine Transaminase; Antiviral Agents; Asian People; Black People; Deprescriptions; Disease Progression; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; North America; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Prospective Studies; Tenofovir; Viral Load | 2019 |
Predictors of mortality in patients under treatment for chronic hepatitis B in Ethiopia: a prospective cohort study.
Topics: Adolescent; Adult; Age Factors; Antiviral Agents; Body Mass Index; Ethiopia; Female; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Risk Factors; Survival Rate; Tenofovir; Time Factors; Young Adult | 2019 |
Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B.
Topics: Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Nucleic Acid Synthesis Inhibitors; Telbivudine; Tenofovir; Time Factors; Treatment Outcome | 2019 |
Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Female; Genotyping Techniques; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; RNA-Directed DNA Polymerase; Tenofovir; Young Adult | 2019 |
A case of entecavir-induced Fanconi syndrome.
Topics: Acidosis; Acute Kidney Injury; Adenine; Aged; Alanine; Antiviral Agents; Fanconi Syndrome; Guanine; Hepatitis B, Chronic; Humans; Hypokalemia; Hypophosphatemia; Male; Nucleosides; Tenofovir; Treatment Outcome; Withholding Treatment | 2019 |
Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Substitution; Drug Therapy, Combination; Female; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB - Is one NUC better than the other?
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Republic of Korea; Tenofovir | 2019 |
Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa.
Topics: Adult; Antiviral Agents; Child; Cost-Benefit Analysis; Developing Countries; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infectious Disease Transmission, Vertical; Mass Screening; Models, Biological; Pregnancy; Pregnancy Complications, Infectious; South Africa; Tenofovir; Vaccination; Young Adult | 2019 |
Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir | 2020 |
Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis.
Topics: Adenine; Alanine; Hepatitis B, Chronic; HIV Infections; Humans; Liver Transplantation; Tenofovir | 2020 |
In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue.
Topics: Activating Transcription Factor 4; Adenine; Antiviral Agents; Apoptosis; Caspase 12; Cell Line; Cell Survival; Endoplasmic Reticulum Chaperone BiP; Epithelial Cells; Female; Glomerular Filtration Rate; Heat-Shock Proteins; Hepatitis A Virus Cellular Receptor 1; Hepatitis B, Chronic; Humans; In Vitro Techniques; Interleukin-18; Kidney Tubules; Lamivudine; Lipocalin-2; Male; Middle Aged; Organophosphonates; Prospective Studies; Protective Agents; Renal Insufficiency, Chronic; Severity of Illness Index; Telbivudine; Tenofovir | 2019 |
Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients.
Topics: Aged; Antiviral Agents; Coinfection; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Duration of Therapy; Female; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; Humans; Lipopeptides; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Patient Acuity; RNA, Viral; Tenofovir; Treatment Outcome | 2019 |
Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Tenofovir; Young Adult | 2019 |
Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Republic of Korea; Tenofovir | 2019 |
Letter: clinical outcomes after long-term entecavir or tenofovir treatment in patients with hepatitis D and advanced fibrosis.
Topics: Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Humans; Liver Cirrhosis; Tenofovir; Virus Replication | 2019 |
Reply to: "Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction".
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Republic of Korea; Tenofovir | 2019 |
The use of tenofovir and telbivudine combination therapy for immune-tolerant chronic hepatitis B patients awaiting assisted reproduction.
Topics: Antiviral Agents; Hepatitis B, Chronic; Humans; Telbivudine; Tenofovir; Thymidine; Viral Load | 2019 |
Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Administration Schedule; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Markov Chains; Organophosphonates; Polyethylene Glycols; Precision Medicine; Prognosis; Quality-Adjusted Life Years; Recombinant Proteins; Tenofovir; Viral Load | 2013 |
[Cost-effectiveness of nucleoside/nucleotide analogues in chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Markov Chains; Models, Theoretical; Organophosphonates; Quality-Adjusted Life Years; Tenofovir | 2012 |
Increased eGFR with telbivudine in combination therapy of chronic hepatitis B infection.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Telbivudine; Tenofovir; Thymidine | 2014 |
Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Disease Management; DNA, Viral; Europe; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Tenofovir | 2014 |
Geographic tongue and tenofovir.
Topics: Adenine; Glossitis, Benign Migratory; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2013 |
Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Spain; Tenofovir; Treatment Outcome; Viral Load | 2013 |
Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.
Topics: Adenine; Adult; Aged; Antiviral Agents; Asian People; DNA, Viral; Female; Follow-Up Studies; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hong Kong; Humans; Kinetics; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Young Adult | 2013 |
Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection.
Topics: Adenine; Adult; Antiviral Agents; Biopsy; Creatinine; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Kidney; Male; Middle Aged; Organophosphonates; Phosphates; Reverse Transcriptase Inhibitors; Tenofovir | 2013 |
Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
Topics: Adenine; Adult; Aged; Antiviral Agents; Chemoprevention; Cohort Studies; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B Antibodies; Hepatitis B, Chronic; Humans; Liver Transplantation; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2013 |
Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Antiviral Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Organophosphonates; Risk Factors; Tenofovir | 2013 |
[HBV vaccine escape mutations in a chronic hepatitis B patient treated with nucleos(t)ide analogues].
Topics: Adenine; Biopsy; Drug Resistance, Multiple, Viral; Female; Genes, pol; Guanine; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver; Middle Aged; Mutation; Nucleosides; Nucleotides; Organophosphonates; Tenofovir | 2013 |
Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: an Indian perspective.
Topics: Adenine; Adult; Aged; Bilirubin; Creatinine; DNA, Viral; Female; Hepatitis B, Chronic; Humans; India; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Platelet Count; Prospective Studies; Severity of Illness Index; Survival Analysis; Tenofovir; Treatment Outcome; Viral Load | 2013 |
Comparison of tenofovir and entecavir in patients with chronic HBV infection.
Topics: Adenine; Adult; Aged; DNA, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir | 2013 |
One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Immunoglobulins; Liver Transplantation; Male; Middle Aged; Organophosphonates; Secondary Prevention; Tenofovir; Treatment Outcome | 2014 |
Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Europe; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hospitalization; Humans; Insurance, Health, Reimbursement; Interferon-alpha; Lamivudine; Longitudinal Studies; Male; Middle Aged; Monitoring, Ambulatory; Organophosphonates; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Tenofovir | 2014 |
Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis.
Topics: Adenine; Adult; Analysis of Variance; Antiviral Agents; Brazil; Cost-Benefit Analysis; Disease Progression; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Markov Chains; Organophosphonates; Tenofovir; Treatment Outcome | 2013 |
Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA.
Topics: Adenine; Adult; Antiviral Agents; California; Cohort Studies; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome | 2014 |
Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure.
Topics: Adenine; Adult; Biomarkers; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2014 |
Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2014 |
Interactive medical case: wasting away.
Topics: Adenine; Adult; Bone Density; Electrolytes; Fanconi Syndrome; Female; Hepatitis B, Chronic; Humans; Hypokalemia; Nausea; Organophosphonates; Osteomalacia; Pain; Reverse Transcriptase Inhibitors; Tenofovir | 2014 |
An initial assessment of correlations between host- and virus-related factors affecting analogues antiviral therapy in HBV chronically infected patients.
Topics: Adenine; Adult; Age Factors; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Host-Derived Cellular Factors; Humans; Interleukin-10; Lamivudine; Middle Aged; Mutation; Nucleosides; Organophosphonates; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Promoter Regions, Genetic; Sex Factors; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tenofovir; Viral Load | 2014 |
Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Prospective Studies; Sensitivity and Specificity; Tenofovir; Viral Load | 2015 |
[Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline].
Topics: Adenine; Antiviral Agents; Consensus; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Hungary; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2014 |
Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare.
Topics: Adenine; Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Male; Organophosphonates; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Severity of Illness Index; Tenofovir; Time Factors; Young Adult | 2014 |
Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients.
Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir | 2014 |
Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients--authors' reply.
Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir | 2014 |
A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.
Topics: Adenine; Adult; Antiviral Agents; Cost-Benefit Analysis; Drugs, Essential; Female; Health Services Research; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Markov Chains; Models, Economic; Organophosphonates; Quality-Adjusted Life Years; Tenofovir; Thailand; Treatment Outcome | 2014 |
Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Monitoring; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Time Factors; Young Adult | 2014 |
Letter: Treatment of HBeAg+ chronic hepatitis B--is tenofovir truly superior to entecavir?
Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir | 2014 |
Letter: Treatment of HBeAg+ chronic hepatitis B--is tenofovir truly superior to entecavir? Authors' reply.
Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir | 2014 |
Viral evolutionary changes during tenofovir treatment in a chronic hepatitis B patient with sequential nucleos(t)ide therapy.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Substitution; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF.
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Genetic Association Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Mutation, Missense; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Organophosphonates; Recombinant Proteins; Tenofovir; Treatment Failure; Treatment Outcome; Viral Load | 2014 |
New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence.
Topics: Adenine; Adult; Cohort Studies; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Guanine; Hepatitis B, Chronic; Humans; Immunoglobulins; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Organophosphonates; Prospective Studies; Recurrence; Retreatment; Risk Assessment; Statistics, Nonparametric; Tenofovir; Transplantation Immunology; Treatment Outcome | 2014 |
Telbivudine plus tenofovir in combination therapy in patients with chronic hepatitis B infection--an Indian experience.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; India; Male; Middle Aged; Organophosphonates; Telbivudine; Tenofovir; Thymidine | 2013 |
Effect of prophylactic versus preemptive lamivudine treatment and tenofovir on HBsAg+ kidney transplant recipients.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Drug Administration Schedule; Female; Graft Survival; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Transplantation; Lamivudine; Male; Organophosphonates; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; Virus Replication | 2015 |
Antiviral therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Gene Products, pol; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Liver Neoplasms; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Replication | 2014 |
Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy.
Topics: Adenine; Antiviral Agents; DNA, Viral; Female; Guanine; Health Personnel; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Professional-to-Patient; Infectious Disease Transmission, Vertical; Lamivudine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Viral Load; Viremia | 2014 |
Mechanisms of hepatitis B virus resistance development.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Deoxycytidine; Drug Resistance, Multiple, Viral; Emtricitabine; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2014 |
Effect of antiretroviral HIV therapy on hepatitis B virus replication and pathogenicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; Deoxycytidine; Emtricitabine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Inflammation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; tat Gene Products, Human Immunodeficiency Virus; Tenofovir; Virus Replication; vpr Gene Products, Human Immunodeficiency Virus | 2014 |
Hepatitis B virus drug resistance tools: one sequence, two predictions.
Topics: Adenine; Antiviral Agents; Base Sequence; Drug Resistance, Multiple, Viral; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Evasion; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Telbivudine; Tenofovir; Thymidine | 2014 |
Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2014 |
Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.
Topics: Adenine; Adult; Antiviral Agents; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Recurrence; Tenofovir; Withholding Treatment; Young Adult | 2014 |
Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report.
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Kidney Transplantation; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains.
Topics: Adenine; Adult; Aged; Antiviral Agents; Base Sequence; Cohort Studies; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2014 |
Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?
Topics: Adenine; Adult; Body Mass Index; Bone Density; Cross-Sectional Studies; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Risk; Risk Assessment; Tenofovir | 2015 |
[Efficacy of 48-week tenofovir disoproxil fumarate therapy in patients who were unresponsive to nucleoside-analogue treatments].
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Young Adult | 2014 |
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Greece; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Netherlands; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Spain; Tenofovir; Time Factors; Turkey; White People | 2015 |
Chronic hepatitis B virus coinfection is associated with renal impairment among Zambian HIV-infected adults.
Topics: Adenine; Adolescent; Adult; Africa; Anti-HIV Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; HIV; Humans; Male; Middle Aged; Organophosphonates; Renal Insufficiency; Tenofovir; Young Adult | 2014 |
Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling.
Topics: Absorptiometry, Photon; Adenine; Adult; Aged; Antiviral Agents; Asian People; Bone Density; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney Tubules, Proximal; Male; Middle Aged; Organophosphonates; Osteoporosis; Phosphates; Prospective Studies; Renal Reabsorption; Risk Factors; Tenofovir; Time Factors; Treatment Outcome; Young Adult | 2015 |
Tenofovir-associated Fanconi syndrome in a patient with chronic hepatitis B.
Topics: Adenine; Aged, 80 and over; Antiviral Agents; Fanconi Syndrome; Fatal Outcome; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Risk Factors; Tenofovir | 2014 |
Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir | 2014 |
Liver biopsy interpretation & the regression of hepatitis B virus related cirrhosis.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Biomarkers; Biopsy; Hepatitis B, Chronic; Humans; India; Liver Cirrhosis; Organophosphonates; Tenofovir; Treatment Outcome | 2014 |
The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Topics: Adenine; Adult; Antiviral Agents; Canada; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Nucleosides; Organophosphonates; Retrospective Studies; Risk Factors; Telbivudine; Tenofovir; Thymidine | 2014 |
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Gastrointestinal Diseases; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Republic of Korea; Retrospective Studies; Tenofovir; Treatment Outcome; Young Adult | 2014 |
Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome | 2015 |
Discovering novel direct acting antiviral agents for HBV using in silico screening.
Topics: Adenine; Albumins; Animals; Antiviral Agents; Binding Sites; Cells, Cultured; Chimera; Databases, Protein; Drug Design; Drug Discovery; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Ligands; Liver; Mice; Middle Aged; Molecular Docking Simulation; Organophosphonates; Protein Binding; Real-Time Polymerase Chain Reaction; Tenofovir | 2015 |
Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal.
Topics: Adenine; Antiviral Agents; Fanconi Syndrome; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load; Withholding Treatment | 2014 |
Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection.
Topics: Adult; Antiviral Agents; Female; France; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Kidney; Longitudinal Studies; Male; Middle Aged; Tenofovir | 2015 |
Partial virological response to three different nucleotide analogues in naive patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
[Tenofovir rescue therapy for chronic hepatitis B patients after suboptimal response to treatment with lamivudine plus adefovir dipivoxil].
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Failure; Treatment Outcome | 2014 |
Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study.
Topics: Adult; Antiviral Agents; Cohort Studies; Comorbidity; Disease Progression; Female; France; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Reference Values; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Tenofovir; Treatment Outcome | 2015 |
[Efficacy of tenofovir-based rescue therapy for patients with drug-resistant chronic hepatitis B].
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Nucleosides; Retrospective Studies; Sex Factors; Tenofovir; Treatment Outcome; Young Adult | 2015 |
HBV carrying drug-resistance mutations in chronically infected treatment-naive patients.
Topics: Adenine; Antibodies, Viral; Antiviral Agents; Brazil; DNA, Viral; Drug Resistance, Viral; Gene Products, pol; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Microbial Sensitivity Tests; Mutation; Organophosphonates; Retrospective Studies; Sequence Analysis, DNA; Tenofovir; Virus Replication | 2015 |
Tenofovir-associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection.
Topics: Adult; Antiviral Agents; Fanconi Syndrome; Female; Hepatitis B, Chronic; Humans; Nephrotic Syndrome; Tenofovir | 2015 |
Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures.
Topics: Adenine; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; High-Throughput Nucleotide Sequencing; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; ROC Curve; Tenofovir; Treatment Failure; Treatment Outcome | 2015 |
Tenofovir rescue therapy in pregnant females with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Apgar Score; Biomarkers; Birth Weight; China; DNA, Viral; Drug Resistance, Viral; Drug Substitution; Female; Genotype; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Live Birth; Male; Middle Aged; Mutation; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Time Factors; Treatment Outcome; Vaccination; Viral Load; Young Adult | 2015 |
Clinical course of chronic hepatitis B patients receiving nucleos(t)ide analogues after virological breakthrough during monotherapy with lamivudine.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load; Viral Matrix Proteins; Young Adult | 2015 |
Renal proximal tubular dysfunction due to tenofovir in a patient with chronic hepatitis B monoinfection.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Immunocompromised Host; Male; Middle Aged; Phosphates; Tenofovir; Treatment Outcome | 2015 |
[The possibility of tenofovir monotherapy as a rescue therapy in patients with chronic hepatitis B].
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Tenofovir; Treatment Outcome | 2015 |
Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Tenofovir disoproxil fumarate treatment in HbeAg-positive patients.
Topics: Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Hospitals, Teaching; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; Turkey; Viral Load | 2015 |
Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2015 |
[Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures].
Topics: Adenine; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Treatment Failure | 2015 |
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Nucleotides; Retrospective Studies; Tenofovir; Treatment Outcome | 2015 |
A case of entecavir resistance which is developed after complete viral suppression during entecavir treatment for nucleoside-naive chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Nucleosides; Organophosphonates; Remission Induction; Tenofovir | 2014 |
Response to potent anti-HBV agents in chronic hepatitis B and combined effect of HBV reverse transcriptase mutations.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Mutation; Organophosphonates; RNA-Directed DNA Polymerase; Tenofovir | 2015 |
Tenofovir monotherapy after achieving complete viral suppression on entecavir plus tenofovir combination therapy.
Topics: Adult; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Odds Ratio; Recurrence; Retrospective Studies; Risk Factors; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2015 |
Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Republic of Korea; Retrospective Studies; Tenofovir; Time Factors; Young Adult | 2015 |
Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retreatment; Tenofovir; Time Factors; Treatment Outcome | 2015 |
Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Tenofovir; Treatment Failure | 2015 |
Remission of splenic marginal zone lymphoma in a patient treated for hepatitis B: a case of HBV-associated lymphoma.
Topics: Adenine; Bone Marrow; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunohistochemistry; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Organophosphonates; Remission Induction; Splenic Neoplasms; Tenofovir; Viral Load | 2015 |
Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Asian; Biomarkers; Databases, Factual; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome; United States; Viral Load | 2015 |
Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice.
Topics: Adult; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Medication Adherence; Middle Aged; Remission Induction; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; United States; Viral Load | 2016 |
Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana.
Topics: Adult; Africa South of the Sahara; Antiviral Agents; Coinfection; Cross-Sectional Studies; Elasticity Imaging Techniques; Female; Ghana; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2015 |
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients.
Topics: Antiviral Agents; Calibration; Chemistry Techniques, Analytical; Chromatography; Chromatography, High Pressure Liquid; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Limit of Detection; Nucleosides; Reproducibility of Results; Tandem Mass Spectrometry; Telbivudine; Tenofovir; Thymidine | 2015 |
Tenofovir-best hope for treatment of chronic hepatitis B infection?
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Seroconversion; Tenofovir; Treatment Outcome; Young Adult | 2015 |
Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2016 |
Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful?
Topics: Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Monitoring; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Recurrence; Tenofovir; Treatment Outcome; Withholding Treatment | 2015 |
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Elasticity Imaging Techniques; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; Female; Follow-Up Studies; Forecasting; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Italy; Lamivudine; Liver; Liver Cirrhosis; Male; Middle Aged; Nucleosides; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Survival Rate; Tenofovir | 2015 |
Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients.
Topics: Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Multivariate Analysis; Nucleotides; Probability; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome | 2015 |
Reactivation of chronic hepatitis B during treatment with tenofovir disoproxil fumarate: drug interactions or low adherence?
Topics: Alanine Transaminase; Antiviral Agents; Central Nervous System Agents; Depression; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Fumarates; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Medication Adherence; Middle Aged; Tenofovir; Transaminases; Viral Load; Virus Activation | 2015 |
Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2015 |
Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate.
Topics: Antiviral Agents; Chemokine CXCL10; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir | 2015 |
Antiviral Therapy in Hepatitis B Virus-Associated Liver Cirrhosis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Tenofovir | 2015 |
[Prevention of mother to child transmission of hepatitis B].
Topics: Adult; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Viral Load; Young Adult | 2015 |
Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2016 |
Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Canada; Cohort Studies; Female; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load; Viremia | 2016 |
Efficacy of tenofovir disoproxil fumarate to prevent vertical transmission in mothers with lamivudine-resistant HBV.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Treatment Outcome; Viral Load; Virus Replication | 2015 |
Fanconi syndrome and chronic renal failure in a chronic hepatitis B monoinfected patient treated with tenofovir.
Topics: Adult; Antiviral Agents; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Kidney Failure, Chronic; Male; Tenofovir | 2015 |
Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; Young Adult | 2015 |
Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Coinfection; Cross-Sectional Studies; Drug Interactions; Drug Therapy, Combination; Hepatitis B, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Models, Biological; Nonlinear Dynamics; Renal Elimination; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Thailand; Treatment Outcome | 2015 |
Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Arabinofuranosyluracil; Cell Line, Tumor; Drug Resistance, Multiple, Viral; Gene Products, pol; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Microbial Sensitivity Tests; Models, Molecular; Organophosphonates; Tenofovir; Virus Replication | 2015 |
More Long-term Assessment of Transient Elastography Is Needed for HIV/Hepatitis B Virus-Coinfected Patients Undergoing Treatment With Tenofovir.
Topics: Antiviral Agents; Coinfection; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Tenofovir | 2016 |
Reply to Boyd and Lacombe.
Topics: Antiviral Agents; Coinfection; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Tenofovir | 2016 |
Efficacy and safety of tenofovir in nucleos(t)ide-naïve patients with genotype C chronic hepatitis B in real-life practice.
Topics: Academic Medical Centers; Adult; Alanine Transaminase; Antiviral Agents; Asian People; DNA, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Republic of Korea; Retrospective Studies; Tenofovir; Viral Load | 2015 |
Long-term follow-up of HBsAg-positive patients in Germany.
Topics: Adenine; Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Germany; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Mass Screening; Middle Aged; Organophosphonates; Prognosis; Prospective Studies; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Time Factors; Turkey | 2016 |
Efficacy of interferon for chronic hepatitis B in patients with nucleoside and nucleotide combination therapy failure.
Topics: Adult; Antiviral Agents; Drug Substitution; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Tenofovir; Treatment Failure; Treatment Outcome | 2016 |
Tenofovir Therapy for Hepatitis B May Be Commonly Prescribed Without HIV Testing.
Topics: Antiviral Agents; Diagnostic Tests, Routine; Female; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Risk Factors; Tenofovir | 2016 |
Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; Humans; Mice; Mice, SCID; Tenofovir | 2016 |
Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Odds Ratio; Organophosphonates; Real-Time Polymerase Chain Reaction; Retrospective Studies; Tenofovir; Viral Load | 2015 |
Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China.
Topics: Antiviral Agents; China; Cost-Benefit Analysis; Drugs, Generic; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Markov Chains; National Health Programs; Quality-Adjusted Life Years; Tenofovir | 2015 |
Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load | 2016 |
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany.
Topics: Adult; Antiviral Agents; Creatinine; DNA, Viral; Elasticity Imaging Techniques; Fatigue; Female; Germany; Headache; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Kidney Diseases; Liver; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2016 |
Combination of Pegylated Interferon and Tenofovir for Hepatitis B Treatment: Screening and Counseling of Patients are Warranted.
Topics: Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Tenofovir | 2016 |
Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy.
Topics: Adult; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Drug Administration Schedule; Drug Combinations; Drug Substitution; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; United States; Viral Load | 2016 |
Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Hospitals; Humans; Incidence; Kidney Diseases; Lamivudine; Male; Middle Aged; Nephrons; Organophosphonates; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Telbivudine; Tenofovir; Thailand; Thymidine; Tropical Medicine | 2015 |
AIC649 Induces a Bi-Phasic Treatment Response in the Woodchuck Model of Chronic Hepatitis B.
Topics: Animals; Antiviral Agents; Biological Therapy; Biomarkers; Dendritic Cells; Disease Models, Animal; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B Virus, Woodchuck; Hepatitis B, Chronic; Immunity, Cellular; Interferon-alpha; Interferon-gamma; Killer Cells, Natural; Lymphocyte Activation; Marmota; Mice; Mice, Inbred BALB C; Mice, Transgenic; Parapoxvirus; T-Lymphocytes; Tenofovir; Tumor Necrosis Factor-alpha; Vaccines, Inactivated; Virus Replication | 2015 |
Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir.
Topics: Adult; Age Factors; Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipoproteins, HDL; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Odds Ratio; Retrospective Studies; Tenofovir; Treatment Outcome; Virus Replication; Young Adult | 2016 |
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Risk; Tenofovir | 2016 |
Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Comorbidity; Diabetes Mellitus; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Nucleosides; Nucleotides; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome | 2016 |
Uncontrolled hepatitis delta virus infection after initial suppression on tenofovir in a HIV/HBV-coinfected patient.
Topics: Adult; Coinfection; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; HIV; HIV Infections; Humans; Male; Tenofovir; Viral Load | 2016 |
Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression.
Topics: Antiviral Agents; Coinfection; Defective Viruses; DNA, Viral; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Tenofovir | 2016 |
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France.
Topics: Abdominal Pain; Adult; Aged; Antiviral Agents; Asthenia; Diarrhea; DNA, Viral; Female; France; Headache; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Hypophosphatemia; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Nausea; Prospective Studies; Seroconversion; Tenofovir; Treatment Outcome; Viral Load; Vomiting | 2016 |
Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2016 |
Analysis of hepatitis B virus genotype changes in patients with chronic hepatitis B infection on tenofovir therapy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Genetic Variation; Genotype; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Young Adult | 2016 |
Sequential Therapy with PEG-IFN alpha-2a and Tenofovir in a Hepatitis B Virus-Infected African Man.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2015 |
Head-To-Head Comparison of Two Years Efficacy of Entecavir and Tenofovir in Patients with Treatment-Naïve Chronic Hepatitis B--The Real Life Data.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Australia; Coinfection; Female; Genetic Variation; Genotype; Hepatitis B virus; Hepatitis B, Chronic; High-Throughput Nucleotide Sequencing; HIV Infections; Humans; Male; Middle Aged; Quasispecies; Sequence Analysis, DNA; Tenofovir; Thailand | 2016 |
[Drug-resistant mutations in hepatitis B virus found in chronic HBV carriers using PCR sequencing technology].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Polymerase Chain Reaction; Telbivudine; Tenofovir; Thymidine | 2016 |
Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Follow-Up Studies; Guanine; Heart Transplantation; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Viremia | 2016 |
Long-Term Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleos(t)ide-Experienced Chronic Hepatitis B Patients.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Kidney Diseases; Male; Middle Aged; Nucleotides; Retrospective Studies; Survival Analysis; Tenofovir; Treatment Outcome; Viral Load | 2016 |
Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA.
Topics: Adult; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Viral Load | 2016 |
Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Function Tests; Lamivudine; Liver Function Tests; Male; Middle Aged; Polymerase Chain Reaction; Tenofovir; Treatment Outcome | 2016 |
[Effect of IL-28B polymorphisms on the natural course of HBV infection].
Topics: Adult; Antiviral Agents; Carrier State; Female; Guanine; Hepatitis B, Chronic; Humans; Interferons; Interleukins; Lamivudine; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Real-Time Polymerase Chain Reaction; Telbivudine; Tenofovir; Thymidine; Turkey | 2016 |
Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil.
Topics: Antiviral Agents; Cross-Sectional Studies; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Public Health; Tenofovir; Treatment Outcome; Viral Load | 2016 |
First case report of renal improvement on tenofovir alafenamide in an HIV/hepatitis B virus-coinfected patient with adefovir-induced Fanconi's syndrome.
Topics: Absorptiometry, Photon; Adenine; Alanine; Coinfection; Dose-Response Relationship, Drug; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infections; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2016 |
Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B.
Topics: Adult; Age Factors; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Regression Analysis; Retrospective Studies; Risk Factors; Sustained Virologic Response; Tenofovir; Time Factors; Treatment Outcome | 2016 |
Similar frequencies, phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate (TDF).
Topics: Adult; Antiviral Agents; Biomarkers; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunophenotyping; Killer Cells, Natural; Liver; Lymphocyte Activation; Lymphocyte Count; Male; Middle Aged; NK Cell Lectin-Like Receptor Subfamily C; NK Cell Lectin-Like Receptor Subfamily K; Phenotype; Tenofovir; Viral Load; Young Adult | 2016 |
Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Markov Chains; Organophosphonates; Quality-Adjusted Life Years; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2016 |
The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Republic of Korea; Retrospective Studies; Tenofovir; Treatment Outcome | 2016 |
Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Creatinine; Cross-Sectional Studies; Disease Progression; Female; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Kidney Tubules, Proximal; Male; Middle Aged; Nucleosides; Nucleotides; Retinol-Binding Proteins; Retrospective Studies; Spain; Tenofovir; Young Adult | 2016 |
Implementation of an in-house quantitative real-time polymerase chain reaction method for Hepatitis B virus quantification in West African countries.
Topics: Antiviral Agents; Benzothiazoles; Costs and Cost Analysis; Diamines; DNA Primers; DNA, Viral; Drug Monitoring; Follow-Up Studies; Gambia; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organic Chemicals; Quinolines; Real-Time Polymerase Chain Reaction; Reproducibility of Results; Senegal; Sensitivity and Specificity; Staining and Labeling; Tenofovir; Time Factors; Viral Load | 2016 |
Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?
Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Tenofovir; Treatment Failure; Treatment Outcome | 2016 |
Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases.
Topics: Acute Kidney Injury; Aged; Antiviral Agents; Creatinine; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney Tubules; Male; Microscopy, Electron; Middle Aged; Necrosis; Risk Factors; Tenofovir | 2016 |
Clinical Relapse After Cessation of Tenofovir Therapy in Hepatitis B e Antigen-Negative Patients.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Prospective Studies; Recurrence; Retrospective Studies; Sustained Virologic Response; Tenofovir; Withholding Treatment | 2016 |
The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence.
Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Immunoglobulins; Immunologic Factors; Kaplan-Meier Estimate; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Postoperative Complications; Proportional Hazards Models; Recurrence; Retrospective Studies; Tenofovir; Treatment Outcome | 2016 |
Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
Topics: Adenine; Adult; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Organophosphonates; Secondary Prevention; Tenofovir; Treatment Outcome; Withholding Treatment; Young Adult | 2016 |
Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Cytotoxins; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Neoplasms; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Virus Activation; Young Adult | 2016 |
[Efficacy of tenofovir monotherapy or lamivudineadefovir dipivoxil combination therapy in treatment of lamivudine-resistant chronic hepatitis B].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Tenofovir | 2016 |
Prevalence and risk factors for viral blipping in chronic hepatitis B patients treated with nucleos (t) ide analogues.
Topics: Adult; Antiviral Agents; Drug Monitoring; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2016 |
Comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis B.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Kidney Diseases; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2016 |
Week 4 viral load predicts long-term suppression of hepatitis B virus DNA during antiviral therapy: improving hepatitis B treatment in the real world.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Australia; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Organophosphonates; Sequence Analysis, DNA; Tenofovir | 2016 |
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Mutation; Organophosphonates; Sequence Analysis, DNA; Tenofovir | 2017 |
Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Renal Insufficiency, Chronic; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2017 |
Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2017 |
The development of dry eye disease during tenofovir and entecavir therapy in a patient with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Dry Eye Syndromes; Female; Guanine; Hepatitis B, Chronic; Humans; Tenofovir | 2016 |
[Changes in serum β2-microglobulin, retinol-binding protein, and cystatin C and their value in identifying early renal dysfunction in patients with chronic hepatitis B undergoing tenofovir or entecavir monotherapy: a comparative analysis].
Topics: Adult; Antiviral Agents; beta 2-Microglobulin; Creatinine; Cystatin C; Female; Guanine; Hepatitis B, Chronic; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Predictive Value of Tests; Renal Insufficiency; Retinol-Binding Proteins; Serum Albumin; Tenofovir; Treatment Outcome | 2016 |
Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asymptomatic Infections; Carcinoma, Hepatocellular; Culture Media, Conditioned; DNA, Viral; Female; Gene Expression; Genotype; Guanine; Hep G2 Cells; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HT29 Cells; Humans; Interferons; Interleukins; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Organophosphonates; Polymorphism, Genetic; Recombinant Proteins; Tenofovir; Up-Regulation; Young Adult | 2018 |
Treatment outcomes in treatment experienced and treatment naïve patients on Tenofovir disoproxil fumarate for chronic hepatitis B.
Topics: Adenine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2017 |
Peripheral Ulcerative Keratitis Secondary to Chronic Hepatitis B Infection.
Topics: Antiviral Agents; Corneal Ulcer; Cryoglobulinemia; Cyclophosphamide; Female; Glucocorticoids; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Middle Aged; Mycophenolic Acid; Ophthalmologic Surgical Procedures; Prednisone; Tenofovir; Vasculitis | 2017 |
Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy.
Topics: Adenine; Adult; Antiviral Agents; Australia; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Salvage Therapy; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Male; Middle Aged; Simeprevir; Sofosbuvir; Tenofovir; Viral Load; Virus Activation | 2016 |
Assessing the clinical and economic impact of increasing treatment uptake in chronic hepatitis B infection using a Markov model.
Topics: Antiviral Agents; Australia; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Hepatitis B, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Markov Chains; Quality of Life; Tenofovir; Time Factors; Treatment Outcome | 2017 |
Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Italy; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; Tenofovir; Treatment Outcome; Viral Load | 2016 |
[A Case of Tenofovir-associated Fanconi Syndrome in Patient with Chronic Hepatitis B].
Topics: Antiviral Agents; Bone and Bones; Calcifediol; Fanconi Syndrome; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Male; Middle Aged; Osteomalacia; Phosphates; Renal Reabsorption; Tenofovir | 2016 |
Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Research Design; Risk Assessment; Spain; Tenofovir; Treatment Outcome | 2017 |
Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Tenofovir | 2016 |
Treatment Efficacy and Safety of Tenofovir-Based Therapy in Chronic Hepatitis B: A Real Life Cohort Study in Korea.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Republic of Korea; Tenofovir | 2017 |
Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study.
Topics: Adenine; Adult; Drug Combinations; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Pilot Projects; Tenofovir | 2016 |
Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Italy; Kaplan-Meier Estimate; Kidney Function Tests; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Failure | 2017 |
Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
Topics: Acute Kidney Injury; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Nucleotides; Organophosphonates; Proportional Hazards Models; Retrospective Studies; Tenofovir; Treatment Outcome | 2017 |
Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
Topics: Antiviral Agents; Cost-Benefit Analysis; Guanine; Health Care Costs; Hepatitis B, Chronic; Humans; Italy; Markov Chains; Quality-Adjusted Life Years; Tenofovir; Treatment Outcome | 2017 |
Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; HIV Infections; Humans; Male; Middle Aged; Switzerland; Tenofovir; Viral Load; Virus Replication | 2017 |
Predictive value of serum ALT and T-cell receptor beta variable chain for HBeAg seroconversion in chronic hepatitis B patients during tenofovir treatment.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Longitudinal Studies; Male; Receptors, Antigen, T-Cell, alpha-beta; Seroconversion; T-Lymphocytes, Regulatory; Tenofovir; Young Adult | 2017 |
Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Multivariate Analysis; Propensity Score; Tenofovir; Treatment Outcome; Viral Load | 2017 |
HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy.
Topics: Adult; Amino Acid Substitution; Clonal Evolution; Demography; Epitopes, B-Lymphocyte; Genes, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Hydrophobic and Hydrophilic Interactions; Lamivudine; Mutation; Protein Domains; Quasispecies; RNA-Directed DNA Polymerase; Tenofovir; Treatment Outcome; Viral Proteins | 2017 |
[Chronic hepatitis B. Tenofovir--the right choice from the beginning].
Topics: Adenine; Antiviral Agents; Drug Approval; Europe; Hepatitis B, Chronic; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
[Drug approval studies of Viread. As effective in HBeAg positive as also in HBeAg negative patients].
Topics: Adenine; Antiviral Agents; Drug Approval; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Multicenter Studies as Topic; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Tenofovir; Viral Load | 2008 |
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
Topics: Adenine; Animals; Antigens, Viral; Antiviral Agents; Deoxycytidine; Disease Models, Animal; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Hepatitis B Virus, Woodchuck; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Marmota; Organophosphonates; RNA, Viral; Rodent Diseases; Tenofovir; Virus Replication | 2008 |
Does the presence of adefovir-resistant variants lead to failure of tenofovir monotherapy?
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Genetic Variation; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Failure | 2008 |
Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
Topics: Adenine; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Mutation; Organophosphonates; Promoter Regions, Genetic; Tenofovir | 2008 |
Two-year data released on Viread for chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Hepatitis B, Chronic; Humans; Multicenter Studies as Topic; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2008 |
[Protocol for the antiviral therapy of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2008 |
Chronic hepatitis B--new goals, new treatment.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Viral Load | 2008 |
Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Mutation; Organophosphonates; Tenofovir; Virus Replication | 2009 |
Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Organophosphonates; Tenofovir | 2009 |
[New molecules in the treatment of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir | 2009 |
[Atazanavir-induced nephrolithiasis].
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir | 2009 |
Decision analysis model for hepatitis B prophylaxis one year after liver transplantation.
Topics: Adenine; Administration, Oral; Antiviral Agents; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Health Care Costs; Hepatitis B, Chronic; Humans; Immunoglobulins; Injections, Intramuscular; Lamivudine; Liver Transplantation; Markov Chains; Models, Economic; Organophosphonates; Retrospective Studies; Salvage Therapy; Secondary Prevention; Tenofovir; Time Factors; Treatment Failure; Treatment Outcome | 2009 |
Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.
Topics: Adenine; Antiviral Agents; Cell Line; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Nucleotides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine | 2009 |
[Therapy of chronic hepatitis B. Tenofovir--first choice in current EASL guidelines].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Resistance, Viral; Evidence-Based Medicine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Organophosphonates; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2009 |
Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.
Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; DNA, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Markov Chains; Models, Economic; Organophosphonates; Quality-Adjusted Life Years; Tenofovir | 2009 |
Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Salvage Therapy; Tenofovir; Viremia | 2009 |
Tenofovir: new indication. In chronic hepatitis B: beware bone toxicity.
Topics: Adenine; Antiviral Agents; Bone and Bones; Bone Diseases; Double-Blind Method; Drug Approval; Europe; Fractures, Bone; Hepatitis B, Chronic; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Viremia; Virus Replication | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guidelines as Topic; Tenofovir | 2009 |
Hepatitis B virus in tenofovir-naive Chinese patients with chronic hepatitis B contains no mutation of rtA194T conferring a reduced tenofovir susceptibility.
Topics: Adenine; Adult; Drug Resistance, Viral; Female; Gene Amplification; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir | 2009 |
Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Nucleosides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Transaminases | 2009 |
[The efficacy of nucleoside/nucleotide analogue on chronic hepatitis B].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Replication | 2009 |
Tenofovir disoproxil fumarate for the treatment of hepatitis B infection.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Hepatitis B, Chronic; Humans; Organophosphonates; Prodrugs; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy.
Topics: Adenine; Adult; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Molecular Sequence Data; Mutation, Missense; Organophosphonates; Selection, Genetic; Sequence Alignment; Tenofovir; Treatment Failure; Viremia; Young Adult | 2010 |
Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy.
Topics: Adenine; Antiviral Agents; Asia; Cost-Benefit Analysis; Decision Support Techniques; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Germany; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Models, Economic; Nucleosides; Organophosphonates; Pyrimidinones; Salvage Therapy; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; United States | 2010 |
Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence?
Topics: Adenine; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Probenecid; Secondary Prevention; Tenofovir | 2010 |
The curative efficiency of tenofovir for patients with chronic hepatitis B after failure of nucleoside/nucleotide analogues.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Organophosphonates; Remission Induction; Tenofovir; Treatment Failure | 2010 |
Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study.
Topics: Adenine; Adult; Antiviral Agents; Female; France; Hepatitis B Antibodies; Hepatitis B Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Surveys and Questionnaires; Tenofovir | 2010 |
Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
Topics: Adenine; Cost-Benefit Analysis; Guanine; Hepatitis B, Chronic; Humans; Markov Chains; Organophosphonates; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; State Medicine; Tenofovir; United Kingdom | 2010 |
Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen.
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Drug Combinations; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Organophosphonates; Rituximab; Tenofovir; Virus Activation | 2010 |
[Antiviral treatment of chronic B hepatitis; 2010 - therapeutic recommendations].
Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Organophosphonates; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Tenofovir; Treatment Failure; Viral Load | 2010 |
[Treatment of chronic hepatitis B. High response rate in general practice].
Topics: Adenine; Antiviral Agents; Cross-Sectional Studies; Germany; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Long-Term Care; Organophosphonates; Patient Care Team; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2010 |
Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Topics: Adenine; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Polymorphism, Single Nucleotide; Tenofovir; Viral Load; Viral Proteins; Virus Replication | 2011 |
Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Young Adult | 2011 |
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome; Virus Replication; Young Adult | 2011 |
Virologic and clinical outcomes in HIV/HBV coinfected patients on tenofovir-containing HAART.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; HIV Infections; Humans; Organophosphonates; Tenofovir | 2010 |
Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; DNA, Viral; Female; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Hepatitis D, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load | 2010 |
Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire; Cross-Sectional Studies; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prevalence; Tenofovir; World Health Organization; Young Adult | 2010 |
[Analogs combination therapy in chronic hepatitis B: when and how?].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2010 |
[Long-term therapy for chronic hepatitis B in HIV co-infected patients].
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine | 2010 |
[Treatment has a positive impact on the long-term evolution of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2010 |
Tenofovir for treatment of hepatitis B virus reactivation in patients with chronic GVHD.
Topics: Adenine; Adult; Chronic Disease; Female; Graft vs Host Disease; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Virus Activation | 2011 |
Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Time Factors; Treatment Outcome | 2011 |
Tenofovir salvage for nucleoside experienced patients: muddy waters?
Topics: Adenine; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Nucleosides; Organophosphonates; Reverse Transcriptase Inhibitors; Salvage Therapy; Tenofovir | 2011 |
Hyperlipidemic acute pancreatitis: a possible role of antiretroviral therapy with entecavir.
Topics: Abdominal Pain; Acute Disease; Adenine; Adult; Alcoholism; Antiretroviral Therapy, Highly Active; Critical Care; Diabetes Mellitus, Type 2; Fever; Guanine; Hepatitis B, Chronic; Humans; Hyperlipidemias; Hypertriglyceridemia; Male; Organophosphonates; Pancreatitis; Plasmapheresis; Reverse Transcriptase Inhibitors; Tenofovir; Tomography, X-Ray Computed; Triglycerides | 2011 |
Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Antigens, CD; Case-Control Studies; CD8-Positive T-Lymphocytes; DNA, Viral; Female; Flow Cytometry; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoassay; Male; Middle Aged; Organophosphonates; Programmed Cell Death 1 Receptor; T-Lymphocytes, Regulatory; Tenofovir; Viral Load | 2011 |
[Efficacy and treatment strategy for drug resistances of nucleos(t)ide analogues for chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir | 2011 |
Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients.
Topics: Adenine; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Enzymes; Female; France; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Organ Transplantation; Organophosphonates; Pilot Projects; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2011 |
Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Deoxycytidine; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2011 |
Proper antiviral therapy for hepatitis B virus-associated acute-on-chronic liver failure.
Topics: Adenine; Antiviral Agents; End Stage Liver Disease; Guanine; Hepatitis B, Chronic; Humans; Liver Failure, Acute; Organophosphonates; Tenofovir | 2011 |
Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2011 |
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Bone Marrow; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompromised Host; Italy; Organophosphonates; Tenofovir; Treatment Outcome; Viremia | 2011 |
Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Middle Aged; Mutation; Organophosphonates; Tenofovir; Treatment Failure | 2011 |
Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Antiviral Agents; Case-Control Studies; Female; Gene Products, pol; Glomerular Filtration Rate; Hepatitis B, Chronic; HIV Infections; Humans; Linear Models; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2011 |
Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir | 2011 |
Antiviral drug resistance testing in patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Data Collection; Decision Making; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies; Surveys and Questionnaires; Tenofovir; Treatment Outcome; Viral Load | 2012 |
The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Genotype; Hep G2 Cells; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Tenofovir; Virus Replication | 2011 |
Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2011 |
Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Risk Factors; Tenofovir; Viral Load; Viremia | 2011 |
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study.
Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Internationality; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Viremia; Young Adult | 2012 |
Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change.
Topics: Adenine; Antiviral Agents; Canada; Drug Approval; Guanine; Health Services Accessibility; Hepatitis B, Chronic; Humans; Insurance Coverage; Lamivudine; Liver Cirrhosis; National Health Programs; Organophosphonates; Tenofovir | 2011 |
Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Canada; Cost-Benefit Analysis; Female; Health Care Costs; Hepatitis B virus; Hepatitis B, Chronic; Humans; Insurance, Health, Reimbursement; Male; National Health Programs; Organophosphonates; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2011 |
[New drugs of treatment of patients with chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Emtricitabine; Hepatitis B, Chronic; Humans; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2011 |
Tenofovir plus entecavir as rescue therapy for multidrug-resistant chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Substitution; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Mutation; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load; Virus Replication | 2012 |
Peripheral blood lymphocyte dynamics and viral kinetics in patients with chronic active hepatitis B virus infection treated by tenofovir.
Topics: Adenine; ADP-ribosyl Cyclase 1; Adult; Antiviral Agents; Biomarkers; CD28 Antigens; CD8-Positive T-Lymphocytes; DNA, Viral; Female; Flow Cytometry; Forkhead Transcription Factors; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunity, Cellular; Interleukin-2 Receptor alpha Subunit; Kinetics; Male; Membrane Glycoproteins; Middle Aged; Organophosphonates; T-Lymphocyte Subsets; T-Lymphocytes, Helper-Inducer; T-Lymphocytes, Regulatory; Tenofovir; Treatment Outcome; Turkey; Viral Load; Virus Replication | 2012 |
Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Cloning, Molecular; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Sequence Analysis, DNA; Tenofovir; Transfection | 2012 |
Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Medication Adherence; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Young Adult | 2012 |
Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2012 |
Safety of long-term nucleos(t)ide treatment in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Evidence-Based Medicine; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Patient Safety; Risk Assessment; Risk Factors; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Biomarkers; Creatinine; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney Tubules; Male; Middle Aged; Organophosphonates; Phosphates; Renal Insufficiency; Tenofovir; Time Factors; Uric Acid | 2012 |
Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; Creatinine; Female; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Kidney Diseases; Male; Middle Aged; Organophosphonates; Retrospective Studies; Risk Assessment; Tenofovir; Young Adult | 2012 |
Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Tenofovir; Viral Load; Young Adult | 2012 |
Commentary: combination therapy with two nucleos(t)ide analogues in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Hepatitis B virus related membranous glomerulonephritis and proteinuria treated with lamivudine and tenofovir.
Topics: Adenine; Glomerulonephritis, Membranous; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Proteinuria; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2011 |
Another drug in the armamentarium to combat hepatitis B virus in adolescents.
Topics: Adenine; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir | 2012 |
Current practice of chronic hepatitis B treatment in Southern Italy.
Topics: Adenine; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Italy; Lamivudine; Male; Middle Aged; Nucleosides; Organophosphonates; Polyethylene Glycols; Practice Patterns, Physicians'; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Young Adult | 2012 |
Long-term hepatitis B virus surface antigen decay in HIV-1/hepatitis B virus-coinfected adults initiating a tenofovir-containing regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2012 |
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Cells, Cultured; DNA, Viral; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-gamma; Interleukin-1; Lamivudine; Organophosphonates; T-Lymphocytes; Tenofovir; Tumor Necrosis Factor-alpha | 2012 |
Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Young Adult | 2012 |
Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir.
Topics: Adenine; Anti-HIV Agents; Coinfection; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Sequence Analysis, DNA; Tenofovir; Viral Load; Young Adult | 2012 |
Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders.
Topics: Adenine; Adult; Analysis of Variance; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2012 |
Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Blood Chemical Analysis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Turkey | 2013 |
The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Drug Approval; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Milk, Human; Netherlands; Nucleosides; Organophosphonates; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Renal Insufficiency; Telbivudine; Tenofovir; Thymidine | 2012 |
Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Lamivudine; Longitudinal Studies; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Tenofovir | 2013 |
Scar undone: long-term therapy of hepatitis B.
Topics: Adenine; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2013 |
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.
Topics: Adenine; Allied Health Personnel; Antibodies, Viral; Antiviral Agents; Canada; Coinfection; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Humans; Interferons; Kidney Diseases; Liver; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2012 |
Should chronic hepatitis B be treated as early as possible?
Topics: Adenine; Adult; Antiviral Agents; Belgium; Cost-Benefit Analysis; Early Diagnosis; Guanine; Health Care Surveys; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Markov Chains; Middle Aged; Organophosphonates; Quality of Life; Secondary Prevention; Tenofovir; Treatment Outcome; Viral Load | 2013 |
Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.
Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Gene Products, pol; Genetic Association Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Male; Middle Aged; Molecular Typing; Organophosphonates; Polymerase Chain Reaction; Randomized Controlled Trials as Topic; Sequence Analysis, DNA; Tenofovir; Treatment Outcome; Viral Load; Virus Replication | 2013 |
Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
Topics: Adenine; Aged; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2013 |
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Antiviral Agents; Australia; Coinfection; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Organophosphonates; Tenofovir; Thailand; Treatment Failure; United States | 2013 |
Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B.
Topics: Adenine; Adult; Anti-HIV Agents; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Retrospective Studies; Tenofovir | 2013 |
Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy.
Topics: Adenine; Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Male; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Forecasting; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B.
Topics: Adenine; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Risk Assessment; Sampling Studies; Severity of Illness Index; Tenofovir; Treatment Outcome; Viral Load | 2004 |
Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient.
Topics: Adenine; Adult; Anemia, Hemolytic; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Tenofovir | 2004 |
Lichenoid drug eruption to tenofovir in an HIV/hepatitis B virus co-infected patient.
Topics: Adenine; Anti-HIV Agents; Drug Eruptions; Hepatitis B, Chronic; HIV Infections; Humans; Lichenoid Eruptions; Male; Middle Aged; Organophosphonates; Tenofovir | 2004 |
Tenofovir therapy for lamivudine resistance following liver transplantation.
Topics: Adenine; Adult; Antiviral Agents; Chronic Disease; Drug Resistance, Viral; Hepatitis B; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Organophosphonates; Retrospective Studies; Salvage Therapy; Tenofovir; Treatment Outcome | 2004 |
Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection.
Topics: Adenine; Administration, Oral; Animals; Antiviral Agents; Dose-Response Relationship, Drug; Hepatitis B Virus, Woodchuck; Hepatitis B, Chronic; Humans; Marmota; Organophosphonates; Tenofovir; Treatment Outcome; Viremia; Virus Replication | 2005 |
Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Evolution, Molecular; Female; Genes, pol; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load; Viremia; Virus Replication | 2005 |
Replacement of tenofovir with adefovir may result in reactivation of hepatitis B virus replication.
Topics: Adenine; Antiviral Agents; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Recurrence; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2006 |
Tenofovir for chronic hepatitis B virus infection in HIV-coinfected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Clinical Trials as Topic; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2006 |
Variant of hepatitis B virus with primary resistance to adefovir.
Topics: Adenine; Amino Acid Sequence; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir; Viremia | 2006 |
Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Regression Analysis; RNA, Viral; Statistics, Nonparametric; Tenofovir; Treatment Outcome | 2006 |
A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient.
Topics: Adenine; Adult; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: is tenofovir the answer?
Topics: Adenine; Adult; Drug Resistance, Multiple, Viral; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Reversibility of cirrhosis in HIV/HBV coinfection.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Organophosphonates; Platelet Count; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Virus Replication | 2007 |
Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Female; Guideline Adherence; Health Care Surveys; Hepatitis B Vaccines; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tenofovir; United States | 2007 |
A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment.
Topics: Adenine; Adult; Arabinofuranosyluracil; Base Sequence; Cell Line, Tumor; Cloning, Molecular; Deoxycytidine; DNA Mutational Analysis; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Viral; Emtricitabine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Molecular Sequence Data; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir; Time Factors; Transfection; Treatment Outcome; Viral Load; Virus Replication | 2007 |
Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Homosexuality, Male; Humans; Lamivudine; Liver Diseases; Male; Organophosphonates; Tenofovir; Transaminases; Viral Load | 2008 |
Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Viral Load; Virus Replication | 2008 |
Potency of tenofovir in chronic hepatitis B: mono or combination therapy?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis.
Topics: Adenine; Adult; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2008 |
[Anti-viral therapy of type B chronic hepatitis. 3. Future of anti-viral agents].
Topics: Adenine; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Hepatitis B, Chronic; Humans; Interferons; Nucleic Acid Synthesis Inhibitors; Nucleosides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine | 2008 |
Europe extends Viread indication for chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Approval; Europe; Hepatitis B, Chronic; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |